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Abstract 
Introduction: CF (cystic fibrosis) and PCD (primary ciliary dyskinesia) are obstructive airway diseases 
characterised by frequent infections and neutrophilic inflammation.  However, PCD has a much 
milder course than CF.   
Pilot data showed that in PCD (n=8) the relationship between LCI (lung clearance index) derived from 
multiple breath washout (MBW), and FEV1 (forced expiratory volume in 1 second) differed from the 
established correlation in CF.   This thesis sought to identify the reasons. 
Materials and Methods: Larger PCD (n=38) and CF cohorts (n=125), a non-CF bronchiectasis 
comparator group (n=28), and healthy controls (n=44) were recruited.  All performed LCI and 
spirometry, and subgroups had more complex MBW parameters (conventional and modified phase 
III analysis and curvilinearity) calculated and HRCT scans scored. 
Results:  As in the pilot data, there was no relationship between LCI and FEV1 in PCD, unlike in CF. 
PCD patients had fewer structural abnormalities than CF despite similar or worse spirometry and LCI, 
and the relationship between HRCT and spirometry or LCI in PCD was again different from that seen 
in CF.  MBW analyses showed that Scond* is near-normal in PCD, suggesting less flow asynchrony, 
compared with CF. 
Conclusions: There are differences in the nature of distal airway disease between PCD and CF.  As 
the non-CF bronchiectasis patients were similar to CF (rather than PCD), this likely results from the 
primary mucociliary clearance defect in PCD compared with secondary impairment in the other two 
conditions.  This may be important as care of PCD patients is extrapolated from that of CF patients, 
which may not be appropriate.  It is important not to extrapolate outcome measures uncritically 
between different disease groups, both clinically and when planning randomised controlled trials. 
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Finally, a better understanding of what causes the better prognosis in PCD may help identify future 
new treatment avenues in CF.  
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Chapter One - Introduction 
 
1.1 Initial Observations 
The work of this thesis sprung from the observation, during routine clinical testing, that the Lung 
Clearance Index (LCI) results of children with primary ciliary dyskinesia (PCD) did not follow the 
pattern of results previously reported in cystic fibrosis (CF) patients (see Figure 1-1, below). 
 
 
Figure 1-1 Pilot data from the original thesis proposal.  The data shows a deviation in PCD from the 
expected CF pattern, with nearly-normal LCIs even in the presence of severely reduced FEV1 
 
In CF, much work has been done establishing the relationship between LCI and spirometry (Davies et 
al., 2008; Gustafsson et al., 2008; Gustafsson, 2005; Aurora et al., 2004; Gustafsson, Aurora & 
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Lindblad, 2003; Gustafsson, 2000).  In summary, there is a strong linear relationship between LCI and 
forced expiratory volume in one second (FEV1, the most commonly used spirometry parameter).  LCI 
is sensitive to small airway changes and becomes abnormal earlier in the course of CF lung disease 
than FEV1, but thereafter the two are broadly correlated.  As LCI worsens (increasing), FEV1 also 
worsens (decreasing). This relationship is discussed in more detail below. 
In PCD, this relationship did not appear to exist.  Some patients with abnormal spirometry had high 
LCIs, but others had more normal LCIs despite abnormal spirometry.  This may occur if a patient has 
particularly poor spirometry technique, but these patients had repeatable spirometry with no 
detectable quality issues.  There were also incidences of patients with high LCIs having extremely 
good spirometry, and since LCI is non-effort dependent this is unlikely to be artefactual, given the 
good technical qualities of the traces.  Overall, it began to emerge that the LCI/ FEV1 relationship in 
PCD was very different to that established in CF. This may be important therapeutically, given that 
PCD has a better prognosis than CF. Differences between the two conditions, both of which are 
characterised by neutrophilic airway inflammation and chronic infection with a similar range of 
micro-organisms, may open avenues of potential novel treatments. 
The work of this thesis was to explore the reasons for this discrepant relationship. This chapter 
discusses in more detail the background to the measurements and the diseases studied, leading to 
the formation of the hypotheses, aims and objectives which are tested in this work.
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1.2 Cystic fibrosis (CF) basic science and aetiology 
CF is an autosomal recessive disorder caused by a defect in the CFTR gene (Cystic Fibrosis Trans-
membrane Regulator).  CFTR is a chloride channel normally found in the epithelial apical cell 
membranes, including in the airway, pancreas, digestive and reproductive tracts.    CF 
pathophysiology is complex, and cannot purely be due to the loss of CFTR chloride channel function 
(Coakley & Boucher, 2007); interactions with other proteins likely contribute to the clinical 
phenotype of CF. 
One well known CFTR interaction is in the down regulation of the sodium channel, ENaC.  This is the 
cause of the enhanced sodium uptake seen in the airways of CF patients, and likely plays an 
important part in CF lung disease due to its effect on the volume of the airway surface liquid  (ASL).  
In CF, increased sodium absorption causes the periciliary liquid layer (PCL) of the ASL to dehydrate 
and deplete, leaving the cilia attempting to beat in the much thicker mucus layer (see 1.51 for more 
details).  This considerable impairment of mucociliary clearance (MCC) leads to accumulation of 
bacteria, and dense patches of thickened mucus that are even harder to clear, and provide ideal 
culture conditions for bacteria.  Importantly, reduction in MCC in CF is a secondary phenomenon, 
not the primary cause of the disease, and impaired MCC is not uniformly found in CF (McShane et 
al., 2004).  There are also other putative factors leading to immune dysregulation, which contribute 
to failure to clear infection, despite a vigorous influx of neutrophils into the airway. Thus CF lung 
disease is characterised by chronic infection and frequent pulmonary exacerbations, and 
neutrophilic inflammation.  
The diagnosis of CF is normally straightforward, with a positive result on new born screening 
followed by a clearly abnormal sweat test.  When diagnosis is not made in the newborn period, it is 
suggested by a combination of clinical features, occasionally with a family history of CF, and a high 
sweat chloride test.  Though many disease-causing CFTR alleles have been identified, some rarer 
mutations remain unknown (Ooi et al., 2014; John Hopkins University, the Hospital for Sick Children, 
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2013) and so in certain circumstances CF may be diagnosed from phenotypic features alone 
(Rosenstein & Cutting, 1998). 
Although CF is a complex, multi-system illness, lung disease is the main cause of mortality and 
morbidity.  Over time, the repeated infections and resultant inflammation cause damage to the 
airway, this in turn decreases lung function and also makes the lungs more susceptible to further 
infections.  The main goal of much CF therapy therefore is to treat infection and other 
manifestations of airway disease aggressively.  
This decline can be monitored over time by increasingly abnormal results using several different 
techniques.  Increasing structural lung damage is visible on HRCT, manifest by increased airway wall 
thickness, parenchymal abnormality and the development of bronchiectasis.  These changes can be 
scored quantitatively (Brody et al., 2006; Brody et al., 2004). Lung disease also causes worsening 
airway obstruction and distal gas mixing, resulting in worsening obstructive spirometry and impaired 
distal gas mixing as shown by washout studies.  Of note, spirometry is much less sensitive than HRCT 
and gas mixing indices (Gustafsson et al., 2008); these latter two are complementary investigations 
(Owens et al., 2011). Raised inflammatory markers in the blood and sputum, especially markers of 
tissue destruction and neutrophil chemotaxis, are evidence of the increased inflammation and tissue 
destruction; these are used more in research studies than clinical practice.
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1.3 Primary Ciliary Dyskinesia (PCD) 
1.3.1 Basic science, aetiology and presentation 
The genetics of PCD are considerably more complex than CF, with mutations in many (c250) 
different genes potentially giving rise to similar phenotypes.  Most people with PCD have immotile 
or dyskinetic cilia on light microscopic examination, and/or a clear defect with the ultrastructure of 
the cilia when examined by electron microscopy.   A more detailed breakdown of diagnostic testing 
is shown in Table 1-1 below. 
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Table 1-1- Taken from (Hogg & Bush, 2012), diagnostic testing for PCD. 
Test Interpretation Role in PCD diagnosis 
Saccharin Test False negatives and false positives, 
screening test at best 
Not useful to diagnose or exclude PCD 
Radionuclide 
mucociliary 
clearance 
Good sensitivity and speciﬁcity but only 
limited experience or access in most 
centres 
Not useful to diagnose or exclude PCD 
Nasal nitric oxide Used as the screening test of choice; now 
also part of the diagnostic investigation 
Normal nasal nitric oxide = PCD very unlikely 
Ciliary motility 
studies 
Can be affected by recent viral infection Normal ciliary beat frequency and pattern = PCD excluded  
If abnormal, repeat after treatment of infection or proceed to ciliary culture 
Abnormal ciliary beat frequency and/or pattern on an adequate sample = deﬁnite PCD 
Transmission 
electron microscopy 
Can be affected by recent viral infection Presence of known disease producing structural abnormality = deﬁnite PCD 
Can be normal with deﬁnite PCD 
Culture of ciliary 
biopsy 
Cilia regrown in culture, used to 
differentiate secondary ciliary dyskinesia 
in PCD 
Normal ciliary beat frequency and pattern = PCD excluded 
Abnormal ciliary beat frequency and/or pattern on an adequate sample = deﬁnite PCD 
Genetic studies >250 potential loci, very few known 
genes 
Two known disease producing mutations in trans = deﬁnite PCD 
Can be no known mutations detected with deﬁnite PCD 
Immunoflorescence 
of ciliary proteins 
Limited experience only and applicable to 
date to very few proteins 
Insufﬁcient evidence to evaluate a role in clinical practice Not yet a stand-alone 
diagnostic test 
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Figure 1-2   A diagram of a normal cilium on the left, with a normal ultrastructure, showing 
microtubular doublets, a central pair, nexin links and radial spokes, and outer and inner dynein arms.  
The electron micrographs on the right show common PCD defects, in A, absence of the outer dynein 
arms, in B, absence of inner dynein arms, in C, absence of inner dynein arms and microtubular 
disorganisation, and in D, absence of both inner and outer dynein arms. 
In the PCD airway, the ASL is thought to be normal, but the cilia do not beat normally to generate 
the wave pattern needed to clear mucus.  Hence, as in CF, mucus builds up, containing bacteria and 
forming sites of infection that eventually lead to lung tissue damage and the development of 
bronchiectasis. However, unlike in CF, reduced MCC is the primary abnormality.  The mucus 
composition is also different from that seen in CF (Bush et al., 2006). 
There are other manifestations of PCD.  In particular, people with PCD often have ear and sinus 
infection secondary to ciliary dysfunction.  Many people of both genders with PCD are sub-fertile as 
in females fallopian tubal ciliary dysmotility impairs the passage of ova along the oviduct, and in 
males the motility of sperm may be affected by immotile or erratic movement of the sperm tail, 
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which are similar in structure to cilia.  Nodal cilia are also involved in body situs in the developing 
embryo and so situs inversus, hetrotaxy and dextrocardia may also result, and many people with 
PCD have these features. Other features of ciliopathy have recently been reviewed (Bush & Hogg, 
2012). 
1.3.2 Similarities between CF and PCD 
PCD is an autosomally recessive disorder that is also characterised by chronic infection with very 
similar organisms to CF patients, including Pseudomonas aeruginosa, and neutrophilic airway 
inflammation.  However, its course and prognosis are much better than CF, with patients having 
near-normal life expectancy and less mortality and morbidity from lung disease.   
The prognosis in CF is continually improving (Dodge et al., 2007) and has improved vastly in the last 
40 years, with the cohort born in the years 1968-70 having only a 50% chance of reaching their 15th 
birthday, but those born in 1992-94 almost always reached age 15.  However, life expectancy is not 
yet normal, with those born in 2000-2003 having a median life expectancy between 40-50 years. 
In PCD, however, though there is far less data to draw on it seems likely that most patients will have 
a normal or near-normal life expectancy (Barbato et al., 2009).  This reduces the information 
available on how disease progression over time may affect biomarkers.  Recent studies suggest that 
in at least some patients, lung function declines with age (Marthin et al., 2010), although a recent 
multi-centre analysis suggested no change in the medium term (2,4 and 6 year follow up)(Maglione 
et al., 2014).  However, patients can progress to transplantation, highlighting the importance of early 
detection (Marthin et al., 2010) and successful monitoring and treatment of lung disease in this 
group.  It is thought the decline in lung function is much more pronounced in CF however, with lung 
function decreasing by 0.8% in PCD patients each year compared with 3.6% for CF (Noone et al., 
2004). There is as yet no longitudinal data on gas mixing indices in PCD.  
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There is little consensus in the literature on how biochemical markers change in PCD over time, 
however abnormality on HRCT has been shown in some studies (Jain et al., 2007), (Santamaria et al., 
2008) and worsens over time (Maglione et al., 2012)(Pifferi et al., 2012).  
PCD is considerably rarer than CF (Barbato et al., 2009) and far less researched, so much of the care 
of people with PCD is extrapolated from best practice in CF (Bush & Hogg, 2012).  PCD patients 
perform daily chest physiotherapy, and antibiotics are a mainstay of treatment, sometimes 
prophylactically, but mainly as treatment of acute exacerbations.    
Whereas obviously a cure for CF is the ideal, were severe CF lung disease to be converted to the 
much milder PCD phenotype, this would be beneficial. Thus a better understanding what factors 
confer a better prognosis in PCD as opposed to CF might open new avenues of treatment for CF.
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1.4 Non-CF Bronchiectasis  
Patients with non-CF bronchiectasis also have a secondary failure of MCC.  Their initial insult to the 
lung may be a serious infection or physical damage, leading to impaired MCC, the vicious cycles of 
infection and inflammation, and the development of bronchiectasis (See 1.5.2 for more details). 
There is little information on the progression of disease in this group and its presumed effect on 
biomarkers.  Some authors have found non-CF bronchiectasis patients show a stabilisation (though 
not return to normal) of their lung function once treated (Bastardo et al., 2009), whilst others report 
a decline (Twiss, Stewart & Byrnes, 2006).  This may be particularly true in developing countries 
(Karadag et al., 2005).  There is no longitudinal data on progression of other biomarkers. 
In this thesis, non-CF bronchiectasis patients have primarily been recruited as a control group, as 
they have bronchiectasis and a secondary MCC impairment, but do not share the other more 
complex features of CF.  Diagnosis is made by HRCT and most will have had at least one scan 
performed.  Patients with bronchiectasis are often treated in a similar way to CF or PCD patients 
with bronchiectasis, with physiotherapy and antibiotics, and monitoring with routine lung function 
testing (Pasteur et al., 2010). 
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1.5 Obstructive lung disease 
Three conditions are studied in this thesis, CF, PCD and non-CF bronchiectasis, as a further control 
group.  For the purposes of this thesis, non-CF bronchiectasis is also non-PCD bronchiectasis.   
Though there are many differences between these conditions they share some common features, 
including obstructive lung disease with impaired mucociliary clearance (MCC) and bronchiectasis. 
1.5.1 Mucociliary clearance 
An important part of host defence against pathogens is MCC.  In summary, the airways have a 
surface liquid (ASL), which consists of two main components, a thin, low-viscosity liquid called the 
periciliary liquid layer (PCL) and then, floating on top of that, a thicker mucus layer.  Cilia, tiny hair-
like filaments on epithelial cells, constantly beat at around 10 Hz in the PCL.  By their beating motion, 
the mucus layer, which can trap any foreign material in the lung (e.g. bacteria, cellular debris, 
environmental contaminants), is slowly moved up and out of the airway and swallowed.  In health, 
MCC helps prevent lower respiratory tract infections, but in obstructive lung disease this process can 
impaired leading to recurrent infections and eventually irreversible airway damage.   
1.5.2 Bronchiectasis 
Bronchiectasis results from destruction of the normal structure of the airways.  It is thought to result 
from a “vicious circle” of infection, failure of host response (inadequate clearance of infection 
leading to inflammation and impaired MCC), leading to further cycles of infection and inflammation 
(Cole, 1986).   
Bronchiectasis commonly occurs in both CF and PCD , but it has many other causes including 
aspiration, foreign body inhalation, immunodeficiency, congenital lung abnormality or post-infection 
(infection may have a known cause such as tuberculosis or measles, but can also result from non-
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specific recurrent persistent bacterial infections)(Stafler & Carr, 2010) .    This “vicious circle” is 
summarised in Figure 1-3 , below. 
 
 
Figure 1-3   The “vicious cycle” of bronchiectasis. Adapted from Cole, PJ “Inflammation: a two-edged 
sword--the model of bronchiectasis” (Cole, 1986).  In PCD, MCC is impaired from birth (primary 
impairment), in CF and non-CF bronchiectasis it is a secondary phenomenon. 
 
In brief, failure of clearance of invading pathogens by normal MCC leads to a host defence reaction.  
Inflammation is a normal part of this response.  The inflammatory process itself, together with 
bacterial exoproducts, further impairs MCC, so infection worsens, yet more inflammation is 
triggered, and a damaging cycle of chronic infection and chronic inflammation begins, whereby both 
processes together combine to cause damage to the airway.  This damage eventually becomes 
irreversible. 
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As MCC in both PCD and CF is impaired, it is unsurprising that bronchiectasis is a feature of these 
diseases.  The nature of this impairment differs, however.  In PCD, a primary failure of MCC occurs 
due to the ciliopathy and MCC is impaired from birth onwards.  In CF, the impairment of MCC is 
secondary, it is believed the airways of CF children are virtually normal at birth and there is evidence 
that MCC is preserved in CF children for some time (McShane et al., 2004).  Less is known about non-
CF bronchiectasis, but it is virtually certain that MCC is impaired as a secondary phenomenon in this 
condition also. 
1.5.3 Inflammation 
In health, inflammation plays a role in normal host defence.  However, in established lung disease, 
inflammation can be damaging, playing an important part in the vicious cycle of bronchiectasis. 
In CF, several studies suggest that the inflammatory response may be exaggerated, and in fact that 
inflammation may precede infection, although this is controversial (Doring & Ratjen, 2007).  Though 
the mechanism by which CFTR affects the inflammatory response is unknown, it seems likely that 
inflammation, in combination with other features of CF, contributes to the development of 
bronchiectasis and in perpetuating the vicious cycle.  Despite this, supressing inflammation too much 
may result in an increased susceptibility to pulmonary exacerbations, so this remains a complex 
issue in CF care (Hodson & Bush, 2007)(Konstan, Vargo & Davis, 1990). 
There are fewer reports on inflammation in PCD, though bronchoalveolar lavage (BAL) and induced 
sputum studies show a similar neutrophilic profile to CF (Barbato et al., 2009; Zihlif et al., 2006; Zihlif 
et al., 2005). In non-CF bronchiectasis there is also neutrophilic airway inflammation in 
bronchoalveolar lavage, though not as severe as that found in CF (Hilliard et al., 2007).
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1.6 Measuring lung disease - assessing interventions and tracking disease progression  
Given how important lung disease is in CF, measures of tracking disease over time are invaluable in 
both clinical practice and research.  A good, validated measure of lung function can be used 
longitudinally in an individual patient to assess disease progression over time, their response to a 
new treatment or intervention, or the severity of a pulmonary exacerbation; or it can be used in a 
patient cohort to assess morbidity in different groups, judge the effectiveness of an intervention 
going through clinical trials, or audit disease progression in different centres (quality improvement).   
The most common physiological measure of lung function used is the FVC manoeuvre, with forced 
vital capacity (FVC), forced expiratory volume in 1 second (FEV1) measured.  The volume-time curve 
produced by this is shown in Figure 1.4 below.   
Forced expiratory flow (FEF) was also recorded.  As mid expiratory flows are of interest, one of the 
most commonly quoted of these is FEF25%-75% or, the average flow during the middle 50% of the 
expiration.  This is calculated from the flow volume curve which is also shown in Figure 1.4. 
 
Figure 1-4 -  Common spirometry FVC curves. The left hand panel shows a volume-time graph from 
which shows FVC (the total volume exhaled) and FEV1 (the volume exhaled at a one second time 
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point) can be calculated.   The right hand panel shows a flow-volume graph from which mid 
expiratory flows are determined. Data taken from Spirotrac software (Vitalograph, Buckingham, UK) 
As lungs grow and then deteriorate over the life course, absolute spirometric values are not useful 
clinically, but must be compared to known results for the age, sex, height, weight and ethnic 
matched controls.  How this is done, from the size and quality of the reference population data set 
to the equations used to generate the predictions, has been the subject of much debate in recent 
years, and is beyond the scope of this thesis.  Until recently, these values were often quoted as a 
percentage predicted of the expected normal value, but that has recently given way to the 
expression as z-scores, which are essentially a number of standard deviations away from the 
population mean that a value falls (see 2.8 Statistical methods for more detail).  These were 
calculated as recommended by Growing Lungs Initiative (Stanojevic et al., 2009)using tools supplied 
on their website. Whereas a measurement 15% below normal could be within or without the normal 
range, a measurement of < 1.96 z-scores below the mean is always abnormal, making z-scores 
preferable for clarity. 
Both obstructive and restrictive defects can be detected using the FVC manoeuvre.  Obstructive 
defects result from pathology that reduces airway calibre (for example asthma, CF, PCD, non-CF 
bronchiectasis), and restrictive may be intrapulmonary (pulmonary fibrosis, for example) or 
extrapulmonary (chest wall restriction).  This is shown in figure XX below. 
FEV1/FVC ratio is often used as an indication of obstructive versus restrictive patterns.  In obstructive 
disease FEV1 will be reduced whereas FVC will be normal, giving a reduced FEV1/FVC ratio.  In 
restrictive disease, both FEV1 and FVC will be reduced, giving a normal or even above normal ratio. 
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Figure 1-5 - Obstructive and restrictive defects on spirometry.  Examples kindly provided by Mr Simon 
Ward of the Department of Lung Function, Royal Brompton.  Panel A shows a normal test with 
multiple repeatable manoeuvres.  Panel B shows a restrictive defect caused by kyphoscloliosis.  Panel 
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C shows a mild-moderate obstructive defect caused by non-CF bronchiectasis.  Panel D shows severe 
obstructive and restrictive defects caused by end-stage CF lung disease 
 
FEV1is by far the most commonly used measure of lung function in the CF clinic (Rosenthal, 2007) 
and an important outcome measure in many clinical trials.  Reduction in FEV1 of more than 10% is 
used as part of some definitions of a CF pulmonary exacerbation, guidelines recommend that 
patients with long term more gradual but still accelerated decline are also assessed for further 
treatment options, and any sudden larger declines should be treated aggressively. 
However, FEV1 is actually an insensitive marker of early lung disease, and a poor predictor of 
morbidity or mortality in CF (Rosenthal, 2007).  Its insensitivity is thought to be at least partly 
because the distal airways do not give any signal until at least 90% are destroyed.  Though large 
airway health is clearly very important in CF, this lack of information from the small airways probably 
contributes to the poor utility of FEV1 in CF, at least in early stage disease. 
There is an additional problem with use of FEV1.  As the life expectancy improves and morbidity 
lessens in the CF patient, with patients remaining well for much longer, it is not uncommon 
particularly in paediatrics to see patients with normal or very near normal FEV1 maintained over long 
periods, as they only have minimal large airway disease (Aurora et al., 2004).  These patients, 
however, may still have CF lung disease and may experience an increase in symptoms over time and 
worsening bronchiectasis(de Jong et al., 2004), and may have exacerbations, but if the FEV1 remains 
in the normal range it is an inappropriate tool for tracking changes in these patients. This is 
particularly a problem when designing randomised controlled trials of treatment. 
The main additional parameters calculated from spirometry are mid-expiratory flows.  This is the 
mean flow (as opposed to volume for FEV1) over a section of vital capacity.  This gives additional 
information to FEV1 and may be more indicative of the health of the small airways.  There are several 
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possible mid expiratory flow measures, most usually FEF25-75% (forced expiratory flow between 25 
and 75% of FVC) as it is commonly included in spirometry software and is used in much of the 
literature. 
Radiography has also proved a useful tool in tracking CF lung disease.  Plain chest radiographs are 
usually taken annually to assess any structural changes caused by disease progression.  It is widely 
recognised, however, that high resolution computed tomography of the chest (HRCT) is much more 
informative, and may be invaluable in judging the severity and extent of important pathology such as 
bronchiectasis (Brody et al., 2004; Long, Williams & Castile, 2004).  The risks of radiography include 
radiation exposure.  Though very small for a plain x-ray, an HRCT requires a larger dose.  Though 
modern scanners and protocols keep this to a minimum, as repeat scans are required to accurately 
track changes over time, there is reluctance in some centres to introduce regular scanning into the 
review of children with CF or PCD.  A physiological test where repeated measures can be made with 
no risk of radiation exposure is therefore preferable.  In research studies, it is also preferable to limit 
radiation exposure as scans would not be clinically indicated. 
Given these problems with both spirometry and HRCT, a wide range of newer tests are currently 
being developed.  Multiple breath washout (MBW) and particularly lung clearance index (LCI) is an 
index of ventilation inhomogeneity which forms much of the basis of this thesis, and is covered in 
detail below. 
 
1.6.1 Physiological measurement of ventilation inhomogeneity 
Ventilation Inhomogeneity (VI) measures to what extent lung disease has affected the normal gas 
mixing and transit within the lung.  In an adult lung, the 23 branching airway generations give rise to 
over 70m2 of alveolar surface area for gas exchange.  Airway generations 0-16 are termed the 
“conducting” airways and airway generations 17-23 the intra acinar region.  “Small” airways are 
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normally defined as those at or below generation 8, having a diameter of less than 2mm.  In the 
conducting airways, gases move primarily by convection with a fast linear gas velocity but as the 
total cross sectional area increases dramatically moving in to the small airways, linear gas velocity 
drops, and the contribution to gas flow by molecular diffusion increases, forming a “convection-
diffusion front”.  Diffusion increases as convection falls, with diffusion predominating in the very 
distalmost airways and the alveoli.  This complex structure gives rise to a myriad of different path 
lengths from the acinar region to the trachea and upper airway.  If these distalmost airways are 
narrowed, occluded or otherwise damaged, they will not ventilate normally.  This inhomogeneity 
between different paths is what is measured in VI tests. 
Many different lung pathologies can cause the damage detected by VI, including inflammation, 
infection, mucus plugging, and gross pathological changes such as bronchiectasis.  VI cannot 
distinguish between these different conditions. The primary measures of VI are the single breath 
washout test (SBW) and the multi breath washout test (MBW), both forms of inert gas washout.  For 
this thesis, I have focussed on the MBW as the indices derived from it are considered more widely 
useful in paediatrics (Robinson, Goldman & Gustafsson, 2009). 
 
1.6.2 The multi breath washout test (MBW) 
Gas flow within the lungs is dominated by two main processes, convection, in the large airways, and 
diffusion in the lung periphery.  In the convective process, a pressure gradient is created between 
the airways and the mouth, allowing bulk, net flow of all gas species into the lungs.  Convective 
velocity falls as airways narrow and surface area increases, and has reached zero by the alveolar 
sacs.  At this point, gas movement is primarily by diffusion as individual gases move along a 
concentration gradient, towards (or away from) the gas exchange surface.  A zone also exists where 
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both these processes are taking place, the “diffusion-convection front”, which corresponds to the 
terminal bronchioles and the first branches of the acini. 
Mathematically modelling gas flow within the lungs is an extremely complex topic with over 60 years 
of literature to draw upon.  The mathematics of the MBW, however, is based on one of the more 
simple models, normally referred to as the “two compartment” model. 
The two compartment model assumes the lung consists of two parallel lung regions, a shared, 
common deadspace, and two deadspace regions leading to each of the mixing units.  This is 
represented simply in Figure 1.6 below. 
 
 
Figure 1-6 - The two compartment model of the lung, where the volume of each unit (Vo/2) is equal, 
there is a common deadspace VDC, individual deadspaces leading to each unit (VD1 and VD2), and 
the tidal volume of each unit is different VT1 and VT2. 
The difference in these tidal volume units gives a difference in ventilation, a very primitive 
ventilation inhomogeneity (VI) of the sort detected by the MBW and reflected in indices such as LCI 
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Early inert gas washouts were conducted primarily using the first respiratory mass spectrometers 
and nitrogen analysers of the mid-20th century.  Their resolution was frequently limited to 1/40th of 
atmospheric nitrogen concentrations, and so many of the early indices using nitrogen washout 
consider this the point representing the end of gas washed out as this was the lower limit of 
detection.  Despite these limitations the physiological significance of VI was recognised, although 
many of the earliest studies focus on its usefulness in mechanistic studies, anaesthetised patients or 
in the aging lung, rather than pathology as a result of disease (Edelman et al., 1968).  With the 
advent of modern desktop personal computers (PCs) in the late 1980s, interest in these measures 
was renewed (Larsson, Jonmarker & Werner, 1988) as for the first time much of the data capture 
and analysis could be automated, making the measures much more accessible.  The development of 
the modern PC controlled respiratory mass spectrometers in the 1990s paved the way for many 
studies of MBW indices in health and disease to begin. 
MBW is relatively straightforward to carry out, and two main methodologies exist.  In the first, 
resident nitrogen within the patients’ lung is washed out by breathing pure oxygen, and in the 
second, a mixture containing a known concentration on an inert tracer gas is breathed by the patient 
until an equilibrium of this gas is established, and it is then washed out by breathing room air (which 
does not contain the tracer gas). 
During this “washout” phase, the volume of each breath (measured indirectly from flow data), and 
the volume and concentration of tracer gas within it, is recorded for later analysis.  The test is based 
on resting, tidal breathing so is completely non-effort-dependent and only requires passive 
cooperation, making it particularly appealing in children, who may lack the ability to correctly 
perform spirometry (Aurora et al., 2005). 
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Figure 1-7 A normal trace from an MBW test.  The black line shows a steady, tidal breathing pattern 
and the green line the tracer gas concentration, washing out as the test progresses. 
In the early work, nitrogen washouts were more commonly used, but inert gas washout became the 
preferred technique in the 1980s.  This was partially due to practical issues (early mass 
spectrometers, that performed the inert gas MBW, were equipped with more sophisticated PC 
capability earlier than was the case with nitrogen analysers) and partially as interest spread into the 
paediatric field concern was raised over the effects of pure oxygen breathing on tidal volume and 
respiratory rate in young children.  Recently (and after the work of this thesis was conducted) this 
has now shifted again, as nitrogen analysers have become more sophisticated and inert gases harder 
to obtain for environmental reasons, nitrogen washouts are again being favoured, and most of the 
next generation of MBW equipment use this method. 
 
1.6.3 Lung Clearance Index (LCI) 
Lung clearance index (LCI) was first reported in 1950s and has probably enjoyed the strongest 
renewed interest since the MBW became popular in the 1990s (Robinson, Goldman & Gustafsson, 
2009).  Calculation is covered in more detail in 2.2.2 but it is essentially the number of volume 
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turnovers (TO) taken to reduce the tracer gas concentration down to 1/40th of its starting 
concentration.   
LCI has many appealing features as a non-invasive non-radiological monitoring tool in lung disease, 
particularly in paediatrics.  It is conceptually quite straightforward and both methodology and 
meaning can be explained to even quite young patients.  The MBW test is non-effort dependent and 
also very robust to any attempted manipulation; any non-tidal breathing or leaking of the test gas is 
readily detectable by the operator.  It gives information from peripheral/small airways, a notoriously 
silent zone (Gustafsson, 2007).  It has been shown to be abnormal in patients with mild lung disease, 
making it clinically useful in monitoring these patients longitudinally and assessing their response to 
interventions (Aurora et al., 2011), but also a potentially useful end point in clinical trials as an 
alternative to spirometry.  It is practical in a clinical setting, with testing times typically in the region 
of 30 minutes or less for most patients, and an analysis time of no more than one hour.  In 
comparison with some other specialised lung function tests it is also surprisingly economical; gases 
are readily available and it is rare for consumables for any one setup to cost any more than £5 per 
patient. 
“Recent work (Lum et al., 2012) shows that, in healthy children under six, there is an increase in LCI 
inversely correlating with body size, with smaller infants showing a higher upper limit of normal than 
that quoted for older age groups.  The authors acknowledge some of this could be methodological, 
related to the use of sedation, supine position, or the use of a facemask (with a larger deadspace) 
rather than a mouthpiece in these patients, but they also suggest that VI is more pronounced in 
younger children, suggesting more heterogeneous ventilation in the developing lung.  Verbanck and 
co-authors have also recently published work showing an increase in VI with increasing age in older 
adults, suggesting that the normal aging lung also shows more heterogeneous ventilation.  Both 
authors suggest equations which could correct for this factor, but these are likely specific to their 
45 
 
own methodology (mass spectrometer using SF6 and non-commercial nitrogen analyser 
respectively).” 
LCI is often quoted as a measure of distal airway function; this is slightly misleading as it is more 
accurately a “whole lung” measure.  Though the bulk of VI reflected by LCI may well be in the small 
airways, it can be influenced by VI in the proximal airways in some cases and so this should be 
considered in interpretation of LCI data. 
One possible drawback of LCI and similar indices is that an entirely occluded airway, or one with 
such a long time constant it cannot substantially contribute to the gas measured during the time 
frame of the test, will not affect the result.  It is therefore possible in patients with advanced 
obstructive lung disease, such as severe CF lung disease, will have an apparently erroneously “good” 
LCI result as so many areas of the lung are entirely non-communicating.  This should in theory be 
detected as a lower-than expected FRC measurement, but in practice this would involve previous 
FRC data for that patient being immediately available, which is rarely the case in clinical settings. 
1.6.4 Moment ratios 
Moment ratios (MR) are slightly more complex to visualise than some other parameters, but they 
are essentially the degree of skewed-ness of the MBW graph, i.e. how much gas (as a proportion) is 
released at the later stages of the washout compared with the earlier stages.  The mathematics are 
quite complex but in brief, the end tidal tracer gas concentration is normalised (so a starting value of 
say 4% is given the figure of 100) and these normalised values are plotted against volume, expressed 
as turnovers (TO) of functional residual capacity (FRC).  The area under the graph is then calculated 
as moment 0, moment 1 is calculated by multiplying the end tidal concentrations by TO, and 
moment 2 by TO2.  Results are expressed as moment 1/moment 0 and moment 2/moment 0, giving 
a weighed plot showing what proportion is released at alter stages of the washout (Robinson, 
Goldman & Gustafsson, 2009). 
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Figure 1-8 - Moment ratio analysis.  In this figure, taken from (Robinson, Goldman & Gustafsson, 
2009), the moment ratios of a healthy subject (a) and a child with obliterative bronchiolitis (b) are 
compared, showing normal vs. abnormal results.  The three plotted lines on each graph show CET 
(end tidal tracer gas concentration) vs. turnovers(area under graph = moment 0), CetxTO vs. TO (area 
under graph =moment 1) and CetxTOxTO (area under graph = moment 2).  A clear increase resulting 
from lung disease can be seen in plot (b) when these graphs are compared.  In this instance, the 
normal result (a) was 1.55, 3.41 (when expressed as moment 1/moment 0, moment 2/moment 0) 
and then in disease (b) 3.41, 24.12. 
MR has not been included in the work of this thesis largely as it is not commonly cited in the 
literature, so little comparison data are available.   It is not normally considered to add anything to 
MBW (Robinson, Goldman & Gustafsson, 2009) and the LCI is more commonly reported and 
conceptually easier to understand and so the focus of this thesis will be on that measure. 
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1.7 Literature review 
A great many studies both establishing MBW and tracking physiology in the relevant disease groups are available.  The tables below summarise key details 
from these papers according to the main theme to provide a concise framework for the discussion of this work below. 
Basic physiology studies  
Authors Year Title Reference Investigations Main findings 
Verbanck S et 
al 
1998 Conductive and acinar 
lung-zone contributions to 
ventilation inhomogeneity 
in COPD 
(Verbanck 
et al., 
1998) 
MBW, spirometry In a group of adult COPD patients, VI as detected during the LCI 
was partitioned into two components of phase III analysis to give 
measures at different zones of the distal airway, Scond and Sacin. 
Gustafsson, 
PM 
2003 Evaluation of ventilation 
maldistribution as an early 
indicator of lung disease in 
children with cystic 
fibrosis 
(Gustafsso
n, Aurora & 
Lindblad, 
2003) 
MBW, spirometry Showed ventilation inhomogeneity as measured by MBW in 
children with CF with normal spirometry, suggesting MBW is of 
greater value than spirometry when detecting early lung disease in 
this group. 
Aurora, P et al 2004 Multiple-breath washout 
as a marker of lung 
disease in preschool 
children with cystic 
fibrosis 
(Aurora et 
al., 2004) 
MBW, spirometry LCI is more frequently abnormal in CF than spirometry, and higher 
than healthy controls.  Healthy control data is consistent between 
laboratories and across the age range in school age children. 
Aurora, P et al 2005 Multiple-breath washout 
as a marker of lung 
disease in preschool 
children with cystic 
fibrosis 
(Aurora et 
al., 2005) 
MBW, 
spirometry, 
plethysmography 
LCI detected lung disease more readily than spirometry or 
plethysmography in school age children with CF; those with PA 
infection have a higher LCI than those without. 
Aurora, P et al 2005 Gas mixing efficiency from 
birth to adulthood 
(Aurora, 
Kozlowska 
MBW LCI is abnormal in infants and young children with lung disease of 
prematurity and CF.  Phase III parameters can be calculated from 
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measured by multiple-
breath washout 
& Stocks, 
2005) 
spontaneously breathing children during and MBW by controlling 
for breath volume. 
Kraemer R et 
al 
2005 Effects of cystic fibrosis 
lung disease on gas mixing 
indices derived from 
alveolar slope analysis 
(Kraemer 
et al., 
2005) 
MBW, 
spirometry, 
plethysmography  
In a large group of CF patients having yearly review throughout 
childhood, LCI is the earliest predictor of lung disease and provides 
a better functional progression than other measures. 
Lum S et al 2007 Early detection of cystic 
fibrosis lung disease: 
multiple-breath washout 
versus raised volume tests 
(Lum et al., 
2007) 
Raised lung 
volume rapid 
thoraco-
abdominal 
compression 
(RVRTC), MBW 
Both MBW and raised volume technique were required to detect 
early lung changes in infants with CF as opposed to controls. 
Gustafsson, 
PM 
2007 Peripheral airway 
involvement in CF and 
asthma compared by inert 
gas washout 
(Gustafsso
n, 2007) 
MBW LCI and phase III indexes are more abnormal in CF than asthma; 
they may improve significantly in asthma with bronchodilator, but 
not in CF. 
Horsley AR et 
al 
2008 Effects of cystic fibrosis 
lung disease on gas mixing 
indices derived from 
alveolar slope analysis 
(Horsley et 
al., 2008b) 
MBW In advanced CF lung disease, phase III measures may have their 
assumptions invalidated by the extent and severity of the 
ventilation inhomogeneity.  In such patients, LCI alone may make a 
better outcome measure. 
Fuchs SI, et al 2009 Lung clearance index: 
normal values, 
repeatability, and 
reproducibility in healthy 
children and adolescents 
(Fuchs et 
al., 2009) 
MBW Short and long term reproducibility of LCI is demonstrated (4.2% 
and 5.2% respectively) in a healthy control group of children and 
young people, using an ultrasonic gas analyser. 
Aurora, P et al 2011 Lung clearance index at 4 
years predicts subsequent 
lung function in children 
with cystic fibrosis 
(Aurora et 
al., 2011) 
MBW, spirometry In CF, abnormal LCI at preschool age is a better predictor of school 
age lung function than spirometry. 
Kieninger E et 
al 
2011 Effects of cystic fibrosis 
lung disease on gas mixing 
indices derived from 
(Kieninger 
et al., 
2011) 
MBW There is some longitudinal tracking of LCI results from infancy into 
childhood in a small group of children with CF.  
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alveolar slope analysis 
Lum S et al 2012 Age and height 
dependence of lung 
clearance index and 
functional residual 
capacity 
(Lum et al., 
2012) 
MBW LCI is independent of age and body size in normal children over six 
years of age, but in younger children there is a size-dependent 
change in the upper and lower limits of normality, and so reference 
equations should be used.  This paper proposes equations for use 
with mass spectrometry SF6 washouts.  
Verbanck S et 
al 
2012 Relationships between the 
lung clearance index and 
conductive and acinar 
ventilation heterogeneity 
(Verbanck 
et al., 
2012) 
MBW Using a combination of provocation challenges and bronchodilators 
in normal and asthmatic subjects, LCI and phase III parameters are 
shown to be sensitive to small airways disease, but may also 
increase as a result of more proximal ventilation heterogeneities.  
Horsley AR et 
al 
2013 Changes in physiological, 
functional and structural 
markers of cystic fibrosis 
lung disease with 
treatment of a pulmonary 
exacerbation 
(Horsley et 
al., 2013) 
MBW, 
spirometry, 
biochemical 
assay, HRCT 
LCI, alongside other established and more novel biomarkers, is 
sensitive to pulmonary exacerbation changes in teenagers and 
adults with CF and therefore may be an acceptable biomarker for 
use in further clinical trials as an outcome measure. 
Nguyen TT et 
al 
2014 Evolution of lung function 
during the first year of life 
in newborn screened 
cystic fibrosis infants 
(Nguyen et 
al., 2013) 
MBW, spirometry LCI is stable in the first year of life in 80% NBS infants with CF, 
though still higher than normal controls. 
Vermeulen et 
al 
2014 Lung clearance index 
predicts pulmonary 
exacerbations in young 
patients with cystic 
fibrosis 
(Vermeulen 
et al., 
2014) 
MBW, spirometry LCI is predictive of pulmonary exacerbation in patients with CF, and 
is also correlated to quality of life measures.  This is also true in a 
subgroup of patients who have normal spirometry, suggesting it 
may be of particular value in these patients. 
Table 1-2 Basic physiology studies.  These studies show the emergence and development of LCI as a useful and robust monitoring tool, particularly in CF lung 
disease.  The most recent studies confirm its suitability for use as an outcome measure in multicentre research studies also.  Studies of PCD lung function are 
rare, but they show a worsening of lung disease over time but overall a less severe picture than found in CF.   
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The majority of MBW work to date has been exploring its use in CF, particularly in paediatrics.  The 
early work by Gustafsson and colleagues (Gustafsson et al., 2008; Gustafsson, 2007; Gustafsson, 
Aurora & Lindblad, 2003) identified LCI as an MBW-derived measure of interest and established a 
possible clinical utility in CF children.  Early CF lung damage, particularly of the small airways, had 
long been suspected by clinicians, but had proved difficult to identify and measure in a non-invasive 
and non-radiological way and conventional spirometry, even in children old enough to perform it 
well, was insensitive to these changes.  Gustafsson’s work involved large cohorts and well 
established control populations, and made a strong case for the utility of MBW in general and LCI in 
particular in this patient group.  Overall, the work served to both identify that there was a need for a 
test of lung function in these populations, by convincingly demonstrating (potentially preventable) 
lung disease in his young, “mild” patients, and to make the case for ventilation inhomogeneity 
measures as a good candidate test for these purposes. 
At a similar time but in a very different patient group, Sylvia Verbanck’s work (Verbanck et al., 1998) 
established the mathematics of phase III analysis and first used the indices of Scond and Sacin to 
partition ventilation inhomogeneity (this will be discussed in more detail in section 4.2 and 4.3).  Her 
adult patients with COPD and asthma could perform non-tidal MBWs as required, breathing 
consistent volumes of 1 litre.  This obviously violated the assumptions of the tidal MBW required for 
LCI calculation, and so her work does not include this index, instead concentrating on the phase III 
development.  For paediatric work, however, and to allow the LCI to be calculated alongside phase 
III, the method required some adaptation by Aurora and colleagues (Aurora, Kozlowska & Stocks, 
2005) to be feasible in a wider patient group.  Building on earlier work, they normalised each 
measured phase III slope by the tidal volume on that breath, producing both phase III and LCI data 
from the same tidal washout in children.  This work was essential in allowing phase III to be used as a 
viable measure in paediatrics. 
51 
 
Despite its widespread use since this development, some problems in implementation of phase III 
measures emerged.  Horsley and colleagues (Horsley et al., 2008b) showed that in patients with 
advanced CF, the Scond measure can reach an asymptote, and as this is used for calculating Sacin, this 
renders both values meaningless, strongly suggesting this measure may be of most use in patients 
with mild disease, or with conditions causing less substantial structural changes, such as asthma. 
Recently, Verbanck (Verbanck et al., 2012) also returned to the measure to explore the relationship 
between LCI and phase III measures.  In an asthmatic group, she showed that a raised LCI correlated 
with raised Scond and Sacin.  However, histamine provocation tests in normal healthy subjects led to a 
raised LCI that correlated with a raised Scond, but in this case neither measure correlated with Sacin at 
all.  From this, she concluded that a raised LCI result can indicate extremely distal VI (as shown by 
her asthmatic subjects) but it can also result solely from a much more proximal VI (as in her control 
patients with raised Scond and LCI but not Sacin).  For this reason, she concluded that an abnormal LCI 
result should not be taken to automatically demonstrate VI in the acinar reason as it may result from 
more proximal disease process. 
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Equipment verification studies 
Authors Year Title Reference Investigations Main findings 
Fuchs SI, et al 2006 Multiple breath washout 
with a sidestream 
ultrasonic flow sensor and 
mass spectrometry: a 
comparative study 
(Fuchs et 
al., 2006)l. 
MBW A novel ultrasonic sidestream gas analyser provides similar results 
to a mass spectrometer for MBW.  
Fuchs SI et al 2008 A novel sidestream 
ultrasonic flow sensor for 
multiple breath washout 
in children 
(Fuchs et 
al., 2008) 
MBW, spirometry MBW performed with ultrasonic gas analyser in 26 CF patients and 
22 healthy controls gives comparable results to tests with a mass 
spectrometer; LCI is more commonly elevated in subjects with CF 
than spirometry. 
Horsley AR et 
al 
2008 Lung clearance index is a 
sensitive, repeatable and 
practical measure of 
airways disease in adults 
with cystic fibrosis 
(Horsley et 
al., 2008a) 
MBW, spirometry A photoacoustic gas analyser can be modified for MBW as an 
alternative to mass spectrometry, LCI is more frequently abnormal 
than spirometry in adults with CF and is therefore a more sensitive 
marker. 
Fuchs SI, et al 2011 Feasibility and Variability 
of Measuring the Lung 
Clearance Index in a Multi-
Center Setting 
 (Fuchs et 
al., 2011) 
MBW MBW measurements in CF subjects were performed at 8 centres 
using an ultrasonic gas analyser, results were comparable between 
centres. 
Pittman JE et 
al 
2012 Variability of a closed, 
rebreathing setup for 
multiple breath wash-out 
testing in children 
(Pittman et 
al., 2012) 
MBW A closed-system MBW circuit performed extremely poorly on an 
initial test in CF patients, leading to hypercapnia and instability of 
tidal volume.  Considerable further work is needed before systems 
of this type are feasible. 
Singer F et al 2012 A realistic validation study 
of a new nitrogen 
multiple-breath washout 
(Singer et 
al., 2012) 
MBW In vivo and lung model tests of a new nitrogen washout MBW using 
a nitrogen analyser is described, and delivers reproducible results. 
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system 
Gonem S et al 2014 Validation of a 
photoacoustic gas 
analyser for the 
measurement of 
functional residual 
capacity using multiple-
breath inert gas washout. 
(Gonem et 
al., 2014b) 
MBW Validation of the modified photoacoustic analyser as an MBW tool 
using an established lung model. 
Horsely A et 
al 
2014 Enhanced photoacoustic 
gas analyser response 
time and impact on 
accuracy at fast ventilation 
rates during multiple 
breath washout 
(Horsley et 
al., 2014) 
MBW Validation of a further modified photoacoustic analyser for the 
assessment of MBW, using a lung model that reflects the 
respiratory characteristics of young children. 
 
Table 1-3 Equipment verification studies.  These studies chart the development of several methodologies for MBW building on the original work with mass 
spectrometers, including using photoacoustic, ultrasonic and nitrogen analysers. 
54 
 
There are a few papers which are methodological validations of different potential analysers for use 
in MBW.  The most extensively tested of these is (Fuchs et al., 2011; Fuchs et al., 2008; Fuchs et al., 
2006) the ultrasonic gas analyser method, which performed well with very little variation between 
gas signals registered by the ultrasonic analyser and the mass spectrometer in a “sidestream” 
comparison (where a single MBW was conducted with a single flowmeter, but two sample lines were 
used with one outputting to the mass spectrometer, and the other to the photoacoustic analyser).  It 
was then trialled again in standalone form with its own pneumotach and flow measurement, and 
again for robustness and practicality in a multicentre test.  It was not used for the work of this thesis 
as it remained a prototype only in the developing laboratory until the later part of 2011, despite its 
initial testing phase beginning in 2006.  The method using a photoacoustic analyser, as used in this 
thesis, was used by colleagues working for the UK CF gene therapy consortium (Horsley et al., 2008a) 
in 2008 but was made available to us in July 2007.  This method has also been tested in more recent 
lung model work (Gonem et al., 2014b; Horsley et al., 2014).  
Most methodologies have produced comparable, though not identical, values compared with the 
gold standard mass spectrometry method.  The additional newer methodologies and their 
comparisons are covered in more detail in 7.6.4, as the majority of commercial systems were 
released after the work of this thesis. 
55 
 
Interventional studies 
Authors Year Title Reference Investigations Main findings 
Gustafsson, 
PM 
2007 Peripheral airway 
involvement in CF and 
asthma compared by inert 
gas washout 
(Gustafsso
n, 2007) 
MBW LCI and phase III indexes are more abnormal in CF than asthma; 
they may improve significantly in asthma with bronchodilator, but 
not in CF. 
Robinson PD 
et al 
2009 Using index of ventilation 
to assess response to 
treatment for acute 
pulmonary exacerbation in 
children with cystic 
fibrosis 
(Robinson 
et al., 
2009) 
MBW, 
spirometry, 
plethysmography, 
exercise testing 
LCI and exercise testing improved in a group of older children and 
teenagers with CF, after being treated with intravenous antibiotics 
for an exacerbation, but there was a considerable heterogeneity of 
response. 
Amin, R 2010 Hypertonic saline 
improves the LCI in 
paediatric patients with CF 
with normal lung function 
(Amin et 
al., 2010) 
MBW, spirometry LCI, but not spirometry, improved with hypertonic saline treatment 
as opposed to a control of isotonic saline, suggesting it is sensitive 
to mild improvement. 
Fuchs SI et al 2010 Short-term effect of 
physiotherapy on 
variability of the lung 
clearance index in children 
with cystic fibrosis 
(Fuchs et 
al., 2010) 
MBW There is no difference in reproducibility of LCI results in CF patients 
at 30 minute interval depending on if a chest physiotherapy session 
is undertaken between the two, or not.  Repeatability of LCI is 
lower in CF than in controls, probably due to variable gas trapping, 
but is also not affected by physiotherapy. 
Amin, R et al 2011 The effect of dornase alfa 
on ventilation 
inhomogeneity in patients 
with cystic fibrosis 
(Amin et 
al., 2011) 
MBW, spirometry LCI and spirometry improved with dornase alpha treatment as 
opposed to a placebo. 
Subbarao et 
al 
2013 Lung Clearance Index as 
an Outcome Measure for 
Clinical Trials in Young 
Children with 
Cystic Fibrosis: A Pilot 
(Subbarao 
et al., 
2013) 
MBW Infants and young children with CF entered a double-blind placebo 
trial of hypertonic vs. isotonic saline, with LCI as an outcome 
measure to access its effectiveness.  Those treated with saline 
improved their LCI over a 48 week testing period, in those with 
isotonic saline LCI remained stable.  The measurement was feasible 
56 
 
Study using Inhaled 
Hypertonic Saline. 
in 93% on children enrolled on the study, suggesting LCI has a 
utility as an outcome measure in this patient group. 
Horsley AR et 
al 
2013 Changes in physiological, 
functional and structural 
markers of cystic fibrosis 
lung disease with 
treatment of a pulmonary 
exacerbation 
(Horsley et 
al., 2013) 
MBW, 
spirometry, 
biochemical 
assay, HRCT 
LCI, alongside other established and more novel biomarkers, is 
sensitive to pulmonary exacerbation changes in teenagers and 
adults with CF and therefore may be an acceptable biomarker for 
use in further clinical trials as an outcome measure. 
Davies, JC et 
al 
2013 Assessment of clinical 
response to ivacaftor with 
lung clearance index in 
cystic fibrosis patients 
with a G551D-CFTR 
mutation and preserved 
spirometry: a randomised 
controlled trial. 
(Davies et 
al., 2013) 
MBW, spirometry LCI improved in patients taking the novel CF medication Ivacaftor.  
This improvement was seen in patients with normal spirometry 
throughout, suggesting LCI may be a more sensitive end point in 
patients such as these. 
 
Table 1-4 Interventional studies.  This shows a development in the use of LCI as an outcome measure in recent years, particularly in CF, showing its response 
to a variety of treatments. 
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More recent papers cover the use of MBW in general and LCI in particular as a possible tool for long 
term clinical modelling and a possible outcome measure for clinical trials.  In two papers, Amin and 
colleagues (Amin et al., 2011; Amin et al., 2010) showed LCI made a good outcome marker in short 
term hypertonic saline and dornase alpha trials in CF patients, and other studies have shown good 
responses of LCI to treatment of a pulmonary exacerbation in CF (Robinson et al., 2009) and 
response to steroids in asthma (Gustafsson, 2007).  The most extensive of these studies was the 
large cohort CF studied by Horsley and colleagues (Horsley et al., 2013), who examined a group of 
older children and adults recovering from a physician-diagnosed CF respiratory exacerbation.  LCI 
was significantly improved on recovery from the exacerbation, alongside other key biomarkers of 
inflammation, physiology measures and imaging parameters.  Also, a study of inhaled hypertonic 
(7%) vs., isotonic (0.9%) saline treatment in young children (less than 6 years old) (the ISIS study) 
showed an effect in a pharmacological intervention sub-study, with LCI adjusted for body size  
significantly improving in those treated with the hypertonic saline(Subbarao et al., 2013).  These 
studies suggested strongly that LCI was a good candidate for use as an outcome measure both 
clinically and in research studies. 
Clinically important differences for LCI remain unclear, even in CF which is best studied in the 
literature, but the treatment effects seen in these studies give values of 1 to 1.5 units with proven 
interventions, for instance intravenous antibiotics (Horsley et al., 2013) , and so this seems a 
plausible estimate of a clinically important difference in CF patients.”  Fuchs and colleagues (Fuchs et 
al., 2010) demonstrated that a physiotherapy session did not affect either the actual LCI result, or 
the degree of variability. 
Anecdotally, it was reported from several centres that LCI in healthy young babies and children 
seemed somewhat higher than would be expected.  A large study (Lum et al., 2012) demonstrated 
that in preschool children there was a negative correlation between body size and LCI, probably 
relating to the difference in ventilation in the normal developing lung in early life, as opposed to the 
58 
 
more stable phase in later childhood and adulthood.  This effect is seen in children up to age 6.  An 
important point to note is that this study does not negate previous findings of an elevated LCI in 
young children with CF by this group – in those studies a contemporaneously recruited control group 
of normal children was used for comparison. 
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HRCT studies 
Authors Year Title Reference Investigations Main findings 
Gustafsson 
PM et al 
2008 Multiple-breath inert gas 
washout and spirometry 
versus structural lung 
disease in cystic fibrosis 
(Gustafsso
n et al., 
2008) 
MBW, 
spirometry, HRCT 
In children with CF, LCI is a more sensitive and specific test for the 
presence of HRCT abnormality than any spirometry parameter, a 
normal LCI almost excludes an abnormal HRCT.  Normal HRCT in 
the presence of abnormal LCI in some patients suggests LCI may be 
even more sensitive to early disease changes in CF. 
Ellemunter et 
al 
2010 Sensitivity of lung 
clearance index and chest 
computed tomography in 
early CF lung disease 
(Ellemunter 
et al., 
2010) 
MBW, 
spirometry, HRCT 
In children and young people with CF, LCI is a better predictor of 
HRCT abnormality than spirometry, and structural changes are 
unlikely in the absence of raised LCI. 
Owens CM et 
al 
2011 Lung Clearance Index and 
HRCT are complementary 
markers of lung 
abnormalities in young 
children with CF 
(Owens et 
al., 2011) 
MBW, 
spirometry, HRCT, 
plethysmography 
In children with CF, LCI has a better correlation with HRCT scoring 
than any other lung function measure. However, some patients 
with normal LCI have abnormal HRCT, and some with normal HRCT 
have abnormal LCI, so the two investigations reveal complimentary 
rather than identical information.  Radiation dose may be lowered 
in this group as a whole by only performing HRCT in those with 
normal LCI. 
Horsley AR et 
al 
2013 Changes in physiological, 
functional and structural 
markers of cystic fibrosis 
lung disease with 
treatment of a pulmonary 
exacerbation 
(Horsley et 
al., 2013) 
MBW, 
spirometry, 
biochemical 
assay, HRCT 
LCI, alongside other established and more novel biomarkers, is 
sensitive to pulmonary exacerbation changes in teenagers and 
adults with CF and therefore may be an acceptable biomarker for 
use in further clinical trials as an outcome measure. 
Fuchs S et al 2014 Tracking Lung Clearance 
Index and chest CT in mild 
cystic fibrosis lung disease 
over a period of three 
years 
(Fuchs et 
al., 2014) 
MBW, 
spirometry, HRCT 
Over 4 years, LCI is a correlates better with tracked changes on 
HRCT scan than spirometry, and also has a better prognostic value 
(86%) for abnormal HRCTs in later years than spirometry. 
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Table 1-5 HRCT studies.  These studies show a development of the view of HRCT and LCI, from initial evidence suggesting they gave identical information to 
more recent studies suggesting they give similar and complementary but not identical information.  In PCD a small number of studies show lung disease as 
seen on HRCT, that may track with spirometry measures. 
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The relationship between MBW and HRCT scanning in CF has also been studied.  HRCT is known to 
be a sensitive modality for detecting early lung disease, and comprehensive scoring systems have 
allowed the results to be scored quantitatively {{170 Brody,A.S. 2004; 171 Brody,A.S. 2006}}.  
Concern remained about radiation dose, even with modern scanners and well developed low-dose 
protocols.   Gustafsson and co-workers investigated the correlation between HRCT and LCI initially in 
CF, and found good agreement between the two, with high LCIs correlating particularly strongly with 
bronchiectasis.  In the majority of patients, both LCI and HRCT were abnormal, even in the presence 
of normal spirometry.  In 6/27 patients, LCI was abnormal but HRCT remained normal.  From this, 
the authors drew several conclusions.  Firstly, that pathology as shown on HRCT (such as 
bronchiectasis) had a large effect on LCI.  Secondly, that LCI became abnormal before HRCT 
pathology was visible, giving rise to patients with normal HRCT in the presence of abnormal LCI, and 
thirdly that LCI accurately identified HRCT pathology and a normal LCI “almost excluded” HRCT 
abnormalities.  A further study (Ellemunter et al., 2010) reinforced these conclusions, showing an 
88% sensitivity of LCI to HRCT abnormalities, from which the authors also concluded that normal LCI 
made structural changes on HRCT unlikely . 
Owens and colleagues (Owens et al., 2011) completed a large study of CF children who underwent 
HRCT and MBW on the same day (previous studies had only looked at the nearest clinically indicated 
HRCT to their MBW measurement, sometimes leaving a gap of months between the two 
investigations).  Key findings included that very few of their patients (even in the presence of normal 
spirometry) had normal HRCT or LCI, and that in agreement with previous data LCI was much more 
sensitive to HRCT abnormalities that spirometry.   Crucially, however, they were able to show in their 
cohort that 5/53 of their patients had abnormal HRCT despite a normal LCI.  They proposed that (in a 
small but important change to Gustafsson’s finding that normal LCI “almost excludes” abnormal 
HRCT as the two showed such similar information) the two measures instead showed different but 
complimentary and overlapping information, and rather than a normal LCI being taken as an 
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indicator of no CF lung disease, instead only those children with a normal LCI should proceed to 
HRCT scanning, as only if both modalities were normal could a clinician say with any confidence that 
the child did not show CF lung disease.  They recommended that it is unnecessary to scan a child 
with an abnormal LCI as it is likely they will have HRCT changes, and even if they do not they are still 
showing evidence of lung damage that should be treated as CF lung disease.  This proposal, if 
adopted would drastically reduce the radiation exposure and fiscal costs of monitoring such children. 
Overall, despite Owen’s work highlighting the existence of a small group with normal LCI but HRCT 
changes, in older children with CF, particularly those with abnormal HRCT and LCI, the studies agree 
the modalities correlate well with each other as CF lung disease becomes more severe.  
Recently, Fuchs and co-workers have published a four year tracking study of LCI and HRCT in 36 
paediatric and adult CF patients.  In it, they showed what the other papers had demonstrated in 
isolation, that LCI was a better predictor of HRCT abnormalities than spirometry in these patients, 
but also that LCI in year one had a predictive value of 86% for HRCT abnormalities in year four, 
compared with less than 20% for FEV1.  This confirms LCIs potential as a tracking measure of long 
term clinical progress in these patients. 
In addition to the original research, several review articles (Kent et al., 2014; Horsley, 2009; 
Robinson, Goldman & Gustafsson, 2009; Gustafsson, 2005) have helped raise awareness of these 
measures and set out a broad overview for potential developments and challenges, but it is only 
recently that a formal consensus statement endorsed by the ATS and ERS has been published  
(Robinson et al., 2013). 
This statement was published after the bulk of the work of this thesis had been done (March 2013), 
and so its recommendations could not be implemented into the methodology.   It covers several 
important areas to the future development of this measure, however, and a broad summary of the 
existing literature.  It acknowledged that no one system would ever likely meet all the foreseeable 
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needs of testing in all patient groups, whilst at the same time establishing requirements for any new 
commercial system seeking validation and making key recommendations for the use of these 
systems in potential clinical practice. 
The manuscript presents several tables covering quality control, software functionality, analyser 
technical data and measurement acceptability criteria, to allow both manufacturers and centres to 
in future produce equipment and results to standardised criteria, which will represent a necessary 
and extremely important step forward. 
However, and acknowledged by the authors, there are some areas where there is little research to 
draw upon and recommendations have been made solely on the basis of expert opinion rather than 
experimental data, specifically some technical recommendations on analyser performance.  This is 
obviously far from ideal, as several previously used research systems do fall outside some of these 
values and no clear explanation is given for why these data would not be deemed acceptable.  Also, 
by the very nature of judgements made on expert opinion, some of the figures given are somewhat 
arbitrary and some of the details as to how they may be improved or compensated for rather vague, 
as there is as yet no empirical evidence to better inform them.  This is clearly stated by the authors, 
and updates to this work when such information becomes available recommended by them, but it 
does put the onus on manufacturers or researchers using equipment that falls outside the 
recommendations to defend this.  
The manuscript also covers the increasing use of nitrogen washouts, as SF6 is becoming difficult to 
source due to environmental concerns. The advantage of nitrogen washouts (affordability, 
availability, shorter test time, and resident nitrogen achieving a better “wash in” than any 
introduced gas likely could to obstructed lung units) are highlighted, along with potential 
disadvantages (effect of 100% oxygen breathing on breathing pattern, unknown interactions with 
sleep and sedation, and that nitrogen is not truly inert and may diffuse into alveoli from the blood).  
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However, it is recommended that attempts to estimate tissue nitrogen and correct for it are not as 
yet made, as there is limited data available to base this on.   
Finally, in the supplementary material a comparison of established and proposed MBW systems, and 
how closely they adhere to the guidelines, is made.  The above issues, including the development of 
new systems and their suitability for measurement is covered in 7.6.4, in the final chapter of this 
thesis.  
The methodology used in this thesis, the modified Innocor with open-circuit wash in method, is 
discussed in the guidelines.  All the parameters of this machine (when used in this manner – this is 
not the closed circuit method as tested by Pittman and colleagues (Pittman et al., 2012), that 
produced very different results) are within the recommendations of the guidelines with two 
exceptions.  The rise time as given in the paper for the method is 154ms. Since the publication my 
experiments suggest (2.3.1) that a lower rise time of just under the required 100ms has been 
achieved, which is an improvement on the minimum requirement.  The second deviation from the 
guidelines is that the sample flow rate should be considerably lower than it currently is (around 20ml 
per minute as compared to 120ml/min found in practice in the Innocor).  This parameter is slightly 
more problematic to address.  The number of 20ml/min is based exclusively on expert opinion, 
without any empirical data to inform it and has not been published previously, and so prior to the 
statement it was not possible to make an estimation of what the decision about sampling rate would 
be and what any methodology should be aiming to achieve.  Also, the authors themselves suggest 
this is an “uncorrected” number, and that higher flows may be acceptable if such a correction is 
made; the Innocor methodology does correct for this lost gas but no mention of this is made in the 
consensus statement either to acknowledge such a correction is performed or suggest if it is 
adequate.   With this in mind, the results generated by this thesis for normal data have been 
compared with published material (3.1) to confirm if the equipment corrections have been adequate 
or if any inconsistencies with other methodologies exist. 
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PCD studies 
Authors Year Title Reference Investigations Main findings 
Ellerman et al 1997 Longitudinal study of lung 
function in a cohort of 
primary ciliary dyskinesia 
(Ellerman 
& Bisgaard, 
1997) 
Spirometry Lung function as measured by spirometry is stable over time in 24 
PCD patients, though worse in those diagnosed in adulthood as 
opposed to childhood. 
Noone et al 2004 Primary ciliary dyskinesia,: 
diagnostic and phenotypic 
features 
(Noone et 
al., 2004) 
Spirometry As well as a detailed overview of the PCD phenotype, lung function 
data is presented showing a spectrum of lung disease amongst 
patients with PCD, and a decline in lung function over time, though 
not as steep as that seen in CF patients. 
Jain et al 2007 Primary ciliary dyskinesia 
in the paediatric 
population: range and 
severity of radiological 
findings in a cohort of 
patients receiving 
tertiary care 
(Jain et al., 
2007) 
HRCT HRCT study in PCD, showing bronchiectasis and peribronchial 
thickening radiological features in this group, with lower zones 
most severely affected.  The authors conclude that scoring systems 
designed for CF are usable in this group. 
Santamaria F 
et al 
2008 Structural and functional 
lung disease in primary 
ciliary dyskinesia 
(Santamari
a et al., 
2008) 
Spirometry, HRCT Spirometry results correlate with HRCT scores in PCD; PCD HRCT 
scores are less severe than a comparable CF group. 
Marthin JK et 
al 
2010 Lung function in patients 
with primary ciliary 
dyskinesia: a cross-
sectional and 3-decade 
longitudinal study 
(Marthin et 
al., 2010) 
Spirometry In a large cohort of adults and children with PCD, lung function as 
measured by spirometry can be abnormal even in young children, 
and progression of lung function over a period of time is variable 
regardless of age at diagnosis. 
Green K et al 2012 Ventilation inhomogeneity 
in children with primary 
ciliary dyskinesia 
(Green et 
al., 2012) 
MBW, spirometry LCI is more often abnormal than spirometry in PCD; phase III 
indexes are also raised.  LCI and spirometry parameters do not 
correlate in PCD. 
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Irving S et al 2013 Lung clearance index and 
high-resolution computed 
tomography scores in 
primary ciliary dyskinesia. 
(Irving et 
al., 2013) 
MBW, 
spirometry, HRCT 
LCI and FEV1 do not correlate in PCD, and neither correlate with 
HRCT parameters.  Includes the work of this thesis. 
 
Table 1-6 PCD studies.  Studies examining lung function show a spectrum of lung disease resulting from PCD, but with less steep declines over time than in 
CF.  HRCT studies show less severe lung damage than is seen in CF patients, and a broad tracking of HRCT and lung function parameters.  One study showing 
MBW parameters and spirometry shows a lack of the relationship between these that is seen in CF, which corresponds with the pilot data of this thesis.
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As reflects a much rarer condition, there is very little PCD literature to draw on in terms of 
physiology and HRCT, and only one paper on MBW.   
The biggest study of spirometry (Marthin et al., 2010) suggests a variable course in PCD, with 28/74 
exhibiting a sharp (>10 percentage points) decline in lung function over time whereas the other 
patients demonstrate stability over the same time period.  Work by Noone and colleagues suggests 
(Noone et al., 2004), that although a decline in lung function is seen over time, this decline is not as 
steep as that seen in CF patients, in keeping with the perception of PCD as a more mild disease.  
Despite this, both of those studies show some individuals with severe lung disease as a result of their 
PCD, requiring intensive treatment.   
It is also known from anecdotal report and isolated case studies that in severe disease lung 
transplantation may be necessary (Skeik & Jabr, 2011; Date et al., 2001; Macchiarini et al., 1994)  
Studies of HRCT in PCD show that HRCT scores are lower in PCD than in CF, with less severe lung 
damage for matched cohorts.   Only one study (Santamaria et al., 2008) compared lung function 
(spirometry) with HRCT scores and showed a correlation between spirometry and the global score of 
HRCT as used, implying that spirometry can reflect the severity of HRCT abnormalities in these 
patients.  This study, however, had more paediatric than adult patients and (though no figures for 
spirometry are given in the data other than when plotted against HRCT findings) appear to be a fairly 
mild cohort so extrapolating this to advanced PCD lung disease may not be appropriate.  
The paper on LCI and spirometry in PCD published during the work of this thesis (Green et al., 2012) 
showed abnormal LCI and phase III parameters, implying that (in some cases quite extensive) VI 
results from PCD lung disease.  Confirming the pilot data of this thesis, they also found a lack of any 
relationship between LCI and spirometry, in contrast to CF.  The authors propose this results from 
extensive peripheral disease (as highlighted by MBW parameters) with an absence of more proximal 
disease (as would be shown from spirometry), resulting in more patients with abnormal LCI and 
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normal spirometry than would be seen in any CF cohort.  The authors did show a higher incidence of 
abnormal LCI than spirometry in PCD patients and from that concluded it remains a potentially more 
sensitive marker of lung disease than spirometry in this patient group.    
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Non-CF bronchiectasis studies 
Authors Year Title Reference Investigations Main findings 
Twiss et al 2006 Longitudinal pulmonary 
function of childhood 
bronchiectasis and 
comparison with cystic 
fibrosis 
(Twiss, 
Stewart & 
Byrnes, 
2006) 
Spirometry 44 children with non-CF bronchiectasis showed a decline in FEV1 
over a 5 year follow-up period.  This decline was more pronounced 
in children with post-infective bronchiectasis and those chronically 
infected with Haemophilus influenza. 
Bastardo et al 2009 Non-cystic fibrosis 
bronchiectasis in 
childhood: 
longitudinal growth and 
lung function 
(Bastardo 
et al., 
2009) 
Spirometry During follow up over 4 years, a cohort of 59 children with non-CF 
bronchiectasis showed stability but no improvement in their 
spirometry findings.  Height for age improved over this time but no 
other anthropometric parameters.  
Kapur et al  2010 Longitudinal Growth and 
Lung Function 
in Pediatric Non-Cystic 
Fibrosis 
Bronchiectasis 
(Kapur, 
Masters & 
Chang, 
2010) 
Spirometry During follow up over a 3 or 5 year period, 52 children with non-CF 
bronchiectasis showed overall stability in lung function and 
anthropometric findings, but no improvement.  Also, lower 
baseline FEV1 and frequent exacerbations may be associated with a 
decline in FEV1. 
 
Table 1-7 Non-CF bronchiectasis studies.  Though a rare group of mixed aetiology limits the number of studies in this group, these two papers show 
spirometry data over time in these cohorts.  Though lung function appears to stabilise in these patients once treated, it does not return to normal values.
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In non-CF bronchiectasis there are few studies on relevant physiological markers, but the 
two available suggest that lung function remains stable over time with correct treatment 
and management, but does not improve back to normal levels, suggesting these children will 
have long term lung impairment.  One study suggests that low baseline results and frequent 
exacerbations are potential predictors for a fall in spirometric parameters over time 
suggesting in some severe cases a worsening of disease despite treatment may occur. 
In summary, the physiological relationships between different parameters in CF, PCD, and 
non-CF bronchiectasis are not uniform. All these diseases are characterised by neutrophilic 
airway inflammation, chronic infection and bronchiectasis, but the underlying 
pathophysiology is different. PCD is characterised by primary MCC impairment, but with 
probably minimal evidence of CFTR dysfunction; CF by CFTR dysfunction and secondary MCC 
impairment; and non-CF bronchiectasis also by secondary MCC impairment, but probably 
minimal CFTR dysfunction. The work of this thesis will build on these results and my original 
observations which led to the thesis proposal to try to better explain this disconnect 
between MBW and spirometry seen in PCD, as opposed to in CF. These different airway 
diseases will allow me to attempt to relate the physiological differences to the effects of 
primary vs. secondary MCC impairment, and normal and abnormal CFTR function. The 
different prognoses of these diseases means that a better understanding of these 
differences may lead to novel avenues of therapy. 
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1.8 Hypotheses of this thesis 
Hypothesis 1 – “the different relationship found in a pilot study between LCI and spirometry 
seen in PCD compared with CF is related to differences in the fundamental pathophysiology 
of the two diseases, rather than to the milder clinical course of PCD as against CF”. 
Hypothesis 2 – “the different relationship between LCI and spirometry seen in PCD 
compared with CF is related to differences in distal airway structure and inflammation 
between the two diseases”. 
72 
 
1.9 Aims of thesis 
1) To confirm the original observation of a different relationship between LCI and spirometry 
between PCD and CF in a larger cohort of patients. 
2) To explore the relationship between LCI and spirometry in a control group with non-CF, 
non-PCD bronchiectasis as a further model of secondary ciliary dyskinesia. 
3) To use sophisticated phase 3 and other MBW analyses further to explore the physiological 
similarities and differences in the airway disease of CF, PCD, and non-CF bronchiectasis. 
4) To determine similarities and differences in structural lung disease in PCD and CF, and a 
non-CF bronchiectasis control group, with specific attention to the relationships between 
proximal and distal disease. 
5) To explore differences in airway inflammation between these groups and relate these to 
structure and function. 
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1.10 Objectives of thesis 
1) To measure LCI and spirometry in a large group of CF, PCD, and non-CF 
bronchiectasis patients, and relate the data to normal controls 
2) To obtain HRCT scans on patients with CF, PCD, and non-CF bronchiectasis, and have 
them scored objectively by independent radiologists, and relate them to the physiological 
parameters LCI and spirometry 
3)      To compare Scond, Sacin and curvilinearity in patients with CF, PCD and non-CF 
bronchiectasis 
4) To assess airway inflammation in patients CF, PCD, and non-CF bronchiectasis, using 
exhaled nitric oxide, blood and induced or spontaneously expectorated sputum, and relate 
these to the physiological parameters LCI and spirometry. 
The next chapter contains the main physiology methods used to address these aims and 
objectives.
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Chapter Two – Methods 
 
2.1 Patients and recruitment 
Ethical approval for the tests undertaken in this thesis was obtained and all subjects 
recruited gave informed consent (assent for paediatric patients) to the procedures.  If 
research tests had already been requested for clinical reasons, only the one test was 
performed and the results used for both purposes, to prevent patients having to perform 
procedures twice.  In some cases (in particular HRCT scans) no ethical approval was sought, 
and in these cases only clinically acquired data was used.  Where this has happened it is 
indicated in the relevant Results section (Chapters 3-6). 
In most cases patients were recruited by me specifically for the work of this thesis.  There 
are some exceptions to this, particularly for the adult patients, but where this has occurred it 
is also clearly indicated in the relevant sections. 
All patients with lung disease were recruited via the wards and clinics of the Royal Brompton 
Hospital in the period 2009 to 2012.  All healthy control subjects were recruited through 
personal and staff contacts, and a small number as friends or family of patients already 
recruited. 
CF patients were diagnosed on standard criteria for this group (a positive result on new born 
screening followed by a clearly abnormal sweat test, or if diagnosis is not made in the 
newborn period, by a combination of clinical features, occasionally with a family history of 
CF, and a high sweat chloride test).  For this study, cases of “atypical” CF or where a 
diagnosis is for any reason in doubt have been excluded. 
PCD patients were diagnosed using the current “gold standard” of an identified defect on 
EM ultrastructure examination (see 1.3). 
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2.2 Spirometry 
Spirometry is deceptively simple, but can be a challenge in children.  Although even young 
children understand the concept of maximally breathing in, and then blowing one hard and 
long single breath out into the spirometer, actually doing this whilst maintaining an 
adequate seal on the mouthpiece is often too difficult for a young child. 
In our clinics, children first attempt spirometry at around 4 years of age, though younger 
children who show signs of understanding the test may be tested (Beydon et al., 2007; 
Aurora et al., 2004). Very rarely do children perform spirometry measurements within 
acceptability criteria straight away, but if these early attempts are rewarded with praise and 
small incentives like stickers, later success is more likely.  Also, many modern spirometers 
include incentive software, whereby children aim to inflate a hot air balloon or blow out 
birthday cake candles during the forced manoeuvre, which can improve success rates. 
For this thesis, there was no pre-determined lower cut off age for spirometry measurements 
to be included, but only children who produced acceptable manoeuvres had their 
spirometry data included and analysed.  In practice that has left only those over the age of 
five. 
Z-scores were calculated as recommended by Global Lungs Initiative (Stanojevic et al., 2009) 
using tools supplied on their website (www.lungfunction.org/). 
Spirometry acceptability criteria were those recommended by the ATS/ERS (American 
Thoracic Society and the European Respiratory Society) (Miller et al., 2005) . 
Two different spirometers were used to make measurements, the EasyOne Plus (ndd, 
Switzerland) and Vitalograph Alpha Touch (Vitalograph, Buckinghamshire, UK) (below).  
Ideally, one machine would have been used consistently, but for historical reasons the Royal 
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Brompton paediatric respiratory physiology team use the Vitalograph produced equipment, 
whereas the research-based Imperial College teams, including the respiratory clinical 
research facility (CRF) where many research patients are seen, have chosen the EasyOne 
range of spirometers.  Both spirometers are fully CE marked, the calibrations checked with 
identical procedures, and approved for the tests conducted so the results should be 
interchangeable. The vitalograph was calibrated before each child was tested, using a 3 litre 
syringe, The machine’s internal sensor was used to determine atmospheric conditions. The 
EasyOne Plus is “calibration-less” as it has no moving parts, but the calibration was checked 
before each session using a 3 litre syringe, and any discrepancy reported to the 
manufacturer for repair.  No calibration errors have been found with the machines used for 
this study.  
The key differences and similarities of these models of spirometer are shown in the 
comparison table below. 
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Vitalograph Alphatouch (Vitalograph, UK) 
 
 
 
 
 
 
EasyOne Plus (ndd Medical, Switzerland) 
Fleisch pneumotachograph Ultrasonic flow analyser 
Colour screen Black and white screen 
Incentives No incentives 
Standalone and PC-based analysis Standalone and PC-based analysis 
Disposable consumables Disposable consumables 
Pre-test calibration by user Remote calibration at annual service by 
manufacturer, pre-test calibration check by 
user 
Higher cost (quotes in region of £1600 
excluding VAT) 
Lower cost (quotes in the region of £800 
excluding VAT) 
 
Table 2-1 Comparison of the spirometers used for this thesis, highlighting the different 
features that may be of use to physiologists.  Both pictures are from manufacturers’ 
websites.  Both perform according to ATS/ERS guidelines but no head-to-head comparison of 
their performance is available. 
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2.3 Basic requirements of a Multi Breath Washout (MBW) test 
2.3.1 Gas analysis 
Various gas analysers can be used for MBW (those used in this thesis are covered in more 
detail in sections 2.3.1 and 2.3.2) ranging from historic nitrogen analysers, mass 
spectrometry, and modern photoacoustic and ultrasonic analysers. 
When a tracer gas is introduced for MBW, usually Sulphur Hexafluoride (SF6), it is normally 
at the lowest possible concentration for which the analyser will be sensitive enough to 
detect 1/40th of that concentration, to accurately record the end point of the washout.  This 
is primarily for reasons of cost; also, excessive tracer gas quantities will lower the fractional 
inspired oxygen tension of the gas mixture.  Modern photoacoustic and ultrasonic analysers 
are able to accurately record gases down to extremely low levels, allowing cylinders with 
very low starting concentrations to be used, making the test cheaper.   
Reducing the signal to noise ratio of an analyser is normally key to getting a successful 
measurement.  Many environmental factors can increase this noise and their relative 
importance varies with the analyser.  Photoacoustic analysers, for instance, are very 
sensitive to vibration, whilst mass spectrometers are not.  Mass spectrometers, however, 
have a delicate vacuum very sensitive to fluctuations in heat and humidity.  
Key to reducing noise in all analysers, however, is proper calibration and maintenance.     In 
addition to calibration, some machines will need mechanical or electrical parts maintaining 
or replacing on a regular basis in order to keep the analyser working as intended and 
keeping noise within acceptable limits.  The routine maintenance tasks needed for the 
equipment used in this thesis are included below in their individual sections. 
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Though many modern gas analysers also record flow and other parameters used in the test, 
the only essential output required is direct analogue data of gas concentration at regular 
time intervals.  If flow is not recorded by the same device, however, it is essential that the 
two signals are aligned. 
2.3.2 Flow measurement 
The subject’s respiratory flow rate, and from that the derived exhaled volume, must be 
measured throughout the washout phase of MBW. The pneumotachs commonly used are 
either Fleisch, screen (sometimes called Lily) or ultrasonic. 
Fleisch Pneumotachs consist of many small capillaries placed in a tube along the axis of flow, 
essentially providing resistance with the pressure being measured at the inlet and outlet of 
the capillaries.  The pressure drop relates linearly to flow, and is converted to an analogue 
flow signal. Screen pneumotachs contain a thin mesh “screen” within the aperture.  Similarly 
to a Fleisch, the pressure drop is measured across the screen and is converted to a flow 
signal. Whatever device is used, it is most common in MBWs for the pneumotach to be a 
standalone piece of equipment with no electronics of its own.  The pressure difference is 
transmitted via pressure lines connected to the flow head to a separate transducer, where a 
flow signal is generated.  The calibration routines for equipment used in this thesis are 
described below. 
A newer technology is the ultrasonic pneumotach.   Developed originally for use in 
spirometers, these devices contain a chamber traversed by ultrasonic beams.  Gas flow 
alters the time taken for the beams to cross the chamber, allowing calculation of flow.  
Essentially, ultrasonic pneumotachs have no moving parts and require no regular calibration 
(though there is an option for the user to check the calibration) throughout their operational 
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lives.  For these reasons, they are obviously very appealing and versions of these are seen in 
the newer MBW machines. 
The chief concern when selecting pneumotachs for MBW remains deadspace.  An 
excessively large deadspace may cause a compensatory increase in tidal volume (Lum et al., 
2012), and preclude accurate flow measurements.  This is particularly important in children, 
who have low flow rates, and it is currently recommended that deadspace should be less 
than 2ml/kg body weight (Robinson, Goldman & Gustafsson, 2009). This was achieved in the 
studies presented in this thesis. 
2.3.3 Signal alignment 
Flow and gas concentration signals must be aligned by determining the delay time (i.e.  the 
lag time gap between the two signals). 
If flow and gas concentration is recorded by a single piece of equipment, there are 
frequently automatic calculations of signal alignment made by the software, though this may 
need to be calibrated daily as alignment can be affected by both instrument stability and 
environmental conditions.  In older setups, however, lag time may be calculated by exposing 
the gas analyser inlet to differing concentrations at known time points, and recording the 
time to registration of the gas signal.  This value is then be used to align the two traces when 
patient data is collected.  How often these need checking is dependent on the methodology 
used, in this thesis, this was done before each patient was studied. 
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2.4 Parameters Measured 
2.4.1 Functional residual capacity (FRC)  
FRC was primarily calculated by gas dilution during MBW in order to calculate LCI.  The 
volume of exhaled tracer gas, and the starting and final end-expiratory concentrations are 
used to derive FRC. 
 
FRC=
net volumeof inert gasexhaled
Cet
start
−Cet
end  
where Cetstart and CETend are the end tidal concentrations of tracer gas at the start and end of 
the washout respectively.  The net volume of inert gas expired, sometimes expressed as VIG, 
is the sum of the integral products of exhaled flow as gas concentration for each washout 
breath, corrected for re-inspired gas. 
When FRC is calculated by MBW, a gas dilution method (as opposed to body 
plethysmography), lung units that are poorly ventilated and only empty with a very long 
time constant will contribute less to this value than more normally-ventilated areas.  This 
measurement of FRC is therefore normally lower than by plethysmography, particularly in 
those with obstructive lung disease. MBW assumes a two-compartment model of the lung.  
Though this does not truly model the complex nature of lung unit ventilation, it is acceptable 
for these purposes and allows clinically relevant measures, such as LCI, to be calculated from 
MBW.  
2.4.2 LCI 
CEV is the cumulative expired volume of gas from the beginning of washout period through 
until the end tidal concentration on two consecutive breaths has fallen below 1/40th of the 
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initial concentration.  CEV is calculated as the sum of all expiratory VT (including that first 
breath post-cut off threshold) over the washout. 
LCI is calculated as: 
    
   
   
 
The dimensionless ratio LCI is related to the degree of impairment of gas mixing within the 
distal airways.  Poor gas mixing elevates LCI.   
Allowing for deadspace is a challenge in these measurements.  Ideally, all indices should be 
assessed at airway opening but this is impractical.  In accord with guidelines external 
deadspace was subtracted it from each VT. 
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2.5 Equipment  
2.5.1 The Innocor 
The Innocor (Innovision, Denmark), is a photoacoustic gas analyser originally marketed for 
exercise testing that can be easily adapted for the MBW. In contrast with the mass 
spectrometer adapted for this test (see AMIS 2000, 2.3.2), the Innocor is relatively 
inexpensive, costing around £30,000.  It is easy to maintain, the analyser is extremely stable 
over time and does not require regular calibration.  A calibration check is made at a once-
yearly service, and if this falls out of expected range the unit is returned to the manufacturer 
for a multi-point calibration.  When checked with known calibration gas once per month, no 
errors have been detected during the work of this thesis.  A straightforward syringe 
calibration of the pneumotach is performed for flow measurement.  It is small 
(approximately 40cm3) and relatively light (approx.  5kg), so is portable (although the gas 
cylinders required are frequently less portable, as small cylinders will rarely allow 
completion of testing of more than two children).  It has a touch-screen interface mounted 
on a Windows XP Embedded (Microsoft, USA) platform, making it easy to use and to 
navigate, and the software is easily modified for the MBW (see Appendix One). 
The Innocor was originally adapted for MBW by the UK Gene Therapy consortium, using a 
similar method to that described below for the current machine.  These modifications are 
described below. (Horsley, 2009; Macleod et al., 2009; Horsley et al., 2008a; Horsley et al., 
2008b) 
The Innocor contains a photoacoustic analyser which measures carbon dioxide, nitric oxide 
and SF6, and also an oxigraph for oxygen measurement.  As oxygen concentrations are not 
required in the MBW test no further explanation of the oxigraph is included here, though its 
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effect on the delay time is relevant to the later hardware modifications (see below) and the 
oxygen signal is used in the standard device calibration. 
The photoacoustic analyser (sometimes called a photoacoustic spectrometer) uses a 
focussed beam of light to apply energy to gas molecules.  The energised molecules vibrate, 
each at a unique frequency, making a sound which is recorded by a sensitive microphone 
from which gas concentration is calculated.  A measurement of each gas species is made 
every 10ms species, giving a semi- continuous signal.  This is converted into an analogue 
trace of the varying gas concentrations over time.  
For SF6 the optimum range (the level with the best signal-noise ratio, whilst avoiding signal 
saturation) for detection is from 0- 0.2%.  This was specifically set at this level by the 
manufacturers of the unit, as it gives the financially attractive option of using a medical air 
mix with just 0.2% of SF6 for tests.  The signal to noise ratio for SF6 is >1000 at half scale, 
making it very unlikely that noise will significantly impair the signal in the range used.  The 
sampling frequency is 100Hz.  The signal rise time (the time taken for the gas signal to first 
register a rise) is less than 200ms in the standard setup, and has been further modified (see 
below).  The sample flow is 2ml/sec, which is distal to the flowmeter in the standard setup.  
In the modified setup for infants, the flowmeter is distal, (see below). 
The Innocor uses a nafion sampling line.  Nafion is a co-polymer similar to Teflon that is 
highly selective for the removal of water – it has exposed sulphonic acid groups on its 
surface that absorb water as a first-order chemical reaction, as opposed to older 
technologies that relied on diffusion to remove water from a sample.  This reaction has no 
effect on the gas composition of the sample, only its water content, so the sample is dry 
when it reaches the analyser.  These tubes are changed once per year but are estimated by 
their manufacturer to have a lifetime of upwards of 10 years.   This can be shortened by 
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exposure to non-ideal atmospheric conditions (particularly high humidity), but if this is 
occurring it is visually obvious as the tubing will begin to discolour from a white to a dark 
brown colour (shown in Figure 2-1 below). 
 
Figure 2-1 Nafion tubing discolouring over time. The nafion itself is surrounded by a 
protective meshwork of nylon filaments.   The tube on the left is new from the manufacturer, 
the tube in the centre had been used for one year in an air conditioned, well ventilated space 
suitable for testing.  The tube on the right had spent approximately 3 months in use in an 
extremely damp environment. 
The Innocor is supplied with a flow head containing a pneumotach.  However, the dead 
space of this piece of equipment is too large for MBW tests, particularly in children.  This 
pneumotach was replaced with a smaller non-standard one (paediatric non-heated screen 
pneumotach, Hans Rudolph, USA) (Horsley et al., 2008a) (2.4.1.4.1). 
The internal flowmeter that receives the flow data from the pneumotach is however suitable 
for use.  It has a +/- 15l/s measuring range (well outside flow rates that would ever be 
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produced during the MBW test).  It performs an automatic offset calibration (sometimes 
called a “flow zero”) but the frequency with which this occurs can be set by the user.  The 
default use for exercise testing is every 2 minutes, but for an MBW every 5 minutes is 
sufficient as at resting respiratory rate and flow there is no drift seen over this time, and this 
also prevents overly-frequent disruption to the flow signal by this zeroing process, so this 
interval was set.  A daily gain flow calibration with a known volume syringe is recommended 
and is easily achieved with a choice of syringe sizes, a user prompt to direct syringe strokes 
which are performed at different rates with an automatic update of the flow table.   
Should the flow fall outside the acceptable range, as is common after the replacement or 
even cleaning of a pneumotach or the replacement of the flow leads (schedules for flow lead 
replacements and pneumotach cleaning are found in the protocol in Appendix One), a more 
complex program to fully and manually update the flow table is available by entering the 
device’s Windows XP embedded management environment.  The daily calibration was 
performed with a 3 litre syringe, and the flow table updated either when this fell out of 
range, or when the pneumotach was washed (once per week). 
As both the SF6 and carbon dioxide signals are measured by the photoacoustic analyser, the 
carbon dioxide gas delay can be used as a surrogate measure for the SF6 gas delay (see 
below).  Though the analyser itself has a known and reasonably stable rise time of <200ms, 
the true gas delay is a variable and much larger time that is heavily influenced by 
atmospheric conditions. 
For this reason, the test software contains an automated program for assessing the delay 
time.  The user (not the patient) performs 10 slow expirations and fast, forced inspirations in 
cycles.  The variation in concentration of carbon dioxide and oxygen over a breath is a 
known phenomenon – the software automatically matches the carbon dioxide and oxygen 
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cycles with the flow cycles and measures the delay it observed between the two.  This gives 
the gas delay for use when analysing the MBW test.  
As stated above, the standard Innocor pneumotach is not suitable for MBW.  The deadspace 
is too large.  However, it is relatively easy to remove the entire rebreathing setup from the 
base machine to allow for a new, custom open circuit setup to be added in its place.  
Hans Rudolph (USA) produce a range of low deadspace screen pneumotachs with flow 
pressure lines that are compatible with the Innocor’s pressure monitoring systems, and one 
of these was selected to give the lowest deadspace whilst tolerating flow similar to that 
across the paediatric age range and attached to the Innocor as shown below (Figure 2-2). 
 
 
Figure 2-2 The Hans Rudolph pneumotach adapted for MBW testing on the Innocor.  A small 
hole is drilled into the barrel to allow the sample inlet needle to sit in the gas flow. 
When attaching the pneumotach to the Innocor it is important to use proper pressure lines, 
such as those produced for intensive care equipment use.  Other tubing, such as oxygen 
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tubing, will not correctly transmit pressure evenly throughout the line, thus distorting the 
flow reading.  The lines should also be inspected and changed on a regular basis (all defects 
detected were in lines that had been in use for at least three months, so in this study, the 
lines were changed every month or when any flow error was detected) as very small, 
effectively invisible defects or damage to the lines can drastically affect flow readings.  If 
flow readings are incorrect, FRC and therefore LCI will not be correctly calculated.   
The only part of the original flowhead setup that is re-used is the “plug” to which the flow 
lines are connected and attached to the Innocor. This can be cut away from the setup as 
bought, or (as for the work of this thesis) obtained by requesting a spare from the 
manufacturer.  The inlets used by the pneumotach pressure lines are shown on Figure 2-3.   
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Figure 2-3 The Innocor flow head “plug” being reused as part of the MBW setup.  The two 
flow ports have pressure lines connected and the rest have been occluded with small rubber 
bungs. 
The other inlets must be occluded (they would normally supply rebreathing gas to the flow 
head) as they are not in use.  This was done with small rubber bungs obtained from the 
manufacturer.  If the inlets are not successfully occluded, a flow of gas can be felt escaping 
from them during initial calibration by pressure on a finger and an SF6 signal around the plug 
detected by the gas probe. 
The nafion tubing can be detached from the flowhead and reused in the modified setup.  
The tubing is supplied with a Luer lock connection at each end.  One end connects to the 
inlet port on the machine, with a small filter in place between to prevent small particles 
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being sucked into the analyser and potentially causing damage.  The other end of the tubing 
is connected by its Luer lock to a cut down cannula needle. This functions as a gas inlet. 
The Hans Rudolph pneumotach has no flow inlet port, so one must be made.  A very small 
hole matching the gauge of the needle used in the nafion was made in the plastic “barrel” 
surrounding the pneumotach, where the inlet can be inserted into the stream of the 
patients’ breath.  This is done with a standard drill. 
A silicon mouthpiece (Hans Rudolph (USA)) is used.  The silicon is softer and more 
comfortable for patient use than older style hard plastic mouthpieces, so better tolerated.  
Also, the soft silicon is easy to cut down to the required size and shape with sharp scissors.  
The mouthpieces are reprocessible rather than single use, however, and are cleaned 
according to manufacturer’s instructions between each patient. 
The filter selected should have the lowest possible deadspace compatible with infection 
control requirements.  A filter made for paediatric use by Air Safety Ltd (UK) provides both 
bacterial and viral filtering and is very small.  When added to the Hans Rudolph pneumotach, 
the entire deadspace is 36ml.  Since a suitable deadspace is < 2ml/kg of body weight, this is 
suitable for most age groups.  The lowest weight of children tested in this thesis was 19kg.  If 
younger children are to be tested the Innocor will accept smaller pneumotachs that may be 
used without filters, but this will potentially give rise to infection control problems. The 
remaining piece of the washout setup is the flowpast system for the open circuit washin.  
The component parts are shown below, are cheap and readily available (Intersurgical (UK)). 
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Figure 2-4 The flowpast circuit, the gas flowing in connector tubing to the patient by means 
of a T-piece connected to the pneumotach.  There is a reservoir bag in the circuit before the 
T-piece to provide a small measure of respiratory reserve for those patients that find it more 
comfortable.  The connector tubing then vents the expired gas several metres away. 
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When fully connected, the overall setup should be as in the diagram shown below. 
 
 
Figure 2-5  The flowpast circuit in diagram form showing the component parts in clearer 
sequence. 
The rise time must be as low as is possible, especially in children.  The standard Innocor rise 
time of approximately 160ms is too slow for paediatric use (as mentioned above) and two 
parts of the Innocor can be further modified to improve this.  These modifications were 
proposed by Dr Kenny Macleod, as part of his PhD thesis on improving the Innocor for use in 
children, and carried out at the Royal Brompton by myself under instruction from him 
according to his method.  This has since been published (Horsley et al., 2014), and this paper 
also includes detailed model work undertaken to verify these modifications. 
The first modification is to disconnect the oxigraph from the circuit the gas takes inside the 
machine.  Oxygen does not need to be monitored during an MBW conducted with an SF6 
tracer.  The oxigraph is separate from the photoacoustic analyser and considerably slower, 
93 
 
so removing it improves rise time.  Figure 2-6 shows the process used to locate and remove 
the oxigraph circuit.  The process is not particularly complex, but it does, however, invalidate 
the warranty on the device.  This is the most complex alteration made, and improves the rise 
time to the greatest extent, normally of around 60-90ms, though there can be some 
variation on this due to environmental conditions.   
 
A)       B) 
Figure 2-6 The removal of the oxigraph.  In the standard setup, the gas sample flows from 
the sample inlet through the oxigraph and then through to the photoacoustic analyser (PGA).  
This leads to a high rise time which can be improved by removing the oxigraph from the 
circuit.  A) shows a cut away diagram produced by the manufacturer showing that the PGA 
inlet is in fact very near the sample inlet, so all that is required is to reconnect the tubing 
from the inlet straight to the PGA.  B) shows the wiring as actually seen inside the machine 
however, which is rather more complex so this can take some time. 
 
Since the oxygen signal is used to track the breathing cycle during the calibration procedure, 
if the oxigraph is removed the delay must be calculated manually by aligning the flow 
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signals.  A protocol for this is included in Appendix One, but in brief the carbon dioxide signal 
and flow are manually aligned for 10 breaths, the degree of adjustment to make this 
alignment recorded, and then the mean of these ten breaths calculated.  In practice, with 
the oxigraph removed, this signal was very stable across several tests and in fact often 
several days. 
The second part that can be modified is the Luer lock connectors on the nafion line.  Though 
convenient and strong, Luer-lock connectors do introduce extra space, and being of 
comparatively large diameter they allow the gas to eddy rather than ensuring its efficient 
transit through in the analyser.  They can be simply removed from the nafion with scissors.  
Once the Luer-lock is removed, a cut down section of cannula needles can be inserted 
directly in to the nafion tubing itself, and the protective coating cut away to allow a good fit.  
This is then secured and sealed with sticky rubber tack such as Blu-tac, and then the cannula 
needle placed in to the drilled hole in the pneumotach barrel as in the original modifications. 
At the filter end, the exposed nafion can be inserted into the filter and again secured with 
blue tack.  These modifications can be made more hardwearing with the use of air drying 
polymer clay. 
In total, these further modifications improved the gas delay from more than 160ms to less 
than 100ms. 
In the standard Innocor, the sample flow rate is 2ml/s, and though this is higher than some 
other methodologies (particularly measurement by mass spectrometry), this lost gas is taken 
into account by having the sampling process running during the flowmeter calibration, so 
this compensation is built-in to the calculation.  For older subjects with large breath volumes 
this is adequate. 
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However, in subjects with smaller breath volumes, this will lead to an over-estimation of re-
inspired gas, as this relatively large proportion of their VT will be measured by the 
pneumotach and analyser but will not enter their lungs.  As net expired gas is calculated by 
subtracting re-inspired gas from the total expired, this over estimation will lead to an under-
estimation of expired gas (perhaps even to the point of showing a negative reading).  This is 
clearly unacceptable as net expired gas must be accurate to measure FRC correctly.  
Dr Macleod’s solution was to reverse the pneumotach so the sampling line is the other side 
of the screen, proximal rather than distal to the patient. This would add the lost gas back 
into the pneumotach measurement. Hence, reinspired gas would be measured accurately in 
these patients, allowing a better measurement of FRC.   Ideally, this would only have been 
done during the inspired portion of the washout, but this is not technically possible with the 
Innocor’s recording software, so this compromise was reached. 
Though Dr Macleod was intending to test the Innocor’s suitability for patients down to 
infancy, the work of this thesis concentrates on older children with breath volumes not 
substantially affected by these problems.  Despite this, it was decided to maintain his 
modifications on the Innocor as it may have allowed younger subjects to be tested clinically 
should the need arise, and also some modifications, in particular the improved analyser 
response time by the removal of the oxigraph, allowed the Innocor to perform closer to the 
“gold standard” mass spectrometry devices. 
The Innocor software is a custom user interface over the top of a Microsoft XP embedded 
(XPe) operating system (above).  XPe allows manufacturers to install a componentized 
version of the operating system, reducing the “footprint” (i.e. the amount of computing 
power required to run the operating system in the background) by only installing essential 
features.  The version on the Innocor supports the use of files and folders to store data and 
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installs most USB keyboards, flash drives or a mouse that may be helpful when running the 
machine, which is all the functionality needed. 
The custom interface running on top of this environment allows the device to be calibrated 
by calculating both the carbon dioxide delay (used as a proxy for the SF6 delay) and aligning 
the flow meter (full protocols for calibration are contained within Appendix One).  In 
addition, the interface allows users to add protocols, necessary for a non-standard test such 
as MBW.  Both the calibration and the protocol programming features are used for the 
MBW. 
Adding an MBW protocol to the Innocor is straightforward.  The exercise device must be set 
to a manual control, (i.e. exercise peripheral connected), the wattage category (ergometer) 
should be set to zero as it is not used.  The protocol is set to have no blood pressure input.  
The test is set to the maximum length of 60 minutes and the protocol named and saved. 
Graphs and parameters displayed during the test are set to the preference of the individual 
operator.  My preferred setup is for an online signal trace of flow, tracer gas and carbon 
dioxide to show in the foreground, with VT and respiratory rate clearly visible in the 
background.  This provides all the parameters needed to check gas concentrations and to 
assess tidal breathing. 
The Innocor has a small sample inlet measuring room air, which is used as zero 
concentration SF6. However, if ambient air is contaminated with SF6, a very characteristic 
error will occur whereby the SF6 signal will read incorrectly,  never reaching the true 
maximum  concentration (reading, for instance, 0.157% in a mix known to be 0.197%) and 
also never truly reach zero, hovering instead around a low value (commonly around 
0.005%).   
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To avoid this error, it is critical that SF6 is not allowed to accumulate in ambient air.  Tests 
should not be performed in a badly ventilated and/or small space, or waste gas from the test 
can start to slowly increase the atmospheric concentrations.  Also, activity in the test room 
should be minimised.  As SF6 is heavy and tends to collect in the lower part of the room, 
movement in a small or enclosed room will send eddies of the gas up into the Innocor 
grating, causing sudden and unpredictable erroneous zero readings intermittently 
throughout the test, producing completely unusable data.  A large enough room for the test 
exhaust to be at least several metres from the machine itself is required for these tests.  
Also, there should be some form of air flow directed at the sampling grill, either provided by 
open windows, an air conditioning system, or fans, to prevent eddies of gas from reaching 
the vent, and from large pockets accumulating. 
If the Innocor testing occurs in the same room as other tests involving higher concentrations 
SF6, particularly the 4% SF6 concentration used in AMIS 2000 MBW tests, this will increase 
the chance of this error occurring. Care should be taken in patients with extremely long 
washin times, as the gas is able to accumulate over a longer period. 
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Figure 2-7 The characteristic error caused by ambient SF6 values above zero.  The SF6 signal 
(A) cannot rise to its true value (0.2%) and (B) will not fall to zero even on the absence of SF6 
at the inlet.  These tests are not analysable, and there is no way of doing a retrospective 
correction. 
Data are saved on the Innocor hard drive, each washout being saved as a separate file, with 
the patient ID, date and time.   Subsequently, data are saved to a USB stick and then copied 
to a Departmental PC for data processing. 
This data is in a proprietary format and must be converted for use.  A program developed for 
research use (used with kind permission of Prof. Per Gustafsson) can convert these files to a 
very simple text file readable by many programs, including the analysis software.  Of the 
data collected during the test, the signals of interest are the flow and the tracer gas SF6.  
However if the carbon dioxide data is used for the delay calculation with the modifications in 
mentioned above then this will also need to be saved. 
Additional software by the same team then converts this data to pseudo-analogue signals of 
flow and gas concentration.  This is based on the commercial software Testpoint (JSDU, 
Milpitas, California, USA). 
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Figure 2-8 Washout software.  This includes sliders for setting inspiration start, inspiration 
end, expiration start and expiration end (A), the flow and SF6 signals (B), the phase III slope 
(C), the sliders for manual adjustment of the phase III slope (D), the initial SF6 concentration, 
the end value (1/40th of initial concentration), and the end tidal concentration of current 
breath (E), The indicator when this level has been reached (F) and the gas delay (G).   
A full protocol detailing the analysis process with this software is available in Appendix One, 
but a brief overview is given below. 
Firstly, the gas delay must be entered.  This can be from the automatic calculation program 
or manually calculated from the carbon dioxide and flow signals, depending on which 
hardware modifications are in use. 
The software automatically detects when the flow signal crosses the zero axis, picking out 
the end-expiration start-inspiration and the end-inspiration start-expiration point of each 
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breath.  The user identifies the first breath of the washout and then the software proceeds 
to identify each breath in turn, with the user manually saving them if they are confirmed to 
be correct. 
If they are incorrectly identified, the user can manually select these points.  This is 
particularly helpful in small children, where small sighs or swallows can occasionally 
interrupt an otherwise good tidal breathing pattern. 
As the user moves through the washout, the end tidal concentration is displayed for each 
breath, alongside the starting SF6 value and the manually calculated 1/40
th point of this.  
When the end tidal concentration falls below this value a red indicator will appear in the 
software, but the end point is still user defined in case this has occurred in error.  
The analysis protocol is to save the first breath that falls below the required level (1/40th), 
and then check that the next breath does so also, to terminate the test.  In obstructive 
disease, it is common for the next breath to rise above the level again, due to trapped gas.  If 
this occurs that breath is saved and the process continued until the concentration of SF6 of 
two breaths in succession fall below the required level. 
Whilst the washout is being analysed, a graph of the washout of SF6 during each individual 
breath is shown along the bottom of the screen.  This is in order to identify and also save the 
phase III slope for each breath.  By default, it is set to curve-match the 65-95% SF6 washout 
region of each breath, but can be modified by the user to allow alteration of the slope as 
described above. A more detailed discussion of the Phase 3 calculations is given below. 
Though not particularly difficult, this procedure is time consuming, particularly for patients 
with long washout times. 
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Two excel files are produced by the software.  The first, “_mo” files contain one summary 
line for each washout analysed, with the LCI as calculated by the software, as well as the 
components of this calculation such as the FRC and the cumulative expired volume of gas for 
each washout. 
A correction to standard temperature and pressures (normally very small) must be 
performed, and the data assessed for acceptability.  Any washout in which the FRC varies by 
less than 10% from the mean FRC for the group of tests was consider acceptable. 
FRC is used in preference to LCI for quality control as it should be more stable over the 
course of the MBW than LCI.  LCI is measuring a dynamic physiological process; particularly 
in patients with severe disease it may well vary between tests due to genuine physiological 
changes, due, for example, to coughing, whereas FRC is unlikely to change by more than 
10%. 
The other file type produced, the “_mb” file is much larger and contains data from every 
user saved breathe of each washout, which is used for phase III calculation.  Full details of 
this process are provided in the protocol in Appendix One, the spreadsheet in use was 
designed for handling Innocor files of this type by Dr Nick Bell and Dr Kenny Macleod as part 
of their work for the UK gene therapy consortium. 
 
2.5.2 The AMIS 2000 (Innovision, Denmark) 
The AMIS 2000 mass spectrometer has long been considered the “gold standard” in MBW 
testing (Robinson, Goldman & Gustafsson, 2009; Gustafsson, 2005; Gustafsson, Aurora & 
Lindblad, 2003)and is the second machine available in our laboratory for testing.  However, 
it is rarely used for routine investigation here as it has a number of drawbacks which make 
the Innocor a more realistic choice for large volume data gathering and routine use. 
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The AMIS 2000 is expensive (cost in excess of £90,000).  The requirement for a vacuum 
necessitates the use of pumps to remove air from the testing chamber (the AMIS 2000 
requires two, a fine and a coarse vacuum), which means the machine is large (approx. 1m3, 
not including the control PC), noisy, and rather immobile (the vacuum requires at least 24 
hours to re-establish if it is turned off, sometimes several days, and a constant power supply 
is essential as accidental shutdowns due to power outage can cause extensive damage).  
They require expert servicing and care, normally two days of the time of a highly 
experienced engineer a year, and further expert attention if any problems develop.  The 
parts can be costly to obtain, both for routine servicing and to repair or replace any faults 
and are becoming rarer as machines of this type become obsolete.   
The final problem is one of software.  As Innovision no longer actively promote the AMIS 
2000 for sale, preferring to concentrate on the Innocor and their other newer products, 
there has been no work done on the software or interface for some years.  The interface 
runs entirely in a DOS environment, based on a PC running Windows 98 (Microsoft, USA).  
Newer PCs, or even newer versions of Windows, are not compatible with it.  Whilst stable, 
this interface prevents networking of the PC or easy replacement of it should it fail, and is 
increasingly requiring specialist training of operators since many are unfamiliar with DOS.  
The AMIS 2000 is a scanning, quadropole mass spectrometer.  A dried sample of gas is 
ionised (bombarded with electrons from an ion source, which then remove electrons from 
the outer orbit producing a charged ion of the gas species), and passed between four 
charged rods (the quadropole).  A given charge on the rods causes deflection of the charged 
ions’ path by a known amount depending on its mass/charge ratio, and when those ions hit 
the detector on that path they can be identified and their quantity assessed.   The charge on 
the rods can be altered, and cycled through relatively quickly, allowing the semi continuous 
identification of several gases.  This is referred to as “scanning”.  The ion impact is turned 
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into a meaningful electrical signal by secondary electron multiplier (SEM), which essentially 
releases an increasing cascade of electrons in response to the ion impact which amplifies the 
ion current to the point it can be read as an electrical signal.  
The rise time on the AMIS 2000 is considerably faster than Innocor, with typical values of 
less than 100ms.  The sampling frequency is faster, at around 33Hz.  The signal to noise ratio 
is determined before each use during calibration, with an optimal operating range of 
between 0.1-4% SF6 so MBW requires a higher concentration than the Innocor.  This is 
obviously more expensive than lower concentration cylinders. 
The mass spectrometer must be calibrated before each use, as the system is highly sensitive 
to environmental change.  The system is highly flexible, allowing a calibration gas to be 
programmed in rather than requiring a specific mix.  The calibration gas is prepared to very 
high accuracy standards (BOC alpha certification, which is +/- 1% of the desired 
concentration) and is frequently in excess of £500 for a single cylinder.  The calibration 
procedure is semi-automated and reasonably straightforward.  The sample inlet is first 
closed to allow a zero reading to be taken, and then exposed to the calibration gas for a few 
seconds, during which the sample concentrations are analysed and then matched to the 
known concentrations of the calibration gas (Appendix Two). 
This AMIS 2000 does have an internal flow measurement sensor that could be attached to a 
screen pneumotach but (as in the case of the Innocor) this is intended for use in adult 
exercise testing and is too large for the deadspace requirements of MBW.  The preferred 
method therefore is to use an external pneumotach and to align the gas signal analogue 
output signal with these readings.   
As an external pneumotach is in use the delay calculation is performed as part of the signal 
alignment between the mass spectrometer and the pneumotach, by exposing the inlet to 
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the test gas at known time points and then comparing these with the points a signal is 
detected.  A full explanation of the hardware for this is included below. 
Figure 2-9 below shows all main components labelled and the machine ready to use. 
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Figure 2-9 The AMIS 2000 washout setup ready to use.  The AMIS 2000 itself is not in shot.  In 
the far left the analogue output box which is receiving the gas signals from the mass 
spectrometer can be seen. 
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The AMIS 2000 outputs to the control PC a continuous, analogue data stream of the gas 
signals as programmed into the test run by the user along an IDE cable to an analogue 
output box.  This separates out these signals into component gas types and then allows this 
data to be passed to the connection box. 
Also attached to the connection box is the pressure sensor.  This is connected by pressure 
lines to the separate Fleisch pneumotach, so both gas and flow data are inputting to the 
connection box. 
The Fleisch pneumotachs used are solid metal, small deadspace models which are now out 
of production.  There is no filter used in the AMIS 2000 MBW setup, and so they must be 
cleaned by immersion in cleaning ethanol for 30 minutes and subsequently properly dried to 
prevent moisture affecting the readings.  They are connected when in use to a flowmeter 
unit that both heats the pneumotach and which is used to adjust the baseline flow to zero 
volts.  A Hans Rudolph (USA) mouthpiece the same as described for the Innocor (above) is 
connected to the pneumotach with a custom made plastic connector (custom made by the 
Royal Brompton Clinical Engineering team).  The tubing for the open circuit wash in is also 
connected to the pneumotach by one of these custom connectors, but is in other ways 
identical to the Innocor setup.  However, it is used in a system without a filter so the open 
circuit must be changed after every patient. 
The final part of the setup is the delay box.  This also attaches to the connection box but 
contains a port for the mass spectrometer gas inlet and a connector for the calibration gas.  
The washout software (see below) contains a program to automatically trigger small 
amounts of the calibration gas to be released into the box at known time points.  This gas is 
detected by the mass spectrometer via the inlet, and that signal transmitted back to the 
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laptop control PC running the software.  From this the delay between release and detection 
is automatically calculated, and used as the delay value for that test. 
The connection box therefore effectively acts as the hub of the test, collecting signals from 
both the flow and the gas analysis, and triggering the delay box to release gas to allow the 
delay to be calculated.  It is itself is connected to the standard laptop control PC by a single 
USB cable that allows this two way flow of data between it and the laptop. 
There are two software environments involved in producing an AMIS 2000 MBW, the 
software of the mass spectrometer itself, and the custom built research software (again 
kindly provided by Prof Per Gustafsson) on the control laptop that is used to control the 
MBW and record the data. 
Though still suitable for purpose, the DOS based environment used to control the mass 
spectrometer is old-fashioned.  It is navigable by the standard DOS command set.    
Unfortunately, as an older platform it is not easily integrated with other systems or with 
most modern peripherals such as printers or USB input devices (in fact, the PC itself has no 
USB connectivity at all).   
Many routine exercise and respiratory tests are pre-programmed into the machine, and 
additionally it is highly programmable for other user requirements.  For capturing analogue 
data for a bespoke test such as an MBW, the most suitable program to base this on is the 
Respiratory Monitoring System, or RMS, option, which allows the specification of gases to be 
set, the calibration for those gases, and then their online near-real time monitoring.   
The first RMS option used is the System Status to ensure all the correct mass spectrometry 
components are functioning.  In this option, the status of the vacuum can be checked, the 
required inlet opened to allow samples to be collected, and the emission (the production of 
ions from the filament) turned on and the SEM (the secondary electron multiplier, see 
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earlier) also switched on.  If these components all appear to be working properly you can 
then proceed to calibration.  A full calibration procedure is given in Appendix Two, but the 
following gives an overview of the process. 
Firstly, the data collection must be optimised for the test gases in use.  In Gas Setup 
program, the inlet is exposed to the calibration gas and the signal strength for each gas 
checked.  Essentially, the mass spectrometer “auto-optimises” itself as the SEM increases 
and decreases its signal response to different species of gas until all are being detected at a 
suitable level.  Too small a response will not be detected correctly and may be 
misinterpreted as noise, and too large a response will produce a “saturated” signal that 
detects a maximal concentration at lower levels.  At the end of the auto-optimisation 
process the signal level in volts for each gas is displayed and this is checked it is within 
acceptable limits.   
It may take several attempts at optimisation for the signals to all be acceptable, particularly 
if the machine has been out of use for a time.  If after repeated attempts the auto-
optimisation function is not correctly recognising gases, the process can be done manually.   
The mass spectrometer displays the concentration of the various mass/charge ratios 
detected by the machine as a series of “peaks”.  Incorrect optimisation normally occurs 
when the machine fails to correctly assign a given peak to the correct species of gas (it may 
be completely incorrect, what more normally occurs is a sub-optimal part of the signal 
leading to or just after the peak has been incorrectly selected rather than its true peak).  
These peaks can then be manually selected to better optimise the signal. If the peaks are not 
clear on manual selection it normally implies a more serious problem with the gas analyser. 
With the signal detection of the gases correct, their concentrations can now calibrated.  This 
is again an automated process whereby the inlet is exposed to a calibration gas of precise 
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known concentrations and then calibrated to these levels.  The results are shown as updated 
concentrations with a signal/noise ratio.  The calibration fails if the signal to noise ratio is 
below 100. 
It is not that uncommon, again particularly in a machine that has been standing idle for 
some time, for the calibration to fail.  Repeating the optimise-calibration process and 
checking simple errors (such as the flow of the calibration gas into the inlet is suitable, either 
too high or too low will give poor readings) normally resolves these problems.  If a correctly 
optimised signal cannot be calibrated with a suitable signal-noise ratio then again more 
serious problems with the gas analyser need to be considered. 
Once suitably optimised and calibrated, the machine is set to “Online Monitoring”.  This 
effectively begins the real time tracking of gas signals, and the process of further calibration 
now moves to the control laptop. 
The software of the control laptop is a research-derived suite of applications for setting up, 
carrying out, recording and later analysing the MBW, again built by Professor Gustafsson’s 
team in the commercial Testpoint environment (JSDU, Milpitas, California USA).  It contains 
an automatic function for calculating the delay involving triggering the delay box (above), 
and from this is can align flow and gas signals.  It also contains the calibration software for 
the pneumotach, which must also be performed before the test is started. 
The subject is connected to the flow circuit almost identically to the Innocor setup (the main 
difference being the lack of filter) and encouraged to take regular, tidal breaths of the gas 
mixture.  Though the recording process is rather more complex (see Appendix Two for full 
protocol), the actual work of carrying out the test is similar to that using Innocor, and many 
of the quality control issues common to both methods (leaks, non-tidal breathing, correct 
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wash-in identification and gas disconnection, correct end point identification) are presented 
below.  There are, however, a few unique problems that can occur. 
The gas calibration requires frequent updating throughout the visit.  A full calibration must 
be done as each patient arrives, and then a smaller “Quick Cal” check (a quick calibration 
against the calibration gas but without the full zero reading at a closed inlet) must be 
performed before each run of the test.  
The mass spectrometry method also requires a higher degree of technical involvement 
during testing from the operator in order to correctly collect and record the data.  This may 
mean that an additional staff member must help in the tests, to calm or distract the child 
and to observe tidal breathing and check for any leaks.  The only remaining problem unique 
to this method is the infection control issue.  Lack of filter use and reuse of equipment is not 
considered desirable in modern clinical or research settings, and even where the test is 
carried out extremely carefully to minimise risk, obtaining local health and safety approval to 
carry out the test in such a way may be difficult, given the risk to groups such as CF patients 
from cross infection by their peers. 
All data saved during an MBW is saved on the control laptop PC, which also has the analysis 
software installed.   
The two software setups for Innocor and AMIS 2000 are broadly similar, both in layout and 
functionality.   The AMIS 2000 setup is however slightly more complex in both in its protocol 
and the data types saved. Again, a full protocol is in included in Appendix Two and the 
overview is as follows. 
When the first washout is loaded, a graph showing the entire washout is on screen.  Again, 
the software selects breaths in turn by recognising the flow zero point and these can be 
modified by the user if required.  Once the first breath is selected, the software loads a 
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different screen showing the phase III slope.  When phase III is identified, the capnogram is 
displayed.  Although capnography is outside the remit of this thesis, the software protocol 
requires this screen be viewed.  The next breath in the washout can then be identified.  
These steps are then repeated until an end point of two consecutive breaths with an end-
tidal SF6 concentration beneath the 1/40
th level (0.1% in this case) have been identified.   
 
 
Figure 2-10 Testpoint-derived analysis software, similar to the washout software used 
previously, showing the sliders for selection of each breath (A), the flow and gas 
concentration traces (B), and the end-tidal indicator (C). 
At the end of the test, two excel files are generated by Testpoint containing the relevant 
MBW data.  One, the Results file provides a summary of the MBW tests analysed giving 
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important parameters such as LCI and FRC for each test run.  There is also a “.MB” file similar 
to the “_mb” generated for Innocor containing information for each breath of each MBW 
that will allow phase III data to be calculated.   
Supplied with the software is a large multi tab spreadsheet into which data from the Results 
file can be pasted, calculating the average values for LCI and FRC for the MBW.   
A second, rather more complex spreadsheet for calculating phase III parameters is also 
supplied (full protocol for its use is in Appendix Two) but essentially data from the “.MB” 
files is cut and pasted into this.  To calculate phase III, the required turnovers must be 
selected, the FRC and equipment deadspaces must be entered manually, and care must be 
taken to only use the phase III values that have been corrected for tidal volume, as both 
these and the unaltered ones will be calculated. 
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2.6 Comparison of the AMIS2000 and the Innocor 
 
2.6.1 Introduction 
Before determining whether to use the Innocor or the mass spectrometer for the work of 
this thesis, I collaborated with Dr Macleod, comparing the results obtained on the two 
devices, in an in vivo comparison of both systems as stand-alone pieces of equipment.  The 
Innocor used was that modified as described in section 2.5.1.  The hypothesis was that there 
would be no systematic difference between the results obtained. As discussed in section 
2.5.1, the primary end-point as the main MBW quality control was FRC, although LCI was 
also assessed. 
2.6.2 Patients and Methods 
16 healthy volunteers were recruited from hospital staff and personal contacts, exclusion 
criteria were a respiratory tract infection within two weeks of testing, and any pre-existing 
respiratory condition.  9 children with CF were recruited from the paediatric outpatient clinic 
at the Royal Brompton.  All were clinically stable at time of testing, and had no new 
pathogens, increase in symptoms or requirement for a change in antibiotics (routine 
prophylaxis was permitted) in the two weeks prior to testing.  Patients completed MBW 
tests on both devices as described above at the same visit to the Royal Brompton, the 
machine order was determined using a random number generator (The Random Number 
Generator, open source software distributed by Saccenti.com).  The aim was for subjects to 
complete three washouts on each piece of equipment (6 washouts in total) but in practice 
this proved difficult in the paediatric patients.  The patients were tested under a joint ethical 
approval between the Royal Brompton and Royal Hospital for Sick Children, Edinburgh, 
entitled “Validation of photoacoustic mass spectroscopy device (Innocor) for multiple breath 
washout of inert gas in infants and children” (REC number 07/S1102/40). 
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2.6.3 Results 
Two young children in the healthy control group were excluded because only one washout 
was completed on each machine.  Among the other patients and across both machines, a 
total of 12 individual washouts were discarded as they did not meet acceptability criteria 
(see section 2.5.1); for these patients LCI and FRC is then calculated from the remaining two 
acceptable washouts for that piece of equipment.  
There was no mean difference between FRC (the primary quality control measure of MBW) 
between the two machines.  There was no difference in LCI in CF patients; there was a 
slightly higher LCI recorded for normal subjects on the AMIS2000 when compared with the 
Innocor.  When the coefficients of variation for LCI and FRC are considered, there was no 
greater between-device variability than the within-device variability for any of the groups 
(see Table 2.2).  When Bland-Altman plots of the LCI and FRC difference versus the mean are 
made (See Figure 2.11 below), no systematic bias was observed.     
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Table 2-2– Comparison data between the Innocor and AMIS 2000.  There is no difference 
between FRC for either group or LCI for CF patients, there is a slightly higher LCI for healthy 
controls (* - p<0.05).  There is no greater coefficient of variation (CV) between devices than 
within devices. 
 
 
 
 Healthy Volunteers CF 
n 14 9 
Age (years, range) 11.7 (3-49) 7.4 (0.4-11) 
 AMIS2000 Innocor AMIS2000 Innocor 
Mean LCI (SD, range) 
7.47 (0.8, 6.5-
9.33)* 
6.91 (0.6, 6.21-
8.64)* 
10.4 (1.5, 7.96-
12.3) 
10.66 (2.2, 7.03-
14.25) 
Mean FRC (SD, range) 
1.62 (0.9, 0.49-
3.35) 
1.5 (0.9, 0.54-
3.4) 
0.86 (0.6, 0.11-
1.75) 
0.87 (0.6, 0.15-
1.72) 
Mean (SD) within 
device CV% in LCI 8.57 (7.16) 4.57 (2.54) 8.95 (6.83) 5.19 (5.02) 
Mean (SD) within 
device  CV% in FRC 10.19 (6.97) 6.00 (3.64) 6.06 (8.68) 6.63 (5.29) 
 Between device 
Mean (SD) CV% in LCI 6.34 (6.72) 6.08 (5.66) 
Mean (SD) CV% in FRC 9.123 (7.08) 9.15 (9.45) 
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Figure 2-11 - Bland Altman plots of the difference versus mean for FRC and LCI (CF patients 
shown in red).  There is no systematic bias. 
2.6.4 Discussion 
The results showed no systematic bias between machines, and indeed the variability 
between machines was similar to the variability between tests on individual machines.  
There was no greater variability seen in CF patients than in healthy controls.  The chief 
limitation of this piece of work was the small sample size, particularly for CF patients.   This 
was primarily because performing three washouts for each piece of equipment was very 
time consuming and arduous for children, and even more so for those with CF who had 
longer test times.  This was even more of a problem in younger children with shorter 
attention spans, and very few paediatric subjects performed all six manoeuvres, and three 
only performed one trial for each piece of equipment. It is accepted that a larger sample size 
would have been ideal, but inspection of the data does not suggest that an important bias 
was missed.   
There was a 0.56 difference in the mean LCI between the two methodologies in the healthy 
control group.  Treatment effects of LCI so far appear to be around the magnitude of one 
unit (Section 1.7) and so this is less than that, but is clearly significant, making it clear that 
significant changes may be missed if these methods were to be used interchangeably. 
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There may be several reasons for this difference.  The differing software used for calculation 
and most importantly breath identification and volume calculation may have slight 
discrepancies.  It is also possible that the two differing test methodologies (for example 
differences in the flow past circuit tubing or the pneumotach) may result in adoption of 
differing tidal volumes of test subjects.  Lung model work conducted by Dr Macleod and 
collaborators (Horsley et al., 2014) also showed the Innocor in this configuration performed 
well on simulated lung volumes.  When tested on a model with an FRC of 0.5l and a 
respiratory rate of 30/min, accuracy of volume calculation was -0.9-2.9%, and on a model 
more similar to the infant lung (FRC 250ml, respiratory rate 60/min, VT 100ml) accuracy was 
-3.8-2.0%. 
Although the data here cannot be used definitively to show that the two methods are 
interchangeable, with no systemic error or bias established, I took the decision to use the 
Innocor for the work of this thesis.  The AMIS 2000 proved too unreliable in day to day 
testing to be used continuously for the level of recruitment needed for this work, as was 
shown by several breakdowns and extended times for repair.  As the Innocor was an 
acceptable alternative the results presented in Chapter 3-6 were obtained on the Innocor.
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2.7 Performing the MBW 
Full test protocols are included in the appendices for both the Innocor and mass 
spectrometer, this section gives an overview of the procedures and the problems that may 
occur for both devices. 
At the start of the test, the MBW program should be set running and the subject instructed 
on the correct placement of the mouthpiece.  The patient wears a noseclip to prevent gas 
leakage, and is encouraged to maintain regular tidal breathing using age-appropriate 
distraction methods. 
Older children and teenagers frequently prefer to play with mobile phones, tablet PCs or 
music players during the tests, and providing these devices do not obstruct equipment and 
they serve to distract them from being conscious of their breathing pattern, this is 
acceptable.  In those with severe obstructive disease in whom it is expected that the MBW 
will take a long time (>20 minutes) it is normally best to set up a film or television show on a 
laptop or tablet to ensure prolonged distraction. 
Younger children tend to need reassurance and a calming situation as much as distraction.  
Again, television shows and films play an important part in this, but also a favourite book 
being read, a favourite toy “participating” in the test with its own noseclip, or sitting on a 
parents lap (providing a suitable upright sitting position can be achieved) can often help to 
ensure the test is satisfactory.  With the very young, a sensory toy, or the opportunity to 
play with soft modelling dough in a colour of their choice during the test may help.  Usually, 
younger children will have less severe disease and therefore the extremely long washout 
times encountered in teenagers or young adults will not occur, as any period beyond 5 to 10 
minutes is frequently intolerable for an active toddler, even with the best distraction 
methods available. 
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Both respiratory rate and a graph of breathing pattern are displayed in real time, so these 
can be used along with observation of the patient to determine if tidal breathing is taking 
place. 
In some cases, patients with a very high respiratory rate may complain of breathlessness 
during the test.  The increased work of breathing through the open circuit is relatively small, 
but patients with severe disease or very high VTs may feel as though an insufficient volume 
of air is available.  This can normally be resolved by increasing the incoming flow through the 
gas regulator. 
Even once tidal breathing is reached, abnormalities may occur in the breathing pattern as a 
result of lung disease.  Two of the most common, cough and dysfunctional breathing/upper 
airway dysfunction, are shown in Figure 2-11 below.  Providing these episodes are brief, 
transitory and have not occurred throughout the entire washout the trace can normally be 
included in the results if it meets other acceptability criteria.  Essentially, the other washouts 
of the test are examined and if the trace with transitory breathing artefacts is within 10% of 
the FRC, and includes similar VT and CEV it will be included in the analysis. 
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Figure 2-12 Cough (A) and dysfunctional breathing (B) in comparison to normal breathing (C).  
In A, the coughs only affected this washout, and the patient was able to maintain a good seal 
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throughout, resulting in a similar CEV and FRC to their other washouts, and so the result was 
included.  In B, the patient had very severe dysfunctional breathing affecting all washouts so 
the data could not be analysed. 
Once tidal breathing is established, the next step is to observe when the tracer gas has 
reached a plateau.  With the Innocor, both a read out of the end tidal concentration and a 
graphical indicator of the SF6 level are available, for the AMIS 2000 these readouts are 
available on both the Testpoint software on the PC and also on the mass spectrometer 
screen itself.  The gas is considered washed in when a level with less than 0.003 % difference 
is occurring within each breath, and is normally shown by a flat line on screen. 
The cylinders used for this test are medical gas quality rather than calibration gas, and may 
be supplied with a variation in the gas concentration around the nominal value (4% for the 
mass spectrometer, 0.2% for the Innocor).  Cylinders at 0.2% with, for instance, 0.197% or 
0.203% are not uncommon.  When a new cylinder is started, the gas should be checked on 
the Innocor before a patient is tested, to ensure the correct value is used for the plateau.   
A common problem with the test is that an acceptable plateau cannot be reached in a 
reasonable time frame.  There can be several reasons for this.  The most common is a leak in 
the breathing circuit, especially around any connections in the circuit, particularly around 
the pneumotach, filter and mouthpiece setup.  These connections should all be thoroughly 
checked and this may resolve the problem.  It is also possible for the sampling needle to 
have worked slightly loose in its hole causing a small leak, or for the patients’ lip to have 
curled under the mouthpiece affecting the seal.  Poor positioning of the nose clip may also 
be a source of leaks – some patients with respiratory disease may have nasal pathology (for 
instance, polyps in CF or rhinosinusitis in PCD) so the nose clip may be uncomfortable and in 
readjusting it the patient has allowed a leak to occur.  
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If the leak appears as a drop in SF6 on expiration, it may be the result of the patient 
breathing extremely deeply or exhaling forcefully impairing the seal between the different 
items in the circuit.  Except in the case of patients with very large lung volumes (VT in excess 
of 1 litre and FRC in excess of 4 litres, for instance, which in paediatric practice would be 
very unusual) it is likely these large, deep, forceful breaths represent a departure from tidal 
breathing and should be discouraged.  A return to a more normal breathing pattern will 
normally resolve these leaks. 
In some cases the lack of gas plateau may not result from leaks, but from genuinely                                           
very severe obstructive disease.  It is unlikely in these patients that conducting a protracted 
washin and washout will provide any clinically useful additional information, and for 
research studies may not be possible in an acceptable study visit time frame. 
When a plateau is established, the T piece connecting the flowpast tubing to the mouthpiece 
is removed swiftly during expiration  
The first quality control point is the disconnection itself.  If it is not completed during 
expiration the first’ washout’ breath will not be room air and will invalidate the mathematics 
of the test.  A “clean” disconnect is normally shown as a sudden, sharp drop down to zero in 
the SF6 concentration in the first breath after the disconnection.  If the drop is more gradual, 
or does not reach zero, the test will not be analysable and the SF6 must be reconnected and 
washin re-established.   
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Figure 2-13 Disconnection of the flowpast circuit, showing a poor disconnection and a 
correctly performed manoeuvre.  On the poor example, the SF6 signal does not reach zero 
before it begins to rise again, therefore the patient did not take a breath of entirely room air. 
 
It is advisable to warn the patient of the impending disconnection, asking them to ignore this 
and just maintain their regular, tidal breathing.  If the patient is surprised by the sudden 
activity around the mouthpiece the breathing pattern may be altered, ruining the 
disconnection and invalidating the MBW.    Judging the correct point in expiration to remove 
the tubing improves with practice. 
Keeping watch for leaks and continuing to encourage a regular tidal breathing pattern are 
the most important aspects during the bulk of the washout.  If the gas seals are good and 
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the breathing pattern is tidal and stable, the test should be successful.  The next point at 
which problems may occur is determining endpoint. 
This occurs when [SF6] has fallen to 1/40
th of its starting concentration, in the Innocor MBW 
0.004% and 0.1% in the mass spectrometer MBW.  The resolution of the display that gives 
end tidal concentrations is to 3 decimal places however, so in practice that means a value 
just below much be reached to ensure the correct endpoint.  The analysis of the test 
requires that two consecutive breaths at or lower than this end tidal concentration. 
At the end of the test, the patient can remove the mouthpiece and nose clip to have a drink 
or at least a short rest before the next MBW begins.  In some very young children who have 
taken time to settle, and by the end of the washout have finally settled, it may be easiest to 
let them remain on the mouthpiece and simply reconnect the tubing when ready to restart 
the next washin, so as not to disturb them.  Given MBWs on young patients are often 
quicker due to lower lung volumes, higher respiratory rate and (crucially) more mild disease 
it is normally possible to complete three tests whilst they remain on the mouthpiece. 
With these quality control points in place, it is normally possible to produce good quality 
MBW washouts in most paediatric patients above the age of five. 
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2.8 Statistical methods 
All statistical tests for this thesis were performed on SPSS 17.0 (IBM, Armonk, USA).   
Equations used for these calculations are given below. 
Graphs were produced on Graphpad Prism (GraphPad Software Inc, La Jolla, USA).  Where 
calculations are shown on graphs these were checked with SPSS results for any discrepancy. 
Normal values for spirometry were calculated by the GLI2012 desktop software, which is 
produced by the Global Lung Function Initiative (GLI), a Task Force of the European 
Respiratory Society (www.lungfunction.org).  
2.8.1 Tests of normality 
The Shapiro-Wilk test was used to determine where data fitted the normal distribution and 
where it did not.  This test is suitable for small sample sizes (n<50) which is the case in most 
populations in this data set, but is also robust up to n=2000 meaning it can accommodate 
the one larger data set (CF complete patient data).  This makes it most suitable as it can be 
applied to all data here. 
It is also able to be visualised as a Q-Q plot (the relationship between expected and 
observed variables) in SPSS which makes it attractive for these kinds of analysis. 
The null hypothesis is that data are normally distributed, and that the test statistic is below 
p=0.05 this null hypothesis is rejected, and the data is not normally distributed. 
2.8.2 Descriptive statistics 
The LCI in disease, and many measures used throughout this thesis, fail tests of normality 
and therefore non-parametric statistics have been used throughout. 
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The exception to this is the presentation of LCI data for healthy volunteers.  This data is 
normally distributed and I wished to compare my results with those presented 
(parametrically) by other authors previously.  These data are therefore presented as mean 
and standard deviation.   
2.8.3 Standard deviation score (z-score) 
The standard deviation score is the number of standard deviations away from the mean that 
an individual data point lies. 
In lung function testing, it is commonly used as spirometry parameters vary with a patient’s 
age and height, making comparisons of the raw data in a mixed population impossible until 
normalised by a z score.  It is a substantial improvement on the older method of using 
“percentage predicted” which gives a considerably less accurate picture of the degree of 
abnormality.   
The complex mathematics (and, in children and teenagers, lookup tables) required to 
perform this calculation manually are beyond the scope of this thesis, and tools made 
available by the Global Lung Function Initiative (www.lungfunction.org) based on the work in 
the 2012 publication by Quanjer at al. (Quanjer et al., 2012) were used here, but in brief, a 
“LMS” model (as described by Cole et al previously (Cole et al., 2009)) was used, where M is 
the expected mean, S is the coefficient of variation, and L is the skewness of the distribution.  
Equations (for adults) and lookup tables (for children) are used to determine these based on 
an individuals’ height, ethnicity, age and gender, and then the z-score is calculated from the 
formula given below. 
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Where X is the measured value. 
 
2.8.4 Confidence limits of the median 
Where the median is quoted as a summary statistic, the range is included to give a measure 
of the spread of the data, and the 95% confidence limits of the median have also been 
quoted. 
Although not as commonly used as 95% confidence limits of the mean, these essentially give 
the same information – the range in which one can be 95% confident the true median value 
lies.  Like the median, they are essentially a ranked measure.  The equations below calculate 
the jth (for the lower limit) and kth (for the upper limit) value in the data that the upper and 
lower limits of confidence lie at, and the data must then be ranked and these points found 
manually.  As these values will not always be a whole number, it must be rounded to the 
nearest whole number and that value used.  This is a compromise peculiar to ranked data, 
and as such the 95% confidence limits of the median will always be an estimate. 
))1((96.1 qnqnqj   
))1((96.1 qnqnqk   
Where n is the total number of observations, and q is the quartile to be calculated (for 95% 
confidence limits this will be 0.5). 
2.8.5 Coefficient of variation (CV) 
The CV (sometimes known as the relative standard deviation) is the normalised measure of 
dispersion of a distribution, in this case applied to single variables so essentially the ratio of 
the standard deviation to the mean. 
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The CV for a single variable describes the dispersion of that variable in a way that does not 
depend on the mean value.  In this thesis it has been used to describe variability in a 
measure that shows increasing SD with increasing mean as a physiological effect. 
2.8.6 Tests of significant difference 
As the data is primarily non-parametric, the Mann Whitney U test (rather than a Student’s t 
test) is used to show whether the median of two data sets significantly different from one 
another.  The generated test statistic, along with the degrees of freedom, gives a p value.  
The null hypothesis is that there is no significant difference between the groups and they are 
drawn from the same population.  The level of significance, p, is the chance that the two 
samples are drawn from the same population - p=0.05, for instance, is a 1/20 chance the 
data are drawn from the same population, whereas p=0.01 is a 1/100 chance. 
2.8.7 Comparisons between multiple groups 
Kruskal-Wallis test (H-test) is a non-parametric ranked equivalent of analysis of variance 
(ANOVA), and allows more than two groups to be compared similar, in this case in similar 
manner to the Mann Whitney test.  A limitation of this is it identifies that one or more of the 
groups is different from one or more of the other groups, but does not identify which 
groups.  The Mann Whitney test must then be used to analyses specific sample pairs for 
significant difference. 
This test has been used to make comparisons between multiple disease and control groups 
within the data set. 
 
2.8.8 Tests of correlation 
Spearman’s rank correlation coefficient (or Spearman’s rho) is a ranked test used on non-
parametric data to test linear correlation between two variables, X and Y, where the test 
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statistic is between 1 and -1, and 1 is total positive correlation, 0 is no correlation, and -1 is 
total negative correlation (in a similar manner to Pearson’s r for parametric data).
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2.9 Ethical approval 
Ethical approval was obtained for all subjects being tested as part of this thesis.  The primary 
ethical approval was entitled “Non-invasive physiological biomarkers in health and disease” 
(REC number 10/H1101/69) and most patients were recruited under this. 
The exceptions are comparison patients in section 2.6 (“Validation of photoacoustic mass 
spectroscopy device (Innocor) for multiple breath washout of inert gas in infants and 
children” (REC number 07/S1102/40)), a subset of older CF and PCD patients in the main 
data set (“Longitudinal assessment of clinical measurements in patients with cystic fibrosis in 
preparation for a clinical trial of CFTR gene therapy - the Run-in Study” (REC number 
07/Q0703/78)) and the group of adult non-CF bronchiectasis patients in the main data set 
(”The reproducibility and responsiveness of the Lung Clearance Index (LCI) in Bronchiectasis” 
REC number LO/12/02345)).  This has been mentioned directly in the text where appropriate 
also. 
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Chapter Three – Initial experiments:  Characterising LCI in PCD 
 
This chapter reports on a series of experiments, the over-arching aim of which was further 
to explore the validity of the preliminary observations, reported in Chapter 1, which led to 
the work of this thesis. These included healthy control data, as one quality control measure 
for the actual measurements; confirmation of the initial observation in a larger cohort; 
exploring whether the measurements are more variable in PCD than CF, and if this is a 
source of error leading to artefactual differences between the two diseases; and the further 
exploration of these relationships by the introduction of an additional disease group, namely 
non-CF (non-PCD) bronchiectasis. 
3.1 Healthy control data 
3.1.1 Introduction and hypothesis 
One explanation for the disparate relationships found between LCI and spirometry in CF and 
PCD is that the measurements were not being correctly performed or there was an 
undetected problem with the equipment. In order to address this possibility, healthy adults 
and children were recruited to measure LCI via MBW on the Innocor device, to confirm that 
the results fell within the expected ranges found by other observers. 
The hypothesis for this experiment is that LCI in normal volunteers, as measured in this 
thesis will fall within the ranges for normal described by others, thus validating this 
methodology 
3.1.2 Subjects and methods 
47 healthy volunteers were recruited.  This sample size was opportunistic and reflected 
those able to be tested during the initial phase of recruitment for the work of this thesis; the 
initial recruitment plan aimed for 50 subjects, the same number in the other large study 
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published using this equipment at that time (Horsley et al., 2008a), but only 47 could be 
recruited in the time frame.  Both adults and children were recruited from hospital staff, 
personal contacts and siblings and friends of current patients at the Royal Brompton 
Hospital. 
Inclusion criteria were no history of serious respiratory disease or smoking, and no mild 
respiratory infections (including upper respiratory tract infections) in the two weeks prior to 
the test.  Height and weight was measured for all participants using a stadiometer 
(Harpenden Stadiometer, Holtain Ltd, Pembrokeshire, UK, accuracy range to +/- 1mm) and 
measurement scales (Seca, Chino, USA, class 1 measurement device)  Measurements were 
taken in indoor clothing without shoes.  
3.1.3 Results of healthy control data 
 Three volunteers were excluded at the recruitment stage, one due to a history of childhood 
asthma and two who admitted occasional smoking on closer questioning, leaving data from 
44 to be analysed. 
The mean age of volunteers was 21.6 years (range 3.2-51.3), 20 patients were children and 
young people under the age of 16, and 24 were adults. There were 22 males, mean height 
was 148cm (range 88cm to 183cm) weight was 50.7kg (range of 15.3kg to 93.6kg).  
41 of 44 subjects completed three washouts, and three completed two washouts.  The three 
who did not perform the full three washouts were all children who declined to continue 
after the second washout.  Six subjects who completed three washouts had one repeat 
discarded, either due to poor quality of the trace (due to cough, leaks, or non-tidal breathing 
pattern) (n=4) or an FRC that fell outside the 10% difference from the other washouts thus 
suggesting it was technically unacceptable (n=2).  No subjects reported any adverse effects 
from the MBW, other than a dry mouth, probably resulting from the dryness of the test gas. 
133 
 
LCI was normally distributed in the healthy control group, so parametric statistics could be 
used.  Other papers (see Table 3-1 below) also used mean and standard deviation as the 
data were normally distributed. 
The mean (standard deviation) of LCI in this healthy control group was 6.6 (0.68), range 5.51 
to 8.35. The 8.35 result appears visually to be an outlier as the next lowest result is 7.61. 
Figure 3-1 below shows a graph of age against LCI for these healthy control subjects. 
 
Figure 3-1 Age versus LCI in healthy control subjects.  There is a relationship between LCI and 
age (p=0.01, r=-0.39). 
3.1.4 Discussion of healthy control data 
Table 3-1 shows previously reported studies in the literature for comparison with these 
results.  It should be noted that whilst the standard deviation is slightly above that reported 
by others, the present cohort spans by far the largest age range. 
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Study Methodology Subjects (n) 
Age (mean, 
range) 
LCI (SD) 
Upper 
limit of 
normal 
Aurora et al 2005 
Mass 
spectrometer 
30 4.3 (3.5– 5.1) 6.9 (0.4) 7.68 
Aurora et al 2004 
Mass 
spectrometer 
33 11.3 (8.2-14.4) 6.5 (0.5) 7.48 
Gustafsson et al 
2003 
Mass 
spectrometer 
28 11.4 (3-18) 6.3 (0.4) 7.08 
Macleod et al 2009 Innocor 29 11.1 (5-16) 6.2 (0.5) 7.18 
Aljassim et al 2009 
Mass 
spectrometer 
18 18 (17-18) 6.5 (0.5) 7.48 
Horsley et al 2008 Innocor 12 11 (6-16) 6.3 (0.5) 7.28 
Horsley et al 2008 Innocor 48 33 (19-58) 6.7 (0.4) 7.48 
Gustafsson 
(unpublisheda) 
Mass 
spectrometer 
44 41.1 (30.8-51.4) 6.6 (0.5) 7.58 
Fuchs et al 2009 EasyOnePro 44 12.1 (5.3-20.3) 6.2 (0.4) 7.0 
Lum et al 2013 
Mass 
spectrometer 
255 
Mean not given, 
range 6-19 
6.54 (0.5) 7.56 
Current study Innocor 44 21.6 (3.2-51.3) 6.6 (0.7) 7.97 
 
Table 3-1 The normal data obtained for this thesis in comparison with previously published 
work.  This table is adapted from a similar figure by Robinson et al (Robinson, Goldman & 
Gustafsson, 2009) including cohorts published since that paper (Lum et al and Fuchs et al) 
The unpublished data a is taken from that paper.  In the recent work by Lum and colleagues, 
data on mean and standard deviation were only available in their cohort for children aged 6-
19 rather than their full paediatric age range. 
The healthy control data for LCI falls within the expected range for that obtained from other 
centres, with a mean of 6.6.  The standard deviation is slightly larger (at 0.7 compared with 
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0.5) than reported elsewhere, and this may result from the wide age range included in this 
study giving a higher variability than the other comparable studies, which mostly 
concentrated on either adults or children, whereas these data includes both. If my data is 
split into the upper and lower 50% for ages, the standard deviation for both groups drops to 
0.6, suggesting this is in fact the case.  The most recent study of normal ranges (Lum et al., 
2012) reports that the upper limit of normal is higher in younger children, but suggests in a 
much larger sample size that for children over age 5 to 6 years, the upper limit of normal 
should be 7.56, with is comparable with the current estimate. 
This higher ULN in young children was not appreciated when the work of this thesis was 
originally undertaken, and because it could only be detected in the extremely large dataset 
of Lum and colleagues (n=255) after the normal data for this study had been obtained.  To 
attempt to offset this and to show results more concordant with one another, Table 3-2 
(below) shows just those studies which do not include children below 6, and the values from 
the present data set then those very young children are removed from the cohort. 
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Study Methodology Subjects (n) 
Age (mean, 
range) 
LCI (SD) 
Upper 
limit of 
normal 
Aurora et al 2004 
Mass 
spectrometer 
33 11.3 (8.2-14.4) 6.5 (0.5) 7.48 
Aljassim et al 2009 
Mass 
spectrometer 
18 18 (17-18) 6.5 (0.5) 7.48 
Horsley et al 2008 Innocor 12 11 (6-16) 6.3 (0.5) 7.28 
Horsley et al 2008 Innocor 48 33 (19-58) 6.7 (0.4) 7.48 
Gustafsson 
(unpublisheda) 
Mass 
spectrometer 
44 41.1 (30.8-51.4) 6.6 (0.5) 7.58 
Lum et al 2013 
Mass 
spectrometer 
255 
Mean not given, 
range 6-19 
6.54 (0.5) 7.56 
Current study Innocor 35 25.9 (6.33-51.3) 6.47 (0.6) 7.65 
 
Table 3-2 As table 1, above, but with only those studies that contained subjects 6 years of 
age or older, as work by Lum and colleagues in 2013 showed a raised ULN in children of this 
age which had not been fully appreciated prior to that study.  The results of this study were 
then recalculated with the 9 children under 6 that had been included removed from analysis.  
The data is very similar to that reported in other studies. 
The Innocor methodology used here has been previously described by other authors 
((Horsley, 2009; Macleod et al., 2009; Horsley et al., 2008a)) so it was not unexpected, but 
nonetheless reassuring, that the results in the present study are comparable.   
In conclusion, this proves the hypothesis that erroneous performance of LCI testing was not 
the reason for the initial observations. Furthermore, the Innocor methodology was robust in 
the age group which were intended to be tested (school age children older than 4 years old).  
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Had the Innocor data not been of sufficient quality the mass spectrometer method of MBW 
would have been an alternative; however, as this machine is significantly more expensive, 
time consuming and unreliable than the Innocor I decided to proceed with the Innocor 
method on the strength of these results. 
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3.2 Confirmation of original observation in a larger cohort 
3.2.1 Introduction and hypothesis 
Although the pilot data for this study suggested that in PCD the relationship between FEV1 
and LCI was dissimilar to that observed in CF, the numbers were quite small particularly for 
the PCD group, as PCD is a rare condition and few patients with this condition had had 
clinically-indicated MBW performed at the time the work commenced.  In order to address 
this, a larger cohort was recruited. 
The hypothesis for this experiment is that LCI and FEV1 in PCD do indeed have a different 
relationship from the established one observed in CF, and that the initial observations were 
not artefactual related to a small study size. 
3.2.2 Subjects and methods 
125 CF and 32 PCD patients diagnosed using standard criteria (See 2.1) were recruited from 
the respiratory clinics and wards at the Royal Brompton Hospital.  There was no attempt to 
match the groups for clinical status. This was a separate cohort to those used in the initial 
observation that led to the work of this thesis.  Participants were excluded if they were 
actively suffering an exacerbation of respiratory symptoms at the time of, or two weeks 
prior to testing, if they had any new respiratory symptoms or newly diagnosed pathogens in 
the previous two weeks, and if they had any other serious comorbidity (for instance, 
awaiting or recently undergone surgery for a congenital heart defect in the PCD patients 
(Brueckner, 2007)).    They were primarily outpatients at the time of testing, although some 
patients were tested during an elective, planned admission (e.g. for regularly scheduled 
intravenous antibiotics), providing that admission did not coincide with an exacerbation, 
increase in symptoms or diagnosis of a new pathogen as stated above.  Patients were also 
excluded if they were currently infected with a pathogen that could prove a serious infection 
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control hazard, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Burkholderia 
cepacia.  In practice only 12 CF patients had to be excluded for this reason. 
Sample size was opportunistic – the CF subject number of 125 represents all eligible CF 
patients that were available and willing to participate who attended outpatient clinic or 
wards at the Royal Brompton hospital during the recruitment period of this study. The 32 
PCD patients also represent those available and willing to participate in that time frame, 
although a more active attempt to recruit was made in the case of this rarer disease, and 
patients not available or eligible to participate at the time first approached were contacted 
at a later date and requested to join the study if they had become eligible (e.g. had 
recovered from a pulmonary exacerbation), and in some cases specific study visits to the 
hospital were arranged to participate in this work (whereas almost all CF visits were included 
in the patients next clinic appointment or elective admission).  PCD recruitment is primarily 
lower than CF due the relative rarity of this condition, for example there are approximately 
900 CF patients registered at the Royal Brompton compared with less than 300 PCD patients 
(also, Royal Brompton is the only PCD centre in London whereas there are several other 
specialist CF centres). PCD patients also in general have a lower disease burden and less 
hospital visits than CF, making it difficult for some families to participate if they were 
unwilling to make a special trip for the research and were not due to be seen clinically for 
some time.  There is also a larger proportion of PCD patients who do not have English as a 
first language (and may not in fact be English speakers at all) than in the CF population, 
primarily due to the different prevalence of these conditions in different ethnic groups.  
Though attempts were made to approach patients only when translation services were 
available or when an English-speaking advocate was present, some families could not give 
informed consent to the study according to principles of good clinical practice due to a 
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language barrier, and thus could not be recruited into the study, which further reduced the 
available pool of patients. 
Basic demographic information on patients at the Royal Brompton is recorded for clinical 
and audit purposes.  The PCD service has to February 2015 129 paediatric patients, with a 
median age of 10, IQR 6-14, 61 being female and 68 male.  There are 169 adult patients, with 
a median age of 36, IQR 27-48, 105 being female and 64 male.  The CF service has 318 
paediatric patients at the beginning of 2014 with a median age of 9.41, IQR 4-14, with 167 
females and 151 males.  The adult CF service has 666 patients at the beginning of 2014 (73 
of whom are post-transplant) with a mean age of 33, range of 16-72, 304 being female and 
362 male (figures kindly made available by the Amelia Shoemark (PCD patients), Hannah 
Wright (CF database manager, Royal Brompton, Paediatrics) and Drs Nick Simmonds and 
Sandra Scott, and Juliana Burgess (Royal Brompton CF adult service). 
Table 3-3 below gives details of the cohorts for this thesis, and there are some clear 
differences between this and the full cohort, with the youngest and oldest patients poorly 
represented in this sample.  Children below 6 were intentionally excluded, due to their 
inability to perform both MBW and spirometry to consistently technically acceptable 
standards, and so this represents a deliberate departure from the full cohort.  There was no 
conscious attempt made to exclude older patients who likely have worse lung disease.  In 
patients with severe disease, washout times required for MBW become unacceptably long, 
with individual MBWs potentially taking more than 30 minutes per run; and they are in any 
case likely less informative than in milder patients.  It is largely due to this technical difficulty 
that those with severe disease are under-represented, and this may explain the lack of older 
patients. 
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Due to the difficulties of recruitment, the 6 PCD patients who provided data for the original 
observation were not available to be re-tested and so their original results was added to the 
32 specifically recruited.  Both are included in this cohort analysed here, to bring the total 
number of PCD patients to 38.  The additional 6 had height, weight and MBW measured as 
the later recruits, but were tested in 2008 before this thesis was begun.  Results for the 
analysis of both a total cohort of 38 and the newly recruited 32 are given in the Results 
section below. 
 
 
Subjects 
(number of 
adult patients) 
Age (mean, 
range) 
Gender 
(males, %) 
Infection with 
Pseudomonas 
Aeruginosa (%) 
CF cohort 125 (14) 16.3 (7.5-59.2) 57 (46%) 83 (66%) 
Total PCD cohort 38 (14) 22.8 (5.7-62.2) 14 (37%) 11 (29%) 
Original PCD cohort 6 (0) 14.52 (13.2-16.1) 3 (50%) 0 
Additional PCD 
recruitment 
32 (14) 22.07 (5.7-62.2) 
13 (38%) 
11 (32%) 
 
Table 3-3 Demographics of the patients recruited for this study.  For the CF patients, a 
completely new cohort was recruited from the original results, as this condition is (compared 
with PCD) much more common and recruitment was easily done from the CF service at the 
Royal Brompton Hospital.  In PCD, the patients in the original observation (n=6) were 
included in the total cohort, n=38, as far fewer PCD patients are available.  In italics, the 
bottom two rows of the table show those 38 PCD patients broken down into original and 
additional recruitment.  
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Patients’ height and weight was measured before physiology measurements (stadiometer 
and scales as above).  Spirometry was performed (as described fully in 2.0) according to 
ERS/ATS guidelines, with the best values of three acceptable attempts being taken as values 
used, using an EasyOne spirometer, calibrated according to manufacturer’s guidelines.   
MBW was performed sitting, using the Innocor protocol (as described fully in 2.4) using SF6 
as the washout gas, and analysed after the visit on the Testpoint software environment.  
72% of patients completed three test runs, the remaining patients completing two.  The 
primary reason for not completing three tests was poor subject tolerance of either 
mouthpiece or noseclip (particularly among the younger children) but other factors were 
involved. During testing of 4 patients the hardware developed a fault that could not be fixed 
in an acceptable time frame to continue with the third run, and (particularly for those being 
seen in conjunction with an outpatient appointment) in some cases there was no time for a 
third run before a clinical appointment elsewhere in the hospital had to be attended or 
before transport home had been booked.   
All patients were required to have reproducible LCI and FRC data (FRC within 10%, above) 
usable from at least 2 MBW runs to be included in this data set. 
 
3.2.3 Results  
Neither LCI nor spirometry were normally distributed in the disease groups (Shapiro-Wilk 
test significance is < 0.05) and so non-parametric statistics are used from here onwards in 
this chapter, unless stated otherwise. 
There was no significant difference between LCI in the PCD and CF cohorts, and both were 
higher (more abnormal) than that seen in the healthy normal data previously given above. 
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Figure 3-2 Comparisons of LCI between healthy controls and disease groups.  Disease groups 
were higher than controls (p<0.0001 for both) but there was no difference between the two 
conditions.  A Bonferroni correction for multiple comparisons was made.  The dotted line 
shows the upper limit of normal (ULN) for these LCI results. 
For FEV1, however, results were considerably worse in the PCD group, with only 4 PCD 
patients showing normal spirometry. 
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Figure 3-3 Spirometry results.  FEV1is significantly worse in PCD (p=0.005) than in CF. The 
dotted line shows the LLN (lower limit of normal -1.64 z scores) for these results. In CF, there 
was a strong (p<0.0001, r=-0.6) correlation between LCI and FEV1.  Where only one test was 
abnormal, this was more likely to be LCI, with 35 patients (28%) having normal FEV1 but 
abnormal LCI, compared with 7 (6%) with normal LCI but abnormal FEV1. 
 
Figure 3-4  LCI and FEV1 in CF.  A clear inverse relationship can be seen between the two lung 
function measures.  Dotted lines show ULN for LCI, or LLN for FEV1. 
145 
 
In PCD, there is a much weaker relationship between LCI and FEV1.  
 
Figure 3-5 FEV1 and LCI in PCD where A) uses the Caucasian equations for South Asian 
children(p=0.056, r=-0.3) and B) uses the Black equations for South Asian children(p=0.044, 
r=-0.3)  . Those cases where the value has been altered are shown in red.  In both cases the 
relationship seen is weaker than that seen in CF.  Where only one test is abnormal, in this 
case it is more likely to be FEV1 (5 patients as opposed to 3 using Black equations, 4 patients 
as opposed to 3 using Caucasian equations), however the majority of patients (30) had both 
indices abnormal (using Caucasian equations one patient had normal results for both 
investigations, using Black equations none did). 
 
This data is complicated by the lack of specific reference equations for South Asian patients 
with regard to spirometry.  In the CF population, one child is of South Asian background and 
(in such a large cohort) omitting this child’s results makes no difference to these statistics, 
whereas the PCD population contains 13 out of 38 patients with a South Asian background.  
The data has been analysed using both the Caucasian equations (according to pre-2012 
recommendations for this group(Stanojevic et al., 2009)) and the Black equations (according 
to the 2012 recommendations(Quanjer et al., 2012)) to cover this population.  When the 
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Caucasian equations are used the relationship is just non significant (p=0.056, r=-0.3) and 
when Black equations are used it is just significant (p=0.044, r=-0.3) (Figure 3-5, above).   
Importantly, when only those children for whom there are suitable reference equations 
(Caucasian and Black children) are analysed, there is no correlation (p=0.2, r=-0.2, n=24).  
When only the newly recruited 32 patients are included (excluding the 6 that formed the 
original observation for the thesis) the result is also non-significant (p=0.38, r=-0.15). 
From here onwards, the adjusted spirometry values where the Black equations are used for 
people of South Asian origin, in line with the most recent recommendations(Quanjer et al., 
2012), have been used. 
As the data is non-parametric, regression analysis and then comparison of those regression 
lines is inappropriate, and a more suitable statistical analysis of this distribution is to 
partition the results into a simple 2x2 cross tabulation, using the ULN of LCI and LLN of FEV1 
as the boundary lines, then producing counts for each cell and conducting chi-squared 
analysis.  Though this is an acceptable solution in CF, in PCD a combination of a smaller 
sample size and a few patients with normal results (particularly for FEV1) means that these 
data do not meet acceptability criteria for the chi squared analysis as the expected counts in 
some cells are too low for the analysis to be performed.    
For that reason, I have graded the patients in whether they fall inside or outside of 2 z-
scores from the mean, as opposed to the ULN and LLN normally used for these results.  This 
does not lead to the loss of any data, as the patients in the CF group with normal results will 
still be included in the analysis, but allows the unwell patients to be divided into a truly 
severe cohort (LCI or FEV1 > 2 Z-scores from the mean) and those with more moderate lung 
disease.   
 
147 
 
 
 
Figure 3-6 below shows this process and the new division of the data this represents. 
 
Figure 3-6 Adapted cross tabulations.  The grey lines show the ULN and LLN as would have 
been used to divide the data into cross tabulations using normal methods.  In the PCD graph 
(left), this would have left three cells of the 2x2 table with expected values less than 5, 
making chi squared analysis impossible.  The black dashed line shows the lines given as an 
additional z-score above which the ULN of LCI and below which the LLN of FEV1 would 
normally be calculated.  This adjustment gives expected values above 5 for all of the cross 
tabulations so chi-squared analysis can be carried out. 
Table 3-4, below, shows the results of this 2 Z-score division on the data. In CF, most 
patients (65) had severely abnormal results for both investigations, 30 showed a severely 
abnormal LCI in the presence of more moderate spirometry results (which is an expected 
result as LCI is thought to be a more sensitive test for lung disease in these patients), 25 had 
moderate results in both investigations, and a small number (7) showed severely abnormal 
spirometry in the presence of a moderate LCI result.  Though this is to some extent 
counterintuitive, other studies show very small but persistent number of CF patients with 
worse spirometry than their LCI result would suggest (Owens et al found 1/60(Owens et al., 
148 
 
2011), Gustaffson et al found 1/43(Gustafsson, Aurora & Lindblad, 2003)) , so this is not a 
wholly unexpected result.  In contrast in PCD, 15 had two severely abnormal results, and 8 
had more moderate results for both investigations.  9 patients had a moderate FEV1 result 
and a severely abnormal LCI, and 7 had a showed moderate LCI result in the presence of 
severely abnormal FEV1.   The Black spirometry equations have been used for South Asian 
children in this analysis, but the results pattern is very similar if the Caucasian equations are 
used. 
 
  Moderate FEV1 Severe FEV1 
CF Moderate LCI 25 6 
 Severe LCI 30 65 
PCD Moderate LCI 8 7 
 Severe LCI 9 15 
 
Table 3-4 The distribution of results seen in CF and PCD.  The CF results show a clear pattern, 
where most patients have highly abnormal results for both investigations, some have more 
moderate results for both investigations, some have a worse LCI than their FEV1 result (which 
is expected as LCI is thought to be more sensitive to changes in these patients), and a very 
small but persistent group have more severe FEV1 than LCI results (again as found in other 
studies).  In PCD, there are more patients with highly abnormal results in both categories 
than any other combination, reflecting the severity of these patients, but there is effectively 
no difference between the other three categories, showing no clear pattern as seen in CF.  
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If chi squared analysis is performed, the CF data shows a highly statistically significant result 
of p<0.0001, suggesting this data represents a strong departure from the pattern that would 
be expected to be observed due to chance.  In PCD, however, p=0.51 suggesting that the 
pattern is not significantly different to the one observed by chance, and further suggesting 
the two variables tested here, LCI and FEV1, are not correlated with one another. 
As with chi-squared, using conventional ULN and LLN cutoffs in these data does not allow 
positive predictive value (PPV) and negative predictive value (NPV), which may yield more 
clinically useful analysis of the results, to be used, as one PCD category would contain no 
data, giving a value of zero and making the ratios of PPV and NPV completely unusable.  So, 
the divisions at 2 z-scores as used for the chi squared above have also been applied here to 
calculate PPV and NPV.  In CF, LCI has a PPV of 0.68 and a NPV of 0.81 for FEV1, and FEV1 has 
a PPV of 0.91 and a NPV of 0.46 for LCI.  This is as expected, a severely abnormal LCI may not 
be discriminatory for a severely abnormal FEV1 since it is often more sensitive to lung 
disease, but a more moderate LCI is a better predictor of a moderate FEV1, whereas a 
severely abnormal FEV1 very often suggests a severely abnormal LCI, however a more 
moderate FEV1 does not necessarily predict a moderate LCI. 
In PCD, LCI has a PPV of 0.62 and a NPV of 0.53 for FEV1, and FEV1 has a PPV of 0.68 and a 
NPV of 0.47 for LCI.  These values show that there is some association between severely 
abnormal LCI and FEV1 (reflected by the 0.62 and 0.68 values) but no strong discrimination, 
and the very low NPV show a more moderate result on either test is a poor predictor of the 
result on the other. 
In summary the relationship between FEV1 and LCI in PCD is much less direct than that 
observed in CF. 
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PCD is not a homogenous disease, different patients show different ciliary ultrastructural 
defects, all of which result in inadequate MCC and the disease phenotype of PCD.  It is 
possible, however, that different ultrastructure defects may lead to differing LCI results.   
PCD patients had a variety of ultrastructural defects.  14 have an outer dynein arm defect, 
11 have an inner dynein arm, 5 have an outer and inner dynein arm defect, 3 have a 
transposition defect, and the remainder have a mixture of rarer defects of the central pair or 
the radial spokes.  One PCD patient had a history of severe asthma, the others had no 
significant co-morbidities unrelated to PCD. 
EM results were available for all 38 PCD patients in the full PCD cohort. These studies were 
carried out by the EM team at the Royal Brompton Hospital, during the PCD diagnostic 
pathway.  The results were kindly provided by the patients’ clinical teams. There were no 
differences in the LCI results within the different morphological PCD groups (Figure 3-7, 
below) 
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Figure 3-7 Ultrastructure defects.  There was no significant difference between the various 
ultrastructural defects in PCD. The red triangles in the ‘Other’ group represent those patients 
with both outer and inner dynein arm defects. 
One weakness of this study is there is no longitudinal data available for patients, to assess 
the change in lung function over time.  In CF and PCD progressive worsening of lung disease 
is often seen over time, but whether changes in LCI reflect this process is currently unknown.  
In the absence of longitudinal data, the effect of age on LCI was assessed to see if worse 
results were obtained in older patients, possibly implying a deterioration over time. 
For both CF and PCD, there was a significant trend towards increasing LCI with increasing 
age. 
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Figure 3-8 The effect of age on LCI in the initial cohort.  Age is a statistically significant 
influence on LCI in both disease groups (CF p=0.002, r=0.3; PCD p=0.001, r=0.5) 
 
3.2.4 Discussion of results aiming to confirm the original observation 
The additional data collected in PCD and CF patients confirms the original observation that 
formed the basis of this thesis, and also the hypothesis of this subsection; that the 
relationship between spirometry and LCI in PCD is not the same as the established 
relationship in CF. 
The large CF cohort recruited confirmed very clearly the known relationship between LCI and 
FEV1; this also provides a biological control, confirming that the LCI results using the present 
equipment obtained from patients with a suppurative lung condition (CF) are also as would 
be expected from the data described by others previously.   
In PCD, interpretation of the results is complicated by the lack of reliable predictive 
equations for South Asian children.  13/38 of the PCD patients fall in this demographic 
group, as opposed to only one CF patient, so the effect of this uncertainty is 
disproportionately large in this patient group.  In this data set, which equations are used 
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affects whether the results are statistically significant.  In the absence of better equations, 
the data has been analysed to both methods that have been recommended in recent years, 
and also analysed having excluded those children this would effect. Furthermore, statistical 
significance reflects a probability, rather than being ‘all-or-none’; at best the relationship in 
PCD is of borderline significance, and of no statistical significance if a correction for the 
multiple correlations performed in this thesis is applied 
It has been stated that it is unlikely that any normal equations for spirometry will be 
produced for South Asian children in the near future, and in any case these might well not 
solve the problem as there is considerable variance in factors such as height and weight 
across populations in the South Asian area so there is no one homogeneous group for which 
an equation can be produced (though the extent to which this may also be the case for 
white and black populations would also have to be explored in that case).  Ideally, predictive 
values based on the child’s body measurements alone would be generated, though a data 
set entirely based on this, and in fact which measurements would be chosen for this, is still 
very much in development. Hence my choice of the current way of dealing with this issue 
(above) appears to be the most logical for the immediate future. 
Using the Black equations to analyse the South Asian results, there is a significant correlation 
between LCI and FEV1 in PCD.  It is, however, fairly weak (p=0.044 and r=-0.3).  It seems 
unlikely that the smaller number alone is responsible as 38 patients still represents a 
considerable data set, even if not as large as the CF population (n=125). When the Caucasian 
equations are used, the result is not significant (p=0.056 and the r remains at r=-0.3, hence 
in fact the variances in LCI accountable for by FEV1 is the same, and less than 10%).  
Importantly, when the South Asian children are removed, leaving 24 white and black 
patients to be analysed, the result is definitely not significant at p=0.2, r=-0.25, so in these 
patients where there is no uncertainty due to ethnicity the result is very clearly non-
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significant. It should also be stated that statistical significance is not ‘all-or-none’, but refers 
to the probability of an event being due to chance. Hence the difference between p=0.44 
(significant) and p=0.56 (non-significant) with the same r2 value is in any case more apparent 
than real. 
There is an inherent degree of uncertainty when using correlation as the chief criterion for 
determining a relationship (or the lack of one) and this is an acknowledged weakness with 
this type of analysis.  The results are visually not that dissimilar, and the possibility of the 
smaller sample size in PCD giving an erroneous lack of significance cannot be ruled out.  
Attempts have been made to address this, by the use of the chi-squared test to predict the 
expected distribution of the smaller PCD sample were it following the same pattern as the 
CF cohort, but by its nature this test requires the data to be grouped into broad categories 
rather than interpreted as absolute values. When chi-squared is used to analyse the 
comparison of FEV1 and LCI in CF, the results are statistically significant, showing a clear line 
along which LCI and FEV1 both progressively worsen as lung disease progresses.  In PCD, the 
same test gives a non-significant result, which does suggest the two measures may be 
different from one another in this condition, but in this sample size it is difficult to confirm 
this, and this is an acknowledged weakness.  Similar results have also been found by another 
group in a patient cohort of similar severity previously (Green et al., 2012), which also is 
supportive of this conclusion. 
PPV and NPV for CF are as would be expected from this well characterised patient group – in 
general LCI and FEV1 are good predictors of one another, though a more moderate result on 
one does not preclude a more severe result on the other, and in general where one is worse 
than the other LCI is much more commonly the more abnormal measure.  In PCD, however, 
severely abnormal results on one measure was at best a weak positive predictor (around 
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65%) of a severely abnormal result on the other, and a more moderate result did not in any 
way predict the outcome of the other test (less than 50%, or worse than flipping a coin). 
There appears to be no effect on LCI results of ultrastructural defect; this is expected, as 
there are no known correlations between pulmonary phenotype and ultrastructural class, 
and furthermore, the small size of the subgroups means that this analysis is seriously 
underpowered. Age affects LCI in both PCD and CF patients, and it appears that LCI worsens 
over time in both conditions, as older patients show higher LCI than younger subjects.  This 
assumes, however, that the older patients represent advanced disease and at this point a 
“healthy survivor” effect cannot be ruled out, and these surviving older patients may in fact 
represent the mildest lung disease of their cohort.  Furthermore, diagnostic awareness and 
treatment may have changed over time, further complicating interpretation. In the absence 
of longitudinal data it is not possible at this point in the analysis to address this issue further. 
This data confirms the relationship between FEV1 and LCI in PCD is not the straightforward, 
highly correlated linear relationship seen in CF, confirming the original observation on which 
this thesis is based.  This is similar to that shown by other authors previously, published 
during the work of this thesis (Green et al., 2012). 
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3.3 Is increased variability a source of error in PCD? 
3.3.1 Introduction and hypothesis 
If LCI results are more variable in PCD than CF, this could be the source of the unexpected 
relationship seen in PCD between LCI and FEV1.  The LCI result is the mean of 2 or more LCIs 
calculated from repeat MBW tests.  If these individual results are more variable in PCD, the 
mean LCI result may be a less accurate indicator of lung disease in PCD than CF, and this 
could be why it may not correlate with FEV1. LCI variability has never been determined in 
PCD. 
The hypothesis for this experiment is that variability in LCI measurements is the same in PCD 
and CF, and thus variability differences do not account for the observations underlying the 
work of this thesis. 
3.3.2 Subjects and methods 
A sample of 38 CF patients matched for age, gender and infection control status with the 38 
PCD patients were studied.  This was a subgroup of the CF patients reported in the previous 
section. The methods were therefore exactly as reported above. The variability of the LCI 
measurements for this cohort were examined by comparing the SD and coefficient of 
variation for each of the patients in this sub group 
 
Subjects 
(number of 
adult patients) 
Age (mean, 
range) 
Gender 
(males, %) 
Infection with 
Pseudomonas 
Aeruginosa (%) 
CF 38 (14) 21.8 (7.2 – 59.1) 14 (37%) 11 (29%) 
PCD 38 (14) 22.8 (5.7-62.2) 14 (37%) 11 (29%) 
 
Table 3-5 The matched cohorts of CF and PCD patients assessed for variability.   
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3.3.3 Results of variability analysis 
When the SD of the LCI tests for each individual patient was plotted against the actual LCI 
(Figure 3-9, below), considerable overlap can be seen between the two disease groups, 
suggesting there is no trend towards higher variability in PCD.  However, it can clearly be 
seen that there is a larger variability at higher mean LCI values, and so the coefficient of 
variation (COV) was plotted against LCI (Figure 3-10) to attempt control for this. 
 
 
 
Figure 3-9 Standard deviation and LCI between CF and PCD, there is no trend towards 
increased SD in one group compared with the other.  There is a higher variability when mean 
LCI is higher, however. 
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Figure 3-10 Coefficient of variation and LCI between CF and PCD, there is no clear trend 
towards increased variability of LCI in either disease group. 
When a Mann-Whitney test for differences between either the SD or the COV between the 
two disease groups shown in Figures 3-9 and 3-10 is performed (the data is non-parametric) 
there is no statistically significant difference between the two. 
 
3.3.4 Discussion of variability analysis 
The work reported here shows that there is no increase in variability seen in the 
measurement of LCI in PCD patients when compared to a matched cohort of CF patients, 
confirming the hypothesis of this section. 
In both conditions, there is a trend towards higher variability with higher LCI.  This increasing 
variability with increasing lung disease would be expected, as LCI is a dynamic physiological 
measurement, and patients with more advanced obstructive lung disease may have an LCI 
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that alters over the course of the testing as a result of coughing or adjusting seated position. 
When the COV is used, both patient groups appear to have similar variability.  There is no 
increased variability in PCD leading to less reliable, more error-prone LCI measurements in 
this group, that if present may have explained the lack of relationship with spirometry 
measures. 
To ideally access repeatability of these measures, repeated sequential measurements would 
have been taken in patients of both disease groups across the disease spectrum in order to 
check for differences.  This is not practical for this methodology as three normal MBW runs 
can often take around 30 minutes (and potentially considerably longer in more unwell 
patients, as the increasing VI leads to much longer emptying times) and so to do an 
extended measurement series would take several hours of tolerating an uncomfortable 
noseclip and mouthpiece set up, which is simply not feasible in these patients.  Finally, of 
most relevance to the work of the thesis is the variability of the measurements actually used 
for the analyses; and no difference was seen. 
 
 
160 
 
3.4 Non-CF bronchiectasis as a control group 
3.4.1 Introduction and hypothesis 
Patients with non-CF bronchiectasis have secondary ciliary dysfunction (1.4), as in CF, but 
not abnormal CFTR function. There were two purposes behind the introduction of this 
disease group 
1. To explore if the difference between the LCI and FEV1 relationships seen in CF 
compared with PCD was due to the effects of a primary ciliary dysfunction or could 
be replicated in a second group of patients with presumed secondary ciliary 
dyskinesia 
2. To explore whether the differences were directly due to CFTR dysfunction as 
opposed to non-CFTR related disease (chronic infection and inflammation in both CF 
and bronchiectasis) 
The hypothesis for this experiment is that non-CF bronchiectasis will produce similar results 
to CF, as the difference seen in PCD is due to differences in ciliary function (primary not 
secondary), not CFTR disease compared with non-CFTR disease. 
3.4.2 Subjects and methods 
28 patients with non-CF bronchiectasis were recruited from the respiratory clinics at the 
Royal Brompton Hospital.  The ten adult patients were recruited by Lizzie Grillo, a 
physiotherapist, rather than myself.  All had been previously investigated using standard 
clinical protocols. The aetiologies of the non-CF bronchiectasis were “idiopathic” (n=18), 
post-infective (n=4, tuberculosis (TB) or measles), immunodeficiency (n=4), severe reflux 
disease (n=1) and bronchiectasis secondary to ulcerative colitis (n=1). Of the 18 idiopathic 
patients, seven were said to have allergic airway disease or asthma as a co-morbidity.     
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Subjects 
(number of 
adult patients) 
Age (mean, 
range) 
Gender 
(males, %) 
Infection with 
Pseudomonas 
Aeruginosa (%) 
Healthy controls 44 (24) 21.6 (3.2 – 51.3) 22 (50%) n/a 
CF 125 (14) 16.3 (7.5-59.2) 57 (46%) 83 (66%) 
PCD 38 (14) 22.8 (5.7-62.2) 14 (37%) 11 (29%) 
Non-CF bronchiectasis 28 (10) 25.2 (5.6 -67) 16 (57%) 0 
 
Table 3-6 Demographics for all recruitment of subjects in three disease groups, and healthy 
controls.  Healthy controls are presumed to be free of PA infection; no patients in the non-CF 
bronchiectasis groups had grown PA in sputum culture. 
As with the PCD and CF groups, participants were excluded if they were actively suffering an 
exacerbation of symptoms, if they had any new symptoms or newly diagnosed pathogens 
within two weeks of testing, and if they had any other serious comorbidity. 
As for the PCD and CF populations above, height and weight and spirometry were recorded 
at the same visit as MBW, according to the same method given above.  Three SF6 washout 
MBW runs on the Innocor analyser were performed wherever possible, and a minimum of 
two repeatable runs were needed for the result to meet acceptability criteria 
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3.4.3 Results from the non-CF bronchiectasis control group 
For MBW data, Figure 3-11 below shows the comparison of LCI results between the disease 
groups and the healthy controls.  The non-CF bronchiectasis group have a significantly higher 
LCI than the control group (p<0.0001 for all three tests).  There is no difference in LCI 
between the three disease groups however. 
 
Figure 3-11 Comparisons of LCI between healthy controls and disease groups.  Disease 
groups were all higher than controls (p<0.001 for all comparisons) but there was no 
difference between the conditions (p>0.05 for all).  A Bonferroni correction for multiple 
comparisons was made. The dotted line shows the ULN for LCI. 
When FEV1 is compared across the three groups, there was no difference between the non-
CF bronchiectasis and the CF groups, however the PCD group has significantly worse 
spirometry. 
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Figure 3-12 FEV1 results.  PCD is significantly worse than both other groups (overall 
significance p=0.0089, PCD compared with CF p=0.005, and compared with non-CF 
bronchiectasis p=0.0079). The dotted line shows the LLN for these results. 
 
When the relationship between LCI and FEV1 is tested in non-CF bronchiectasis, the 
relationship is similar to that seen in CF (p=0.0008, r=-0.6). 
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Figure 3-13 FEV1 and LCI in non-CF bronchiectasis shows a correlation despite a relatively 
small sample size p=0.0008, r=-0.6, n=28).   
The small size of this group makes further comparative analysis by chi-squared based tests 
impossible, as even with the compromise of categories delineated by 2 z-scores as used 
above for PCD and CF, the numbers in each group remain too small to analyse by these 
methods. 
 
3.4.4 Discussion of results of the non-CF bronchiectasis group 
Patients with non-CF bronchiectasis do show VI resulting from lung disease, and the LCI 
results obtained were similar to those seen in CF, proving the hypothesis propounded at the 
start of this section.  As this condition is also rare and of a very mixed aetiology, the 
demonstration that VI is occurring in these patients in the paediatric age range is only 
confirmed from one other paper published during the work of this thesis (Gonem et al., 
2014a), and similar results have been shown in adult populations (Rowan et al., 2014). 
Despite the LCI results being elevated to a similar degree, FEV1 was less abnormal in these 
patients compared with PCD, and was similar to that seen in CF. 
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Importantly, the relationship between FEV1 and LCI in non-CF bronchiectasis is similar to CF, 
as opposed to PCD, providing evidence in support of the hypothesis that it is secondary 
versus primary ciliary dyskinesia causing this different relationship in PCD, as opposed to the 
effect of CFTR versus non-CFTR lung disease. 
A primary defect, present at birth, should result in uniform changes throughout the lung, 
whereas a secondary defect may be patchy, occurring initially in areas most affected by 
infection and inflammation.  These patchy changes may result in higher VI as they result in 
greater ventilation differences between lung units than the more uniform changes seen with 
a primary MCC defect. In this context, although secondary reduction in MCC is well 
described in CF, it is not invariably present (McShane et al., 2004) at least early on in the 
course of the disease, whereas impaired MCC from the outset is the hallmark of PCD. A 
weakness of this study is the non-CF bronchiectasis cohort is even smaller than the PCD 
cohort, as reflects the rare nature of this condition, particularly in children. All eligible 
paediatric patients were approached to take part in this research, but many well patients 
were primarily under the care of their local teams and were unwilling to make the trip to the 
Brompton, and many are primarily seen during an exacerbation or with an increase in 
symptoms, making them ineligible to take part.  Also, for clarity, patients with bronchiectasis 
in whom PCD was suspected as a possible but not confirmed diagnosis by an experienced 
paediatric respiratory consultant (for example, if clinical history had suggested PCD but a 
sufficient sample of ciliated epithelium could not be obtained for microscopy studies despite 
repeated brushing) were excluded from the study.  Similarly, patients with bronchiectasis 
who were suspected as having a non-CF or atypical CF CFTR dysfunction (for example, where 
extended CF genetic analysis was pending in a patient heterozygous for a known CF 
mutation, or where the patient had been found to have abnormal nasal potential difference 
measurement) were also excluded from this group.  Although the numbers of patients 
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excluded for these reasons were small (n=10), in a rare disease such as this it did reduce the 
recruitment pool available.   
Many more adults than children have bronchiectasis, particularly those who have developed 
it following serious infection, but as this study is primarily a paediatric one I have decided 
only include 10 additional adults, to give a similar composition of adult and paediatric 
patients as the PCD group.  This ensured the group remained a good control for this 
experiment, as had it been further weighted in the direction of adult patients the 
enrichment of likely more severely affected patients would have generated a degree of 
uncertainty about the conclusions.  Despite this small sample size, the relationship between 
LCI and FEV1 in bronchiectasis shows a considerably lower p value than the equivalent result 
in PCD (p=0.008 as opposed to p=0.05, and r=-0.6 as opposed to r=-0.3). 
Importantly, when r values are considered, in CF LCI accounts for 49% of the variance in 
FEV1, compared with 36% in bronchiectasis, and 9% in PCD.   
In terms of FEV1 PCD patients had significantly worse results than either of the other two 
disease groups.  This was a surprising finding, as PCD lung disease is normally considered 
more mild than CF lung disease.  It is possible however that patients in the study represent 
the more severe end of this disease spectrum, and that patients with more mild PCD were 
less likely to be recruited to the study, as they make fewer hospital visits, limiting both the 
chances to recruit them and their familiarity with staff recruiting. They may also be less 
inclined to see the possible benefits of research if they do not feel their condition to be 
particularly serious.   
One of the strengths of this study is the comparatively large cohorts of PCD and non-CF 
bronchiectasis patients that were recruited.  As both these conditions are rare, much 
published work is on significantly fewer patients than the cohorts recruited here.  This gives 
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greater certainty that the effects described here are valid, rather than being artefacts of a 
small study.  Non-CF bronchiectasis in particular is rare in children but provides a useful 
comparator group of secondary ciliary dyskinesia with no CFTR disease and so their inclusion 
helps to determine which of these two disease mechanisms is likely to be responsible for the 
results obtained.  The sample size was opportunistic, but a retrospective estimate of power 
can be made from the standardised difference of an LCI measure.  If the standard deviation 
of LCI measurements is taken to be 0.7, as found in the current control group, and a patient 
number of 28 is used (which is the smallest cohort in the study, namely non-CF 
bronchiectasis), then the study is powered to detect changes of up to 0.8 of an LCI unit with 
80% power.  In the case of the PCD cohort (the only group that did not show a clear 
statistically significant correlation between FEV1 and LCI) with 38 difference patients a 
difference of 0.6 of an LCI unit could be detected with 80% power.  There is no firm 
consensus in the literature as to what actually comprises a clinically significant change in LCI. 
However a recent large study of CF lung function (Horsley et al., 2013) following treatment 
of an acute pulmonary exacerbation with intravenous antibiotics showed an improvement of 
0.8 of an LCI unit, so it appears reasonable to assume changes of this magnitude are 
significant.                                                                              
The availability of CF patients matched for age, gender and P. aeruginosa status with the 
PCD cohort is an important strength as it provides a direct comparison group being 
recruited, tested and analysed according to the same protocols as the PCD patients, and the 
ability to match removes potential sources of error (such as the potentially serious effect of 
P. aeruginosa on lung disease progression) and allows us to determine to what extent the 
results may be extrapolated to the wider population, which may not be true if the PCD 
results were merely compared to published data. 
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The main weakness of these physiology measurements is that longitudinal data are not 
available for these patients.  This is discussed further in Chapter Seven.  
The uncertainty surrounding reference equations for South Asian children is also a weakness 
of the PCD arm of this study, albeit one that applies to most studies of this patient group at 
the present time.  Although guidelines propose methods of analysis to minimise error 
resulting from this, that these children are not tested against normal values obtained for 
their own ethnicity is a far from ideal compromise in research in this area.  As CF is most 
common in Caucasian populations, this makes very little difference in that group, but in PCD 
could represent a source of error. 
No non-CF bronchiectasis patients recruited were colonised with P. aeruginosa.  Though this 
was not an unexpected finding, it represents a weakness as a proportion of both PCD and CF 
cohorts were infected with this pathogen.  Given the difficulties recruiting the non-CF 
bronchiectasis cohort due to the relative rarity of the condition in paediatrics, and that their 
care is often shared with more local centres that may not perform cough swab as routinely 
as in the PCD and CF patients so full microbiology data may not be available anyway, it was 
simply not feasible to continue recruiting until enough chronically infected patients were 
found.  This is unavoidable, but is nonetheless a weakness of this study. 
The disparate nature of the bronchiectasis also represents another (again possibly 
unavoidable) weakness.  Ideally, a homogenous group with the same underlying cause for 
their bronchiectasis would have been used, but the numbers of paediatric patients available 
simply gave too small a recruitment pool in this group. 
Ideally, PCD patients would have been able to be classed into groups of any of differing 
genotype, ultrastructure, or immunofluorescence abnormality to determine if different 
groups had differing lung function, or differing lung function relationships, but the PCD 
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cohort is small and this stratifying information was not available for many PCD patients at 
the time of this study.  Though an attempt has been made to class according to 
ultrastructure defect and no difference were seen, these groups were small and the majority 
of patients fell into only two groups (outer or inner dynein arm defects) and so again further 
sub division was not possible. 
The results reported here are in accord with what is in the published literature.  The 
relationships between LCI and FEV1 as seen in CF are well documented and the data 
supports these, increasing confidence in our measurement.  There is only one paper on 
MBW in PCD, and our results support their data in that the relationship between FEV1 and 
LCI is not as observed in PCD, and that PCD patients may show significant VI as assessed by 
LCI despite having a milder course of disease than CF patients.  There is no published 
literature in children with non-CF bronchiectasis and MBW, but data in adults is similar 
(Rowan et al., 2014). 
In summary, I have shown that healthy volunteers give expected results, and the 
relationship between FEV1 and LCI in CF as expected and as shown by other authors 
previously.  I have confirmed the original observation of the thesis in a larger group of PCD 
patients, and further explored this, ruling out possible sources of error or confounding 
variables such as age and variability, and introduced a control group in non-CF 
bronchiectasis patients, who show secondary ciliary dyskinesia with no underlying CFTR 
dysfunction, who show results similar to CF suggesting that it is secondary as opposed to 
primary ciliary dyskinesia (rather than CFTR disease versus non-CFTR disease) that causes 
this discrepancy seen in PCD.   
Further physiological measurements (mid expiratory flow data and phase III analysis) have 
been undertaken in order to further assess why the discrepant relationship between FEV1 
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and LCI is seen in PCD when it does not occur in CF or non-CF bronchiectasis. This is covered 
in the next chapter. 
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Chapter Four – Physiological markers of distal airway disease: 
mid expiratory flows and phase III analysis 
 
The previous chapter confirmed the original observation that led to this thesis, that there 
was a different relationship between LCI and FEV1 in PCD compared the established 
relationship in CF.  It also explored LCI in healthy control data and added another disease 
group, namely non-CF bronchiectasis patients with no primary CFTR defect (as in PCD) but 
with secondary ciliary dyskinesia (as in CF).  The bronchiectasis patients to date are similar to 
CF suggesting the different relationship results from an effect of primary versus secondary 
ciliary dyskinesia rather than CFTR versus non-CFTR disease. 
Although LCI is a whole airways measure, it is thought to primarily reflect distal airway 
function, and certainly reflects more distal airway disease than FEV1, which mostly reflects 
large, proximal airways obstruction. The potential explanations for the different 
relationships are (1) that proximal and distal disease is similar in nature, but different in rate 
of progression in the different diseases; and (2) that the nature of either or both of the 
proximal or distal airway disease is different in PCD as opposed to CF. To explore this 
further, this chapter looks in greater detail at other physiological measures that are thought 
to more reflect distal airway disease, and their relationships to one another in CF, PCD, and 
non-CF bronchiectasis patients. 
The parameters examined are FEF25-75%, (thought better to reflect small airways disease in 
spirometry than FEV1), and phase III analysis, which seeks to partition the VI detected during 
MBW into components from the conducting airways and the diffusion-convection front.  
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Additionally, a recent development in examining the MBW, curvilinearity, will be introduced 
and discussed. 
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4.1 FEF25-75% and other physiological markers 
4.1.1 Introduction and hypothesis 
That FEV1 (primarily a measure of large airway function) and LCI (thought largely but not 
completely to reflect small airways) do not correlate in PCD could be because there is a 
different relationship between large and small airway disease in CF and PCD, although their 
nature and extent is similar.   Alternatively, the distal airway disease in PCD may be different 
from than that seen in CF.  If the relationships between LCI and FEF25-75% are the same in CF 
and PCD and FEF25-75% is equally abnormal, this would not support the latter hypothesis. 
The hypothesis for this work is that LCI and FEF25-75% will correlate in all three disease groups, 
suggesting the lack of relationship between LCI and FEV1 in PCD results from a mismatch 
between large and small airways disease in these patients, rather than intrinsic differences 
between the nature and extent of distal airway disease in CF and PCD. 
4.1.2 Subjects and methods 
All CF, PCD and non-CF bronchiectasis patients (the same group as used in spirometry data in 
the previous chapter) had height and weight measured, and spirometry and MBW at the 
same visit.  All patients performed spirometry to ERS/ATS standards of acceptability, and had 
at least two acceptable MBW runs within the inclusion criteria for this study (see Chapter2 - 
Methods). 
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Table 4-1  Demographics at recruitment of subjects in three disease groups, as seen in Chapter 3. FEV1 and LCI results are included from the previous chapter, 
and FEF25-75% results are now given. 
 
Subjects 
(number of 
adult 
patients) 
Height (cm) 
(mean, 
range) 
Weight 
(kg) (mean, 
range) 
Age (mean, 
range) 
Gender 
(males, %) 
Infection 
with 
Pseudomonas 
Aeruginosa 
(%) 
FEV1 (z score) 
(median, 
range, 95% 
cl) 
LCI (median, 
range, 95% 
cl) 
FEF25-75% (z 
score) 
(median, 
range, 95% 
cl) 
CF 125 (14) 
156 (114-
184) 
48 (19-91) 
16.3 (7.5-
59.2) 
57 (46%) 
83 (66%) 
-1.92 (1.48--
5.48), (-2.3--
1.75) 
9.49 (5.55-
19.20), (8.96-
9.8) 
-1.80 (1.9--
5.85), (-2.3--
1.47) 
PCD 38 (14) 
159 (121-
194) 
55 (20-100) 
22.8 (5.7-
62.2) 
14 (37%) 
11 (29%) 
-2.75 (0.77--
5.55), (-4.21--
1.98) 
10.71 (5.77-
18.69),(9.17-
10.96) 
-2.33 (0.24--
5.78), (-3.29 --
2.16 
Non-CF 
bronchiectasis 
28 (10) 
148 (101-
196) 
44 (14-73) 
25.2 (5.6 -
67.0) 
16 (57%) 
0 
-1.59 (0.35—
4.65), (-2.26--
0.8) 
9.13  (6.23-
22.83), (6.91-
10.78) 
-1.74 (1.2—
4.09) 
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 Z-scores were calculated for FEF25-75% by the Excel sheet calculation macro provided by the 
Growing Lungs Initiative on their website, based on the work of Stanojevic et al. (Stanojevic 
et al., 2009) 
4.1.3 FEF25-75% Results 
As with FEV1 (chapter 3), FEF25-75% is more abnormal in PCD patients compared with CF or 
non-CF bronchiectasis (p=0.009 for both comparisons, Figure 4-1, below). There was no 
difference between the CF and non-CF bronchiectasis group.  The non-CF bronchiectasis 
group is not matched (as the CF group is so much larger) so it is to be expected that there 
may be some difference in lung function between the groups. 
 
Figure 4-1 FEF25-75% results.  PCD is significantly worse than the other disease groups (overall 
significance p=0.015, PCD compared with CF p=0.009, and compared with non-CF 
bronchiectasis p=0.009).  A Bonferroni correction for multiple comparisons was made.  
Dotted line shows LLN. 
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In contrast to the results with FEV1, FEF25-75% showed a correlation with LCI in all patient 
groups, as shown in Figure 4-2 below.  The correlation was most significant in CF, but was 
seen in all three disease cohorts. 
 
 
Figure 4-2 FEF25-75% in the three conditions, all are significantly correlated with LCI (CF, 
p<0.0001, r=-0.6, equation of best fit Y=2.05-0.4X; PCD, p=0.006, r=-0.4, equation of best fit 
Y=-0.63-0.19X; Non-CF bronchiectasis p=0.006, r=-0.4, equation of best fit Y=0.07-0.18X). 
 
4.1.4 Discussion of FEF25-75% predicted results 
As with FEV1, FEF25-75% in this cohort was lower in PCD than in CF and non-CF bronchiectasis.  
Hence PCD patients have spirometric evidence of small airway disease at least as severe as 
CF patients, and absence of small airway disease in PCD is not the explanation for the 
different relationship between LCI and FEV1 in the two diseases. The results in all three 
disease groups show correlations between FEF25-75% and LCI, in direct contrast with the 
relationships between FEV1 and LCI discussed in the previous chapter. As the relationship 
between FEF25-75% and LCI is similar in the three diseases, the nature of the distal airway 
disease may be similar also, although this will be further tested below. 
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That non-CF bronchiectasis patients have results for FEF25-75% equivalent to those of CF 
patients is in contrast to the better FEV1 (previous chapter).  This suggests that small airways 
disease is more prominent in this group than large airway disease as measured by FEV1. 
Firstly, the results suggest that LCI and FEF25-75% are giving equivalent signals in PCD as they 
are in CF. There is no gold standard physiological measurement of small airway disease, but 
it is likely that this is reflected in these two measurements.  It was possible the lack of 
correlation between FEV1 and LCI seen in the previous chapter merely reflected that LCI was 
a poor predictor of any level of airway disease in PCD.  By showing there is a correlation 
between LCI and FEF25-75%, I have shown that LCI is likely reflecting actual small airway 
disease in these patients as assessed by another physiological marker, and thus the lack of 
relationship between LCI and FEV1 results from a genuine disconnect between small and 
large airway disease in these patients. 
Secondly, this shows that some spirometric and MBW parameters can correlate in PCD.  
Though the variability analysis in the previous chapter made it unlikely that either measure 
was simply producing poor data in PCD, these results act as a positive control, and the lack 
of a relationship reported in the previous chapter was likely genuine, and not due to poor 
test reproducibility. 
The r values (of between 0.4 and 0.6) for correlations between FEF25-75% and LCI are not 
particularly high, showing that only a limited  amount of the variability in the LCI is 
accounted for by the small airway disease measured by FEF25-75%.  LCI is known to reflect 
proximal and distal changes so this is not unexpected.  
Overall, this work confirms that PCD patients have small airway disease detected by FEF25-75% 
so it is not merely a lack of small airway disease in PCD that causes that lack of relationship 
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between FEV1 and LCI observed in the previous chapter; and also that spirometry and MBW 
can produce internally consistent results in PCD. 
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4.2 Phase III analysis 
4.2.1 Introduction and hypothesis 
Phase III analysis was initially reported as part of the single breath washout test.  Essentially, 
in health the “phase III” (the alveolar phase, see Figure 4-3 below) is flat, because there is 
very little VI as all the alveoli are ventilating uniformly, keeping a stable, consistent 
concentration. 
 
Figure 4-3 A normal expirogram of a tracer gas in one breath, showing the change in 
concentration (y axis) against volume expired (x- axis).  The Phase III slope (the alveolar 
phase - red line) as distinct from Phase I (the anatomical dead space) and Phase II (the 
bronchial phase) is labelled.  
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In disease, however, it was noted the phase III was rarely flat, instead rising, in some cases 
quite sharply.  This is indicative of VI as lung units with different time constants due to 
disease are emptying at different rates, giving the graph a sloped appearance (see Figure 4-
4, below) (Verbanck et al., 1997). 
 
 
 
Figure 4-4 The same graph as above in a patient with CF lung disease.  Note that the phase III 
region is no longer flat but has a definite slope, caused by regions of the lung containing 
different concentrations of the tracer gas. 
Over the course of a multi-breath washout, it was observed that two different processes 
appear to affect the elevation of the phase III slope.   This is due to the region of the lung 
units affected by VI.  This is of interest both clinically and for research as it should provide 
information on the site of VI within the lungs.  The first process is VI between large lung 
units in the conducting airways.  This is termed convection-dependent ventilation 
inhomogeneity (CDI) and results from convective flow differences between lung units 
(essentially different lung units filling and emptying at different rates) due to different 
pressure-volume characteristics of these units.  The slowest emptying unit (which will have 
the highest tracer gas concentration for the longest) by definition empties late in the 
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expiration, leading to a slope as this high-concentration compartment contributes at the 
very end of the breath.  This convective sequential emptying produces a steady increase of 
phase III slope across the washout, as the best ventilated units empty quickly dominating the 
early part of the signal, and the slow-emptying, worse ventilated units dominating the later 
part of the curve.  Different methods of expressing CDI have been used, but the most 
prevalent in the literature and so the one that is used in this thesis is Scond. 
The second process is VI between the acinar units and is termed diffusion-convection 
dependent inhomogeneity (DCDI).  This rather more complex process results from 
differences in the emptying rates of the lung units at the diffusion-convection front, for 
instance from unequal narrowing of parallel airways due to disease process, or different 
daughter branches of the airways being of different volumes.  This is sometimes seen in the 
lung periphery of normal subjects, but is particularly pronounced in lung disease.  This 
produces an initially high phase III slope that only increases by very small amounts (if at all) 
across the washout, and remains high, as the differences between these units does not 
change across the washout.  DCDI is normally expressed as Sacin. 
Details on calculation of these indices are provided below, but in brief, Scond is the 
normalised slope increase over the 1.5 to 6 lung volume turnover of the washout (where 
convective gas mixing is known to contribute) and Sacin is the calculated by subtracting that 
CDI component from the phase III slope of the first breath(Verbanck et al., 1997). 
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Figure 4-5 Adapted from (Gustafsson, 2005).  Two examples of the phase III slope (SnIII) 
multiplied by the VT for each turnover.  In example a) phase III is high in the initial turnovers, 
but then there are no large changes of the washout.  This is a child with obliterative 
bronchiolitis, with a very raised Sacin reading.  In example b) phase III begins low but increases 
throughout the washout.  This child has CF, giving a very high Scond reading. 
In some conditions, such as asthma (Macleod et al., 2009; Gustafsson, 2007) phase III 
analysis can show evidence of VI despite a normal LCI.  Also, by contrasting Sacin and Scond, 
different information about the airways affected by disease processes can be obtained.  
However, in severe obstructive lung disease such as that seen in CF it is possible for both 
indices to be greatly elevated, indicating disease processes at all airway levels (Horsley et al., 
2008b), and in such cases it may be that the phase III slope does not provide a great deal 
more information than that from  LCI alone.   
In the early studies, phase III was not calculated from a tidal breathing MBW such as used to 
calculate LCI (Verbanck et al., 1998) but a fixed volume MBW where patients breathe at set 
lung volumes, normally 1 litre.  In paediatrics, patients can rarely control their breathing 
volumes with as much accuracy as adults, and also for many children such large breath 
volumes would be very uncomfortable.  Also, if an MBW is conducted this way and the 
patient’s tidal volume is different from this (as would almost certainly be the case with 
children) it means  separate washouts must be conducted to measure both LCI and phase III, 
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as for LCI the patient must breath at comfortable tidal volumes for the measure to be 
correctly calculated.  This obviously presents a problem in the measure’s use, particularly in 
paediatrics.  Also, the variation of breath size over the paediatric age range means a 1 litre 
breath in a six year old versus a fourteen year old, for instance, would be reflecting very 
different physiological process. 
Based on work by Aurora and colleagues ((Aurora, Kozlowska & Stocks, 2005)) the phase III 
slope can be normalised to allow for a natural tidal volume by multiplying the phase III slope 
as measured for each breath by the (tidal) volume of that breath before the phase III 
parameters of Scond and Sacin are calculated.  As well as making the measure viable in 
paediatrics, it allows the same MBW tests to be used to calculate both LCI and Scond and Sacin. 
There are also no clear guidelines on acceptability and repeatability of these measures 
available as yet, and so exclusion of individual breaths (normally due to variations such as 
sighs or gasps) is entirely on a user personal judgement, and, if multiple breaths are 
excluded, at what point an entire test becomes unusable is also not clear.  Hence, phase III 
analysis was performed twice 6 months apart to test intra-observer reproducibility. 
The first hypothesis for this experiment is phase III analysis will show similar levels of very 
small airway disease in CF, PCD and non-CF bronchiectasis. 
4.2.2 Subjects and methods 
Phase III analysis was performed for all PCD patients (n=38), non-CF bronchiectasis patients 
(n=27) and then an aged-matched (to the PCD group) sample of 38 CF patients (n=103 total).   
Phase III analysis is time consuming, and so it was decided to analyse a CF group matched to 
the PCD group rather than all CF patients. 
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Subjects 
(number of 
adult patients) 
Age (mean, 
range) 
Gender 
(males, %) 
Infection with 
Pseudomonas 
Aeruginosa (%) 
CF 38 (14) 21.8 (7.2 – 59.1) 14 (37%) 11 (29%) 
PCD 38 (14) 22.8 (5.7-62.2) 14 (37%) 11 (29%) 
Non-CF bronchiectasis 28 (10) 25.2 (5.6 -67) 16 (57%) 0 
Healthy control 24 (14) 14.2 (4.6-33.2) 14 (58%) n/a 
 
Table 4-2 Phase III patient group.  All PCD and non-CF bronchiectasis patients were 
measured, with a matched sample of CF patients. 
One non-CF bronchiectasis patient was excluded from the analysis at this point as an 
unusual breathing pattern prevented reliable identification of phase III slopes at the initial 
phase of all washouts. 
In terms of identifying Phase 111 for analysis, a default value of 65-95% of the expired gas 
concentration is normally used, and software used to fit a straight line to that region of the 
expirogram (Gustafsson, 2005). 
In practice, it is not uncommon for there to be a final, extremely steep portion of the 
expirogram, (Phase IV, the start of airway closure).  If a Phase IV is seen it may extend into 
the 65-95% concentration region, meaning the portion used for the Phase III line fit will need 
to be manually altered. 
In healthy subjects or those with only mild disease, cardiac oscillations may be seen on the 
phase III slope.  These oscillations in the signal are physiological but may affect the results of 
the automatic line fitting software, so again the slope can be manually altered by selecting a 
more appropriate part of the curve for the software to produce a fit to.  This manipulation is 
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open to a degree of operator bias if needed, but this is only in the minority of healthy adult 
patients.  
 
Figure 4-6 The expirogram of SF6 in a single breath of an MBW in a healthy volunteer.  Very 
clear fluctuations can be seen in the phase III slopes that may prove technically challenging 
to curve fit to for automatic software.  These are however cardiac oscillations and phase III 
remains normal and flat.  The straight line shows the phase III slope as determined by the 
user, the red section highlights the percentage portion of the breath automatically detected 
to represent the slope. 
To calculate Scond and Sacin by this method, the normalised phase III reading is plotted against 
turnovers over each washout.  Acceptable washout should give results within 10% of the 
mean, and this mean is the figure quoted as a result.  
In mathematical terms, Scond is calculated as the normalised slope difference per unit of 
turnover (TO) in the region of the MBW where there is a signal from gas mixing in the 
convective airways, known to be between turnovers 1.5 and 6 (Verbanck et al., 1997). 
Sacin is calculated by subtracting the convection-dependent inhomogeneity (in this case Scond) 
from the phase III slope for the first breath and then multiplying by the turnover (TO) of the 
first breath. 
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There are no agreed definitions of ULN in phase III analysis.  Table 4-3 summarises the 
literature and a group of healthy controls (chapter 3 reference) recruited after the 
methodology was applied to my protocols (late 2009).  This also excludes some healthy 
volunteers, on whom a phase III slope could not be reliably identified due to extensive 
cardiac oscillations, giving leaving 24 in this group.  Though the data are broadly consistent 
(ULN Sacin around 0.1, ULN Scond around 0.5) there are outliers. These studies used a variety of 
methodologies, and so until more standardised data sets are acquired the true normal 
values are uncertain.  Due to this, the measurements I made (final column) are used because 
equipment and protocols were the same as for the disease groups. 
 
Verbanck 
1999 
Gustaffson 
2007 
Macleod 
2007 
Verbanck 
2012 
Current 
study 
Age (range 
unless not 
specifed) 
38 (SD 4) 15 (SD 2) 11.1 (5-16) 27 (SD 5) 14 (4.1- 49.2) 
n 10 11 29 25 24 
Sacin (mean 
(SD)) 
0.067 (0.026) 0.090 (0.022) 0.12 (0.06) 0.086 (0.03) 0.088 (0.07) 
Scond (mean 
(SD)) 
0.031 (0.015) 0.045 (0.021) 0.017 (0.02) 0.026 (0.1)) 0.038 (0.023) 
Reference 
(Verbanck et 
al., 1999) 
(Gustafsson, 
2007; 
Gronkvist, 
Emery & 
Gustafsson, 
2002) 
(Macleod et 
al., 2009) 
(Verbanck et 
al., 2012) 
n/a 
 
Table 4-3 Published values of Scond and Sacin in healthy controls.  Although they are largely 
similar there are outliers, likely arising from the use of different methodologies.  Scond as 
measured by Macleod and co-authors is lower than that found elsewhere, and Verbanck and 
co-author’s 1999 Sacin is also lower than the other values. 
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Verbanck and co-workers (Verbanck et al., 2013) also  showed there is an increase in values 
in the normal aging lung, and a small difference in adults between genders, and produced 
equations to calculate an ULN for each individual.  However, as her methodology (adults 
only, nitrogen washout, fixed tidal volume) is very different to mine these have not been 
used here. 
 
4.2.3 Results of phase III analysis 
Full results of the phase III analysis are shown in Table 4-4 below.  There was no significant 
difference in Sacin between CF and PCD, but the non-CF bronchiectasis group had lower 
(more normal) Sacin than either CF or PCD (overall, p=0.0135, non-CF bronchiectasis 
compared with CF p=0.005 and PCD p=0.04).  Scond was significantly lower (more normal) in 
both PCD and non-CF bronchiectasis compared with in CF (p<0.0001 for all comparisons, 
Figure 4-7, below).   
There was no difference between LCI, FEV1, and FEF25-75% in this subgroup of CF and PCD, but 
all these parameters were significantly better in the non-CF bronchiectasis cohort. This is 
different to the relationships reported between the entire cohort in Chapter 4, because this 
selected CF cohort had worse lung function than the overall group.  Though not originally 
selected on the basis of similar lung function results, by chance this produced a well 
matched group of PCD and CF patients. 
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Figure 4-7 Phase III analysis.  Sacin is significantly lower in non-CF bronchiectasis than in CF 
(p=0.005) and PCD(p=0.03) (graph A), Scond is significantly lower in PCD and non-CF 
bronchiectasis (p<0.001 for both) than in CF (graph B). 
 
When compared with LCI, phase III data shows a very similar pattern across the three 
disease groups.  In all cases, LCI correlated with Sacin measures (Figure 4-8 below) but no 
significant correlations were seen with Scond. 
LCI has been presented here rather than FEF25-75% as a comparator variable, as though mid-
expiratory flows reflected smaller airways than FEV1, it seems unlikely they would bear a 
significant relationship to the very small airway pathology reflected by phase III analysis.  
These comparisons were performed (data not shown) and in fact no clear relationships were 
seen. 
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Figure 4-8 Sacin and Scond and LCI.  This is statistically significant for all three groups, (A) CF 
p<0.0001, r=0.7, (B) PCD p=0.0003, r=0.5, (C) non-CF bronchiectasis (p=0.0003, r=0.6.  There 
are no significant relationships with Scond (D, CF, p=0.8, r=0.05; E, PCD, p=0.2, r=0.2; F, non-CF 
bronchiectasis, p=0.055, r=0.4). 
 
Repeatability of phase III analysis was also addressed.  There was no other skilled observer 
to allow inter-observer variability to be calculated.  Hence I compared my own scoring of 
these data at two time points 6 months apart.  The follow up analysis was done by renaming 
the files using a random number generator with the original identity of the file hidden until 
after the scoring was completed.  All repeats were done within 6-7 months of the original 
scoring. 
All 103 patients had all acceptable MBW runs re-scored.  A Bland-Altman plot of the 
variation of these results is shown below. 
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Figure 4-9 Bland-Altman plots of Sacin and Scond measurements on two separate occasions.  
Dotted lines show the upper and lower limits of agreement for these measures.  No clear bias 
in one direction or the other is seen, and the scores for bias are very low, at 0.02 for Sacin and 
-0.002 for Scond.  However, these measures have very low mean values (shown by the x axis) 
and so the degree of variability is a concern. 
The bias score for both tests was low, at 0.02 for Sacin and -0.002 for Scond, and (as can be 
seen in the graphs above) and crucially there is no clear bias emerging in any one direction 
for either measure.  Also, the majority of tests (54 for Sacin, 69 for Scond) there was no 
difference between scores, suggesting that the same decisions on both the location of each 
slope and the inclusion or exclusion of individual breaths or washouts was made on both 
occasions. 
Where the results have been changed substantially, it was in all cases the result of a decision 
to include or exclude one of the three washouts examined from the calculated mean, rather 
than a substantial discrepancy on the positioning of the phase III measurement on individual 
breaths. 
Of the 103 data points, 4 measurements in Sacin show variation outside the expected upper 
and lower limits of agreement, and 4 also (not the same patients) show variation in Scond.  
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However, the mean score for these tests is extremely low, with the ULN laying somewhere 
around 0.1 for Sacin and 0.05 for Scond, and these limits of agreement are equal to that in the 
case of Scond and double this in the case of Sacin, suggesting a very high variability, well 
outside the 10% reproducibility criteria of this measure.   This reflects the difficulty of using 
an endpoint that relies of subjective judgement.   
4.24 Modification to Sacin* and Scond* 
Since the initial plans were made for this thesis, further work was been done on phase III 
analysis in patients with obstructive lung disease(Verbanck et al., 2013), in light of increasing 
evidence that Scond and Sacin were unsuitable for use in patients with moderately advanced CF 
lung disease, due to unavoidable errors in their calculation.  This error arises as Scond, the 
measurement of VI between convection-dependent lung units, is conventionally measured 
from the regression of the phase III slope plotted against turnovers between 1.5 and 6 
turnovers of the LCI, but in advanced lung disease VI may be such that this curve may be 
effectively asymptotic, with a plateau being reached well before 6 turnovers.  This plateau 
made Scond insensitive to further increases in VI due to worsening disease.  As Sacin is 
calculated from Scond it too becomes insensitive under these circumstances. 
To resolve this, Verbanck calculated a modified Scond (nomenclature Scond*), calculating Scond* 
between 0 and 3 turnovers, excluding the very first breath which is retained for the 
calculation of a modified diffusion-convection dependent variable, Sacin*.  Modelling shows 
that Scond* reflects VI between convection-dependent units as well as Scond in mild disease, 
but continued to correlate with LCI in more advanced disease, therefore being a more 
accurate reflection of advancing VI in this context. 
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As in the previous measure, a result is calculated for each washout; results within 10% of the 
mean are considered acceptable, and the mean of these acceptable results is the result 
quoted for that test. 
Scond in the current data does not approach the asymptote suggested previously (0.15) in all 
but 4 patients, but LCI and Scond do not correlate in any of these disease groups, as shown in 
Figure 4-8, suggesting that there may be a “blunting” of the Scond to further increases in VI .  
As the error in Scond calculation is caused by the slope of the line reaching a plateau, analyses 
may inadvertently have included part of this plateau, and if the response has become 
blunted it seems possible this is occurring (see Figure 4-10 below). In light of this, Scond* and 
Sacin* were recalculated for these patients. 
 
Figure 4-10 Representation of changes to phase III calculation.  In panel A, Scond calculated 
using 6 turnovers (slope of black line) and Scond * calculated using 3 turnovers (slope of red 
line) are virtually the same as the values rise steadily throughout the washout.  In panel B, an 
asymptote is quickly reached making the slopes of Scond (black line) different to that of Scond * 
(red line).  This black line likely represents Scond at or very near the asymptote value.  In panel 
C, the asymptote is not fully reached so quickly as in panel B, but there is still a plateauing of 
the value occurring before 6 TOs are reached, so Scond is likely affected by this phenomena (as 
the red and black slopes are different) though not as much as in panel B, and for this patient 
Scond * probably still represents a better reflection of their phase III profile than Scond. 
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The relationships between the three disease groups become different using the recalculated 
measures Sacin* and Scond*, t. For Sacin*, there is now no statistical difference between the 
groups, whereas previously Sacin in CF and PCD was higher than in non-CF bronchiectasis.  
The recalculation lowers the value for CF and PCD (rather than raising the value in non-CF 
bronchiectasis), suggesting that by the previous method, Sacin was overestimated and 
including a component that should be more accurately classed as Scond. 
For Scond, CF was more abnormal than the other two disease groups, and there was no 
difference between PCD and non-CF bronchiectasis.  In the recalculation, CF is still worse 
than the other groups, but now PCD and non-CF bronchiectasis are statistically significantly 
different.  Scond* values have increased as the plateauing effect has been removed and 
increased sensitivity to rising VI in the conducting airways achieved. These results are seen 
graphically in Figure 4-11, and summarised in Table 4-4 below. 
  Sacin (range) Sacin* (range) Scond (range) Scond* (range) 
PCD 
0.205 (0.14-
0.97) 
0.210 (0.07-
0.73) 
0.05 (0.003-
0.105) 
0.084 (0-0.23) 
CF 
0.334 (0.005-
0.96) 
0.248 (0.05-
0.59) 
0.099 (0.08-
0.157) 
0.137 (0.03-
0.28) 
Bronchiectasis 0.16 (0.02–0.64) 
0.184 (0.05-
0.60) 
0.046 (0-0.147) 
0.055 (0.01-
0.16) 
P value (between 
3 groups) 
0.0135* 0.128 <0.0001* <0.0001* 
 
Table 4-4 Results of phase III analysis between the three groups, showing medians and 
ranges, using Sacin and Scond and then Sacin* and Scond*. P values given are the Kruskal-Wallis 
significant difference between three groups. Though the overall significance of Scond is not 
altered by using the revised analysis, Sacin* shows no significance difference between groups 
using the revised analysis. 
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Figure 4-11 Sacin* and Scond * between groups, there is no significant difference between Sacin* 
across all of the three groups, whereas in Scond * CF is significantly worse than either of the 
other two groups (p<0.0001 for both), and PCD is worse than non-CF bronchiectasis 
(p=0.001). 
In the previous subsection, Sacin correlated with LCI, but Scond did not.  When Sacin* and Scond* 
are compared to LCI, however, all three disease groups show correlations between LCI and 
both phase III parameters, suggesting the “blunting” of Scond at high LCI values has been 
successfully corrected for by using Scond*. 
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This is shown in Figure 4-12 below. 
 
Figure 4-12 Scond* and Sacin* correlated with LCI.  All correlations are significant in all three 
disease groups (graph A Scond * and LCI in CF, p=0.0006, r=0.5; graph B Scond * and LCI in PCD, 
p=0.03 r=0.3; graph C Scond * and LCI in non-CF bronchiectasis, p<0.0001, r=0.8); graphs D, E 
and F correlation of Sacin* and LCI p<0.0001 for all three disease groups, r=0.7 for CF, r=0.6 for 
PCD, and r=0.7 for non-CF bronchiectasis) showing the insensitivity of Scond at high LCI has 
been improved by the switch to Scond *.  There were no significant relationships found 
between Scond and LCI previously.  Sacin* and LCI correlations have higher r values than Sacin for 
PCD and non-CF bronchiectasis, and CF is the same value, again showing that agreement is 
better than previously. 
Conceptually, this can present a problem, as Sacin is calculated from Scond, so for it to correlate 
in both instances and Scond only in one seems rather odd. This is possible when the extent of 
196 
 
abnormality demonstrated by these patients is considered.  A worked example is given 
below. 
 
 
Worked example of changes depending on which Phase III parameter calculated 
For a patient with an abnormally raised LCI of 14, total phase III for the first breath was 
calculated 0.55 
Scond was calculated from the slope of the rise in phase III between turnovers 1-6 to be 0.09.  
This only mildly raised value was not consistent with the very raised LCI value of 14, but the 
calculation included a portion of the plateau, artificially lowering the Scond value. 
Sacin was calculated from this. 
0.55-0.09 = 0.46 
0.46 is a highly abnormal value for Sacin and was consistent with the raised LCI of 14. 
 
When Scond* is used, and calculated as the slope of the rise in phase III between turnovers 0-3, 
excluding the first breath, this was 0.2. This increased Scond* was now consistent with the 
increased LCI, as the blunting effect is now removed. 
Sacin* was calculated from this. 
0.55-0.2=0.35 
Though lowered from 0.46 to 0.35, this value remains highly abnormal and continues to be 
consistent with the raised LCI of 14. 
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4.2.5 Discussion of phase III results 
It was hypothesised that PCD and CF had similar disease changes on phase III analysis.  This 
was partially correct, Sacin* was the same in the two groups, however Scond*, a measure of 
conducting airway VI, was lower in PCD.  Non-CF bronchiectasis patients were more similar 
to PCD than CF, which is a departure from previous sections where they were predominantly 
similar to CF.   
Phase III analysis is a complex topic and there is as yet no objective automated analysis 
algorithm.  With the more recent calculations of Scond* and Sacin*, measures more relevant to 
severe lung disease have been developed. This may contribute further to the understanding 
of distal airway disease in patients, though the utility in clinical or research work remains 
unproven as yet. 
These results show that in the very distalmost airways, as manifest by Sacin*, hypothesised to 
be the VI as measured at the diffusion/convection front in the alveolar periphery, is the 
same in all three disease groups, showing quite advanced distal airway disease.  Though a 
lack of published reference ranges mandates caution, the results were substantially higher 
than any seen in any groups of healthy controls, and closer to cohorts of severe CF 
(Verbanck et al., 2013; Verbanck et al., 2012; Gustafsson, 2007; Verbanck et al., 1999). 
Scond*, however, also a measure of distal airway disease, namely VI from the conducting 
airway regions, is dissimilar between the three groups.  CF patients have the worst VI, 
followed by PCD, and non-CF bronchiectasis patients have the mildest changes. 
In this case, non-CF bronchiectasis results are more similar to PCD than CF. They are closer 
to normal Scond* than either of the other two conditions, which suggests more mild disease 
changes, which has been previously suggested by their more normal spirometry.  However, 
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they showed equally bad Sacin*, suggesting that a large amount of VI is occurring in these 
patients at the very distalmost airways.  
This area of analysis is controversial and has several problems. Firstly, the subjective nature 
of the assessments is not ideal for quantitative physiological measurement.   Ideally, there 
would be an automated algorithm available.  This is included in many of the next generation 
commercial nitrogen MBW machines, but these were not available during the timeframe of 
this thesis.  Per Gustafsson and Sylvia Verbanck taught me this technique and its’ 
interpretation, but the lack of formal peer review and standardised algorithms is not ideal.  
However, rescoring the results gives an increase in confidence in the measurements, but this 
is not ideal. 
The bias scores are good with no obvious systematic bias, showing that by following a 
protocol (Appendix One) for the slope identification, and basing which breaths can be 
included or excluded on judgement learnt from an expert in the field, reasonably consistent 
scores were obtained.  The slope of individual breaths was reproducibly identified, 
suggesting that this component of the protocol is robust, but in some cases I took a different 
decision to include or exclude entire washouts from the analysis.  In all but one case, the 
second set of scoring was more conservative, opting to remove a washout where any doubt 
as to the quality of the data rather than include it. .  It is possible that increased experience 
of this analysis, both for this and for other projects in the interim, gave me more confidence 
to judge a run as not meeting an acceptable standard in the later analysis.  Of the five results 
changed in any substantial manner, 4 were originally based on 3 washouts, but on the 
second analysis I excluded 1 washout each, so the result was calculated from two washouts.  
In the last patient, I had originally included only two washouts, but on the second analysis I 
decided to include the third which I had originally rejected, changing that result also. 
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As would be expected as only 5 results for each measure in the 103 patients analysed were 
significantly changed, these decisions made little impact on the overall statistical significance 
testing for this section.  These plots displaying these recalculations have been omitted for as 
they add little else to this discussion, but no conclusions are changed as a result of their 
omission. 
An additional problem is that normal data are inadequate.  Such that does exist (Verbanck et 
al., 2012) suggests there may be an (admittedly extremely small, Sacin altered by less than 
0.04, Scond by less than 0.02, over a range of 55 years) age effect on phase III also, increasing 
even in healthy controls due to the natural ageing process in the lung.  This data set however 
was produced on a nitrogen analyser whereas the work of this thesis is based off SF6 
washout and so the two are not directly comparable to use these equations. In my 
(admittedly small) sample of healthy controls there was no age effect seen, but Verbanck’s 
cohort contains many more older adults than mine does.  There is a tendency for LCI to 
increase with age in the CF, PCD and non-CF bronchiectasis groups, but this could result from 
increasing lung disease with age also. 
If the age correction equation is applied, it suggests that the ULN for my patients would be 
between 0.1 and 0.15 for Sacin and 0.04 and 0.07 for Scond, which is similar to that shown by 
other authors using SF6, suggesting the true ULN lays somewhere within that range.  My own 
normal data give an ULN of 0.095 and 0.06 respectively.   If this is applied, then only the non-
CF bronchiectasis patients would have median values less than that ULN, with most CF and 
PCD patients showing abnormal scores for both parameters.   
These results confirm the existence of small airway disease as VI demonstrated by Sacin* and 
Scond* in all three patient groups.  Though CF shows most severe changes in Scond*, and non-CF 
bronchiectasis the most mild, all patient groups have many abnormal results, and indeed in 
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the most distal measure, that of Sacin*, there is no significant difference between the groups.  
Given the severity of PCD patients results in most other measures examined so far in this 
thesis, the comparatively lower Scond* results are surprising, and this is an unexpected 
finding.  Though the similar Sacin results suggest that distal disease is present in PCD, it may 
be that this disease is different to that seen in CF, and this leads to the lower Scond values. It 
is possible these conducting airway changes being more pronounced in CF represent greater 
focal areas of abnormality compared with more diffuse changes in PCD.  In chapter 5, this 
will be assessed by HRCT scan. 
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4.3 Curvilinearity analysis 
4.3.1 Introduction and hypothesis 
An additional overall analysis of VI based on different principles, curvilinearity analysis, and 
the parameter “Curv” (Verbanck et al., 2013; Verbanck et al., 2013), will be evaluated. 
Though often considered to be a measure of small airway disease, LCI is more accurately a 
measure of disease throughout the entire airway length.  A raised LCI hypothetically could 
solely be due by large airway changes ((Verbanck et al., 2012)), though realistically these 
circumstances are an interesting model phenomena rather than replicating anything 
observed clinically.  LCI is sensitive to disease of even the smallest airways but cannot be 
said to be truly specific to disease in this region. 
An important driver of VI as reflected in LCI is excessive physiological deadspace at any point 
in the airway tree, and in particular, deadspace in the acinar region can account for a 
significant amount of VI leading to an abnormal LCI, particularly in patients with widespread 
obstructive lung disease.  This sensitivity is both expected and desirable – unlike equipment 
deadspace, the effects of which must always be minimised, excessive physiological 
deadspace in the acinar region is indicative of disease process within the lung and its 
detection using LCI is important in the assessment of small airways disease. 
The other main driver of VI as detected by LCI is specific ventilation inhomogeneity, where 
changes due to disease cause regions of the lung of a varying size to receive less ventilation 
than in health. 
As LCI is sensitive to both dead space and specific ventilation defects, it is impossible to 
disentangle these two processes in the final LCI result.  In reality, most obstructive lung 
diseases would show components of both of these processes, but determining which one is 
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predominating in individual cases may provide more physiological insight into the nature of 
the disease.  Though phase III analysis can attempt to partition lung disease into different 
lung regions, both Scond* and Sacin* are also sensitive to multiple processes – Sacin* to both 
specific ventilation inhomogeneity and deadspace in the acinar region, and Scond* to both 
specific ventilation inhomogeneity between conducting airway units, and also to flow 
asynchrony (the best ventilated areas emptying preferentially at the beginning of 
expiration).  To address this, the curvilinearity of the multiple breath washout has been 
studied (Verbanck et al., 2013; Verbanck et al., 2013).  
MBW traces resemble a half-life decay graph, with the tracer gas initially falling quickly and 
then a longer “tail” as the last of this gas is washed out.  Generally speaking in disease the 
entire graph is elongated but in some individuals the initial fall may be slower, and in others 
the pronounced tail end of the washout is disproportionately elongated. 
Several attempts have been made to describe this mathematically, moment ratios being an 
early example.  Another approach is measurement of curvilinearity (Curv), a ratio of the 
slope of the first part of the washout compared with the second “tail end” of the washout.  
In simulations, zero would represent a perfectly evenly ventilated two compartment lung 
model (such as would never occur in vivo) and one would represent a washout containing an 
infinitesimally slowly emptying unit. Curv is a dimensionless measure solely describing the 
shape of the washout curve. 
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Figure 4-13 The “half-life decay curve” of a tracer gas during a MBW test.  The top graph 
shows a washout in a healthy control, and the lower shows the elongated later part of the 
washout in a CF patient (note the X-axis has a different scale).  The bottom panel shows the 
both washouts superimposed on the same graph.  These results represent two ends of the 
spectrum, generating a low Curv result (in the normal control) and high result in the CF 
patient, as it is simply a ratio between the slope of the line over the first half of the washout, 
and the second half of the washout. 
Verbanck et al. undertook a series of experiments in both models and in vivo, recruiting CF 
and asthma cohorts and normal controls (Verbanck et al., 2013; Verbanck et al., 2013; 
Verbanck et al., 2012).   They examined Curv in several scenarios, and also observed the 
relationships to other MBW indices, namely LCI, Sacin* and Scond*. 
Figure 4-14 below is adapted from (Verbanck et al., 2012).  It shows a series of model 
washouts, the first (Sim1) is a standard washout with a lung clearance index of 5.  Sim2 
shows the deadspace, and thus LCI, increasing but the Curv value (based the gradient of that 
line) remains the same.  For Sim3, a specific ventilation inhomogeneity has been introduced 
to the model, increasing both LCI and Curv, as the gradient of the second half of the washout 
becomes less steep compared to the first half. 
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Figure 4-14 Adapted from ((Verbanck et al., 2012)).  This shows three model simulations 
where different properties of the model were manipulated to give different LCI and Curv 
values.  In sim1, a washout with an LCI of 5 is shown.  In sim2, the deadspace is increased 
giving a higher LCI but the same Curv.  In sim3, a specific ventilation inhomogeneity is 
introduced, raising both LCI and Curv.  Note that the authors prefer for this purpose to use a 
log scale for the tracer gas concentration (y-axis) to make the effect of increasing Curv easier 
to identify visually. The horizontal line across the graph shows the 1/40th gas concentration 
at which an actual in vivo MBW test would normally be terminated and is the point the LCI 
value is taken.  This work is based on model simulations alone rather than in vivo 
comparisons of different phenomena within the diseased lung, and so interpretation must be 
cautious. 
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To demonstrate these specific ventilation defects and their effect on the slope of the 
washout and therefore the Curv value, further model simulations were reported in a second 
paper (Verbanck et al., 2013).  Figure 4-15 below is adapted from that paper, and shows in 
panel a) and b) different percentages of the lung volume (20% and 50% respectively) 
receiving a decreasing  proportion of ventilation, from normal homogenous ventilation (the 
straight line on both graphs) up to only 10% of the expected ventilation. This increases both 
Curv, and LCI (LCI can be seen as “Turnovers” along the x axis).  Panel c) shows an increasing 
portion of the lung receiving only 20% of the ventilation expected, a slightly different 
demonstration of the same phenomena resulting in increased Curv and LCI values. 
 
Figure 4-15 Adapted from (Verbanck et al., 2013).  In these model simulations, the authors 
show increasing curve effects from varying portions of the lungs receiving differing 
ventilation from a homogenous (the straight lines) portion up to abnormal values increasing 
Curv and LCI.  In panel a) 20% of the lung receives a varying proportion, in panel b) 50%, and 
in panel c) 20% of the ventilation is sent to varying portions of the lung model.  The red 
horizontal line shows the 1/40th gas concentration cut off. 
They then studied a CF cohort and normal controls (Verbanck et al., 2013).  Figure 4-16 
below is adapted from that paper.  In panel A,  the results are presented as the two model 
descriptions given above.  The grey area is the data obtained from normal patients, and then 
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the increasingly curved traces are from the CF patients, the closed circles showing a patient 
with particularly pronouced VI.  As these are actual MBW traces rather than simulations, 
they terminate at the dotted line representing the gas concentration at 1/40th of the starting 
concentration where the MBW will be stopped. 
As can be seen, CF patients show an increasing in curvilinearity compared with normal 
controls suggesting this measure gives some information about the role of specific 
ventilation inhomogeneity in CF lung disease, although it must be stressed again that,in the 
absence of any gold standard, caution must be observed in interpreting the results. 
 
Figure 4-16 Adapted from (Verbanck et al., 2013).  Panel A shows the washout curvilinearity 
as in Figures 4-14 and 4-15 above, but in vivo data from a CF cohort and normal controls 
rather than model simulations.  The pink area on both graphs shows the data from healthy 
control volunteers, the other lines represent the results from CF patients.  The solid circles 
show a particular CF patient with severe VI.  In Panel B, a graph of these patients phase III 
slopes over the washout can be seen.  For reference, the same CF patients’ phase III results 
are also identified. 
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Panel B of Figure 4-16 shows the phase III data from the same patients (again the normal 
patients form the small grey area at the base of the graph).  As can be seen, these CF 
patients also show abnormal phase III slopes. 
The interaction between phase III measures and Curv formed the next part of their studies. 
If the patient with the closed circles is followed from one panel to the next, the phase III 
slope shows an Scond*-like picture.  To recap, that is that the phase III slope is high with the 
first few breaths and remains high for the remainder of the washout (as opposed to an Sacin*-
like picture where the slope would continue to increase across the washout).  
This patient, with a raised Scond* and a severely abnormal Curv picture, demonstrates that, as 
suggested by Verbanck’s model work, these measures, as well as LCI and Curv, are 
interconnected. 
Two main processes affect Scond*.  One is based on specific ventilation inhomogeneity, and so 
raises LCI and Curv as well.  The other is based purely on flow asynchrony, namely that well 
ventilated units will empty preferentially in expiration.  This does not affect LCI or Curv.  It is 
likely these variations explain why some conditions, specifically asthma, may cause elevated 
Scond* measurements despite limited elevation of LCI in these patients. 
Sacin* and Curv may also interact.  A key driver of a raised Sacin* is deadspace in the acinar 
region, specifically caused by either intra-acinar volume assymetry or heterogenous 
structural changes at the level of the acinar entrance.  This also raises LCI, but as above Curv 
is not sensitive to deadspace phenomena and so remains the same in the presence of these 
changes.  Raised Sacin* however can also be caused by specific ventilation inhomogenities in 
the acinar region also (it is thought parallel differences in airway cross section at the level of 
respiratory bronchioles can result in this as the unit most restricted has an inequality of 
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ventilation and so functions as a slow emptying unit).  This will increase Sacin* and Curv (and 
also LCI). 
In summary, flow asynchrony in the conducting airways (better ventilated units emptying 
first) can raise Scond* but not Curv (or LCI), and an abnormal acinar deadspace can raise Sacin* 
but not Curv (though this will raise LCI).  Increased specific ventilation inhomogeniety, where 
areas of the lung do not receive appropriate levels of ventilation due to disease process, will 
effect all these indices, though Scond* is insensitive to those in the DCDI region and Sacin* 
insensitive to those in the CDI region. 
The hypothesis underpinning these analyses is that PCD will show the same results for Curv 
as CF, and non-CF bronchiectasis will show more mild changes, as seen in the spirometry and 
some of the Phase III results, specifically Scond*. 
4.3.1- Methods 
The same patients from the phase III analysis work also had Curv calculated from the same 
washouts (demographics are shown in Table 4-2).  Curv was calculated using Excel to 
perform slope fitting on the two halves of the washout (start of the washout to turnovers 
equal to one half of an LCI (when the end tidal concentration has fallen to 1/20th of its’ 
starting level, as opposed to 1/40th for a full LCI), and then that point until the end of the 
washout where the full LCI is calculated) and then calculating the ratio of these two results. 
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4.3.2 Results of Curve analysis  
There was no significant difference between Curv for PCD and CF.  Non-CF bronchiectasis 
was significantly lower (less abnormal) than CF.  A small healthy group had Curv < 0.43, the 
upper limit of normal in the small healthy control group. Figure 4-17 below shows the 
results. 
 
Figure 4-17 Curv in the three disease groups, the result is statistically significant (Kruskal-
Wallis p=0.017).  CF patients show significantly higher Curv than non-CF bronchiectasis 
(p=0.006).  There is no difference between CF and PCD nor between PCD and non-CF 
bronchiectasis.  Only non-CF bronchiectasis shows a median Curv value (0.35) lower than the 
highest value in the normal control group. 
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In Verbanck’s data, LCI and Curv have a linear relationship in both the CF cohort and healthy 
controls.  Since both reflect changes in specific ventilation inhomogeneity this is to be 
expected, and is confirmed by current data (see Figure 4-18 below). 
 
Figure 4-18 Relationship between Curv and LCI in the three disease groups, All are 
statistically significant [graph A (CF p<0.0001, r=0.6), graph B (PCD p=0.0002, r=0.6) and 
graph C (non-CF bronchiectasis p<0.0001, r=0.8)]. 
The relationships between phase III and Curv are rather more complex.  Verbanck showed a 
correlation between Scond* and Curv in CF patients, not confirmed in this study.  Figure 4-19 
below shows her results reproduced alongside mine; and the area highlighted in her graph is 
the range of values my patients occupy.  Despite the lack of statistical significance in my 
cohort, the two do not look overly dissimilar, and it is possible that a lack of results at the 
most mild and most severe end of the spectrum, combined with three clear outliers, is 
causing the lack of relationship in my cohort.  
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Figure 4-19 Graph adapted from (Verbanck et al., 2013) showing her CF patients (filled black 
circles) and her healthy controls (empty circles), the results for my CF cohort have been 
superimposed on her data in red.  The current result is not statistically significant (p=0.2, 
r=0.2), unlike Verbanck’s finding (in black), and it is possible the presence of outliers and the 
lack of data at the two ends of the spectrum in my cohort is causing this, as visually the 
overlap between the results is good, making it seem quite plausible the results are consistent 
and could be drawn from the same population.  It is also possible that this was simply not a 
large enough sample to detect this effect. The normal data from my study remains, like hers, 
low for both indices. 
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In PCD, there is no correlation shown between Scond* and Curv.  There are no PCD results in 
the literature with which to compare this result, but (section 4.2, above) Scond* results are 
extremely low for PCD when compared with CF, despite equally severe Curv results.  Figure 
4-20 below shows this result. 
In contrast, non-CF bronchiectasis (also shown on Figure 4-20 below) show very strongly 
correlated results between phase III and Curv.  These patients have shown only very mild 
disease changes in general for Curv and phase III analysis, and in this case both their Scond* 
and Curv results are more similar to what is shown in Verbanck’s healthy control/well CF 
group. 
 
Figure 4-20 Scond* and Curv in PCD and non-CF bronchiectasis.  Panel A shows PCD results.  
The result is not significant (p=0.9, r=0.02) and considerably lower Scond* results (particularly 
when compared to Curv results similar to CF) are seen.  Panel B shows non-CF bronchiectasis 
which is highly significant (p<0.0001, r=0.75), and both Scond* and Curv values are more mild 
than seen in PCD or CF. 
Verbanck showed that Sacin* and Curv were not correlated in CF.  Sacin* is affected by 
deadspace in the acinar region and to which Curv is insensitive, so this is expected. This is 
confirmed here. 
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No correlation was seen between Sacin* and Curv in this CF cohort, in line with Verbanck’s 
findings.  However, there was a weakly significant relationship in PCD and very strongly 
significant relationship in non-CF bronchiectasis.  Visually, the PCD and non-CF 
bronchiectasis graphs are not that dissimilar to CF (Figure 4-21, below), and so though they 
are correlated (particularly in PCD where they are only weakly significantly correlated) it may 
be a chance finding.  
 
Figure 4-21 Sacin* and Curv in CF (panel A, not significant, p=0.08, r=0.3), PCD (panel B, 
p=0.04, r=0.4) and non-CF bronchiectasis (panel C, p=0.0002, r=0.7).   Overall, the three 
graphs do not visually appear to be very dissimilar however. 
 
 
4.3.3 Discussion of Curv analysis 
Curvilinearity is a novel method of assessing VI in patients with obstructive lung disease, and 
has the potential to provide additional information on the mechanism of VI in these 
patients.  Though strongly correlated with LCI, is it sensitive to specific ventilation 
inhomogeneities throughout the airway but not deadspace effects, which make up an 
important component of LCI measurement. 
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As this is a very novel test, there are only data in CF and asthma available, and from a single 
group of workers, hence conclusions must be preliminary.  Particularly in areas of 
disagreement, a third dataset would be valuable but is not as yet available. 
Broadly, the CF results reported here are similar to those of Verbanck et al, though the 
present data are from a more severe cohort and this may be responsible for the lack of the 
relationship seen between Scond* and Curv.  Both were abnormal in the vast majority of these 
CF patients, and Curv and LCI were correlated, as would be expected. There was no 
relationship seen with Sacin*, which is also as expected. 
In PCD, LCI and Curv also correlated, showing similar relationships between these measures 
of VI as is seen in CF.  Curv was equally abnormal in PCD as in CF.  There was no relationship 
between Curv and Scond*, and Scond* is considerably lower in PCD than CF.   
Curv may produce additional information relevant to the Scond* analysis as it is sensitive to 
only one of the factors causing a raised Scond*.  To recap, Scond* is caused by VI in the 
conducting airways occurring due to two main mechanisms, specific ventilation 
inhomogeneity between conducting airway units at this level, and flow asynchrony.  Curv 
should be only influenced by specific ventilation inhomogeneity.  Curv is similar in PCD to CF, 
whereas Scond* is significantly and remarkably lower, it can be inferred from this that PCD 
patients have less flow asynchrony that CF, although this conclusion must be tentative.  If 
this conclusion is accepted, PCD patients may not show the widespread airway narrowing 
that in CF leads to flow asynchrony, and perhaps show either fairly preserved airways or 
complete occlusion, but this is only a hypothesis. 
There is a relationship between Sacin* and Curv in PCD, such as is not found and would not be 
expected from CF data.  Since Sacin* can be raised by either deadspace effects or specific 
ventilation inhomogeneity, it seems possible that they may have a less pronounced 
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deadspace effect at this level than CF patients.  However, visually the CF and PCD graphs are 
very similar and r=0.4, making Sacin* quite a poor predictor of Curv in these patients despite 
the statistical significance. 
Non-CF bronchiectasis patients have more mild disease in general than PCD or CF as shown 
by the additional tests in this chapter.  Curv, with a median value of 3.5, which is within the 
normal values found from Verbanck’s healthy control data (0.4), and mine (0.43), though my 
sample size is smaller.    LCI, Sacin* and Scond* are all correlated very tightly with Curv in this 
group.  As the group contains many more low, probably normal, values for all these indices 
that is to be expected.   
The chief weakness with this area of study is that, though peer reviewed and published it is 
still at a time of writing a very novel measure, currently only explored by a single group.  As 
well as a lack of data on PCD and non-CF bronchiectasis, there is only the single study on 
even more common conditions like CF and asthma, and as yet any potential Curv has for use 
alongside the other MBW indices in terms of monitoring or responses to treatment is 
unknown. 
The second weakness is this is the first attempt to my knowledge at the time of writing to 
attempt these calculations on SF6 washout data, as atmospheric nitrogen is used as a tracer 
gas in the work of Verbanck et al.  Though nitrogen and SF6 MBW tests are broadly similar 
there are subtle differences due to the differing diffusibility of SF6 and nitrogen and it cannot 
be necessarily assumed the results for the different gases will be directly comparable to one 
another without a far larger body of work, which is beyond the scope of this thesis. 
Despite this, that the results are similar (though marginally worse) in the present CF cohort  
to those published is encouraging and suggests this test is replicable, and should be further 
studied alongside other MBW indices. 
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To relate to the hypothesis of this chapter, the contribution of Curv has been to 
demonstrate a similarity of the values in PCD to CF, providing further evidence that the lack 
of relationship between distal and proximal airway disease in PCD does not result simply 
from a lack of distal airway disease in PCD.  The only measure throughout this chapter that 
this is not the case in is Scond*, which is dramatically decreased in PCD.   Though it could be 
hypothesised this represents some preservation of ventilation of the conducting airways, the 
raised Curv in this group raises the possibility this in fact results from a lack of flow 
asynchrony in this group, as that is the only parameter that Scond* is sensitive too and the 
others lack.  The distal airway disease in PCD may be quite different from that in CF, i.e. as 
suggested above an airway is either well preserved or completely occluded, rather than the 
widespread narrowing seen in CF small airway disease. 
One way of trying to resolve this issue is for more direct imaging of ventilation in PCD 
patients to be obtained, perhaps through use of the helium III MRI technique, which is 
discussed in more detail in Chapter Seven. 
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4.4 Summary of Chapter 4 
This chapter confirmed that the extent of distal airway disease, as reflected by LCI, Curv, Sacin 
and FEF25-75%  is the same in PCD as it is in CF, suggesting any lack of relationship between it 
and proximal disease as shown by FEV1 does not result simply from a lack of distal disease.  
Despite this, differences in Scond are seen, with Scond much lower in PCD, more similar to 
healthy controls and non-CF bronchiectasis patients with milder disease.  It is possible this 
results from lower flow asynchrony in these patients, although this is only based on the 
findings from the novel and as yet incompletely explored Curv parameter.  If this is the case 
it may reflect widespread airway narrowing in CF, as opposed to a more “all-or-nothing” 
airway damage in PCD, but this is only hypothesised. 
The next chapter will look at structural disease changes visible on HRCT, so see in more 
detail if differences in the nature of PCD distal disease can be seen, and if the established 
relationship in CF between structural and functional features is also seen in PCD. 
219 
 
Chapter Five – Proximal and distal HRCT findings in CF, PCD 
and non-CF Bronchiectasis, and relationship with physiological 
parameters 
 
The work reported so far has confirmed the original observation on which this thesis is 
based, namely that LCI and FEV1 have a different relationship in PCD compared with CF.  The 
results reported in the previous chapter suggest that distal airway disease, as shown by LCI, 
FEF27-75% and phase III assessment can be as extensive in PCD as it is in CF, so the differing 
relationship does not result from a lack of distal disease in PCD, but the nature of that 
disease may be different.  A comparison group of non-CF bronchiectasis patients have been 
shown to have similar (albeit slightly more mild) changes in LCI and spirometry, and a similar 
relationship  between these measures as is seen in CF, suggesting the differences in PCD 
result from the effects of primary versus secondary ciliary dyskinesia, as opposed to CFTR 
versus non-CFTR mediated disease  This difference could relate from more uniform changes 
resulting from primary ciliary dyskinesia, as opposed to patchier changes resulting from 
secondary defects. However, it is acknowledged that this is speculative in the absence of 
detailed airway morphometry. However, this is not likely to be feasible. 
It seems this different distal airway disease in PCD does not correspond as well to proximal 
airway disease as in the established relationship seen in CF.  In CF, the proximal and distal 
disease are correlated reasonably well, though it may be that distal airway damage occurs 
first. This is supported by previous work showing the significant correlation between LCI and 
FEV1.  In PCD, my hypothesis is that proximal and distal disease do not predict one another, 
as PCD distal disease may be different to CF.  It may be that the two types of disease are 
progressing at different rates, but as this is a cross-sectional study that cannot be tested 
here, but will be covered in Chapter Seven.   
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HRCT scanning provides detailed information about lung structure, and is recognised as a 
highly sensitive technique that can detect early changes in patients with obstructive lung 
diseases.  Unfortunately, it requires radiation and so there are concerns about its frequent 
use, particularly in young patients with mild disease and increasingly more normal life 
expectancies.  In the CF literature, LCI is shown to be highly correlated with HRCT (Owens et 
al., 2011; Ellemunter et al., 2010; Gustafsson et al., 2008), particularly bronchiectasis score, 
and though the two methodologies do not produce exactly the same information, the 
correlations are strong enough that if LCI (a non-invasive test with no radiation dose) is 
abnormal, the performance of HRCT may be unnecessary, because in general, if LCI is 
abnormal, HRCT will be abnormal, and so only performing HRCT scans on children with a 
normal LCI will greatly reduce the number of scans. 
Distal and proximal airway changes are visible on HRCT scan, the former in particular 
manifested by air trapping and small mucus plugs, the latter by bronchiectasis, large plugs, 
and airway wall thickening.  If the current hypothesis is correct, namely that distal and 
proximal airway disease are less well correlated in PCD compared with CF, then differing 
relationships between HRCT parameters and LCI and spirometry would be expected in PCD 
compared to the (more established) relationships in CF; and also that there would be a 
different relationship between proximal and distal HRCT measurements in PCD compared 
with CF and non-CF bronchiectasis. 
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5.1 HRCT parameters in CF, PCD and non-CF bronchiectasis 
5.1.1 Introduction and Aims 
The physiology data to this point indicates a mismatch between proximal and distal lung 
disease in PCD, when compared to the relationship in CF and non-CF bronchiectasis.  HRCT 
scan scoring results can be considered to be indirectly representative of distal and directly 
reflecting proximal airway pathology, and so the aim of this chapter is to compare the 
relationship between results for proximal and distal HRCT changes between the disease 
groups, and then compare HRCT with the physiology results (5.2, below). 
Previous studies have shown that CF patients have more severe lung disease on HRCT than 
age and gender matched PCD patients (Santamaria et al., 2008; Jain et al., 2007), which 
would be expected as PCD patients have a better life expectancy and reduced mortality and 
morbidity from lung disease compared with CF. It may be that as well as there being 
different relationships between structural proximal and distal parameters, CF patients in 
general will show more severe pathology in the present study groups. 
 
5.1.2 Subjects and methods 
High resolution CT scans were acquired on a 64 channel multidetector scanner (Siemens 
Somatom Zoom, Siemens Medical Solutions, Erlangen, Germany). Each CT comprised 
contiguous thin-sections (1.25-mm) through the entire volume of the lungs obtained during 
inspiration, and in addition, interspaced (1-mm sections at 10-mm increments) during end-
expiration.  
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The CTs were scored independently by one or two blinded radiologists with an interest in 
thoracic imaging, with no input from the author, who was blinded to results.  All the scoring 
was performed directly from workstations with access to image manipulation. 
A Royal Brompton  scoring system (Horsley et al., 2013) (Horsley et al., 2013)(Horsley et al., 
2013)was used to apply an individual score to the presence and severity of specific CT 
elements on a lobar basis: the extent of bronchiectasis was quantified according to the 
percentage of each lobe involved (0 = none, 1 = <25% of lobe, 2 = 25-50%, 3 = 51-75% and 4 
= 76-100%) and the severity of bronchiectasis was defined according to the degree of 
dilatation compared to the size of the accompanying vessel (0 = absent, 1 = trivial dilatation, 
2 = >1 but less than 2x diameter of vessel, 3 = 2-3x diameter of vessel and 4 = > 3x diameter 
of vessel). An assessment of bronchial wall thickness in each lobe was made by comparison 
with the diameter of the adjacent vessel (0 = absent, 1 = trivial wall thickening, 2 = wall 
thickness up to 0.5x diameter of vessel, 3 = wall thickness >0.5x and up to diameter of 
vessel, 4 = wall thickness >1 and up to 2x diameter of vessel and 5 = wall thickness >2x 
diameter of adjacent vessel). Small mucus plugs depicted on CT as centrilobular nodules or a 
tree-in-bud pattern and large mucus plugs were categorized as being absent (0), mild (1), or 
extensive (2). Air trapping (scored only on the interspaced expiratory images), consolidation 
and ground glass opacification were quantified as a percentage of the lobe involved to the 
nearest 5%.  A mean of scores from both observers was calculated for each element (in this 
thesis, this is called the “individual feature scoring system”).  
The subset of patients in whom HRCT results were available was recruited.  21 patients with 
PCD and 21 matched (age, gender, infection with PA) CF patients were originally recruited as 
an extension to the CF gene therapy run-in study, who had had HRCT performed on the 
same day as their MBW and spirometry measurements.  14 of these patients were adults, 
and 7 were under the age of 18.   
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In addition to these research patients, during the work of this thesis eight further paediatric 
PCD patients had HRCT for clinical reasons, and then had clinically indicated MBW and 
spirometry performed within 1 month of the HRCT scan.  These patients were clinically 
stable during that period, which was considered by clinical and radiological colleagues to be 
a reasonable time frame for a legitimate comparison to be made.   As it is the more common 
condition, it was relatively straightforward to find CF patients who also had clinically-
indicated scans in this time frame and were matched to the PCD patients for age, sex and 
infection with PA. These were recruited to act as matched controls for the PCD patients.   
Lung function (as assessed by either spirometry or LCI) was not intentionally matched in 
these groups, but when the data was examined there was no difference between LCI, FEV1 
and FEF25-75% (see Table 5-1 below). 
In non-CF bronchiectasis, no ethical consent for research HRCTs in children and young 
people had been sought, and this was not practical within the timeframe of the work of the 
thesis, so all paediatric scans are from patients having HRCT for clinical reasons.  
Concurrently with the work of this thesis, an adult physiotherapist at the Royal Brompton, 
Lizzie Grillo, was recruiting adults with non-CF bronchiectasis to take part in a physiotherapy 
intervention study, during which participants would have spirometry and an MBW test at 
baseline and then again following a full physiotherapy session.  As part of this protocol, 
HRCT scans were also taken on the same visit as the other investigations.  I was asked to 
perform LCI analysis for the study, and the HRCT scans were scored by the same radiology 
team using the same methodology (see above) as my data, and so the baseline MBW and 
HRCT scans of these adults with bronchiectasis fulfilled the same criteria for my study.  As I 
did not have ethical approval for recruiting and performing scans of these patients, Mrs 
Grillo kindly allowed a subset of them to be used here.  Although this cohort is still smaller 
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than the PCD and CF cohorts, it goes some way to providing a more suitable control group 
that the paediatric patients alone would have provided. 
All HRCT scoring was undertaken by experienced thoracic radiologists in the Royal Brompton 
Hospital, led by Professor David Hansell.  Drs Simon Gill, Anthony Edey and Nevin Wijesekera 
performed scoring for the 21 research-recruited PCD and CF patients for individual features, 
Dr Arjun Nair performed all scoring for the non-CF bronchiectasis, the remainder of the PCD 
and CF scoring, and coordinated the scoring.   All radiologists were blinded to diagnosis at 
the time of scanning.  20 of the 82 scans across all patient groups were scored by Dr Nair 
alone due to time constraints, the other 62 were scored by Dr Nair and one of Drs Gill, Edey 
and Wijesekera. Each radiologist viewed the same scan for each patient.   As multiple 
radiologists were involved, a kappa agreement score between the different observers was 
calculated (see Results, below).   
 
 
Subjects 
(number 
of adult 
patients) 
Age (mean, 
range) 
Gender 
(males, 
%) 
Infection 
with P. 
Aeruginosa 
(%) 
LCI (median, 
range, 
95%cl) 
FEV1 z score 
(median, 
range, 
95%cl) 
FEF25-75%  z 
score 
(median, 
range, 
95%cl) 
CF 29(14) 25.3  
(8.1-59.2) 
11 
(38%) 
11 (38%) 12.01 (7.6 – 
19.01), 
(10.54-
12.86) 
-3.05 (0.13 - 
-5.38),(-3.85-
-2.24) 
-2.82 (1.76 - 
-5.82),(-3.93 
--2.13) 
PCD 29 (14) 25.8  
(6.36-62.2) 
11 
(38%) 
11 (38%) 10.92  (7.42 
– 18.69), 
(9.61-11.89) 
-3.43 (-0.1 - -
6.08), (-4.15-
-2.54) 
-2.69 (-1.31 - 
-5.8), (-3.53--
2.2) 
Non-CF 
bronchiectasis 
23 (11) 30.5 
(5.6 -69.3 
14 
(60%) 
0 10.73 (6.23 
– 22.83), 
(7.67-11.38) 
-1.71 (0.35 - 
-4.63),(-3.04-
-1.43) 
-1.88 (0.77 - 
-4.09),(-2.43-
-0.93) 
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Table 5-1 Demographics of the HRCT cohort; PCD and CF are matched, the non-CF 
bronchiectasis control group are an opportunistic sample having HRCT for clinical reasons 
(paediatric patients) or from a physiotherapy study (adult patients). The non-matched non-
CF bronchiectasis cohort have statistically significantly better spirometry values than CF or 
PCD (p=0.012 for FEV1 and p=0.004 for FEF25-75%), there are more males and the infection 
status was different (none were infected with P aeruginosa), p< 0.0001 for both. 
All patients have an HRCT score for each parameter, however in some cases one or more 
lobes was partially or fully collapsed or consolidated, thus preventing the scoring of that 
area.  In these cases no score is entered for that lobe to contribute to the mean for that 
feature.  This represents a compromise recommended by a consultant radiologist (Prof. 
David Hansell, personal communication). 
In CF patients, there were 2 patients with areas of collapse and 2 others with areas of 
consolidation, in PCD patients, 5 with areas of collapse and 5 others with consolidation, and 
in non-CF bronchiectasis 7 patients had collapsed areas and another showed consolidation. 
 
5.1.3 Results of HRCT scores in the different disease groups 
Kappa score was calculated for all scans scored by multiple radiologists and found to be 
good.  The overall score was 0.7, with 0.8 for both extent and severity of bronchiectasis, 0.6 
for wall thickness, 0.7 for small and large mucus plugs, and 0.6 for air trapping.  This was 
done with the three radiologists aiding Dr Nair treated as the same secondary observer, but 
when broken down the score remained the same, suggesting this is a robust methodology 
with a consistent protocol followed 
Full results of all scores are shown in Table 5-2, along with the Kruskal-Wallis test for 
difference between the three disease groups. 
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Figure 5-1 shows the results graphically and the statistical significance for individual 
comparisons between groups from the Mann-Whitney tests. 
 
 
 
  
Extent of 
bronchiectasis 
(median 
(range) ) 
Severity of 
bronchiectasis 
(median 
(range)) 
Wall 
thickness 
(median 
(range)) 
Large  mucus 
plugs 
(median 
(range)) 
Small 
mucus 
plugs 
(median 
(range)) 
Air 
trapping 
(median                    
(range)) 
PCD 1.25 (0-3.33) 0.83 (0-2.83) 
1.3 (0.2-
2.25) 
0.17 (0-0.83) 
0.5 (0-
1.67) 
58 (0-
88.33) 
CF 2.67 (0-3.92) 1.92 (0-2.83) 
1.79 (0-
3.08) 
0.71 (0-1.33) 
0.67 (0-
1.33) 
52 (10 - 
78.33) 
Bronchiectasis 
1.33 (0.17–
3.42) 
1.00 (0.17-
3.92) 
0.84 
(0.17-
2.5) 
0 (0-1) 
0.2 (0-
1.7) 
19(0-74) 
P value 
(between 3 
groups) 
0.0006* 0.02* <0.0001* 0.0079* 0.175 <0.0001* 
 
Table 5-2 HRCT features as scored for the three disease groups.  Figure 5-1 below shows the 
difference between individual groups, this table shows the p value for the Krushal-Wallis test 
of difference between the groups (* indicates statistical significance).   
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Figure 5-1 Between-group differences for HRCT parameters.  In A, the CF patients have 
significantly worse extent of bronchiectasis than PCD or non-CF bronchiectasis (p=0.0027 and 
p=0.0004 respectively) in B the CF group  more severe bronchiectasis than the PCD group 
(p=0.009) but not non-CF bronchiectasis.  In C, CF is again significantly worse than PCD 
(p=0.0031) and non-CF bronchiectasis (p=0.0002), and PCD is worse than non-CF 
bronchiectasis (p=0.027).  For D there is no significant difference between the scores for 
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small mucus plugs for the three groups.  For E, large mucus plugs, non CF bronchiectasis have 
significantly fewer than CF (p=0.0045) but not PCD and there is no difference between PCD 
and CF.  Finally, F shows air trapping, non-CF bronchiectasis was again significantly lower 
than CF (p<0.0001) and PCD (p=0.0001).  There is no difference between PCD and CF.  
Overall, for proximal airway pathology, as shown by scores of extent and severity of 
bronchiectasis, wall thickness and large mucus plugs, CF patients had the worst scores.  For 
small mucus plugs, a marker of distal disease, there was no difference between the three 
groups.   Air trapping, also a marker of distal airway disease, was less severe in non-CF 
bronchiectasis than the other two conditions, but there was no difference between PCD and 
CF.    
Scores for non-CF bronchiectasis were generally less severe than the other two disease 
groups, and in particular very few had large mucus plugs, with the vast majority of patients 
scoring zero for that measure. 
As the differences between proximal and distal disease in PCD and CF are central to this 
investigation, a total score of bronchiectasis (the most confirmedly proximal HRCT 
abnormality) was calculated for each patient and compared with the most distal measure, 
air trapping.  The results of these correlations are shown below (Figure 5-2). 
 
Figure 5-2 Total bronchiectasis score versus air trapping score.  All relationships are 
statistically significant (graph A (CF) p<0.0001, r=0.7; graph B (PCD) p=0.02, r=0.4; graph C 
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(non-CF bronchiectasis) p=0.0002, r=0.7).  r has been quoted for graph B to provide similar 
information to that given in the other two figures, but is not comparable as the relationship 
does not appear to be linear.   
All results are statistically significant, but there is a clear visual difference between CF and 
non-CF bronchiectasis, in both of which there is a clear and linear relationship, and PCD, 
which does not, showing instead a “threshold” relationship.  This is cross sectional data and 
it is not possible to say if this is the same pattern increasing PCD lung disease would follow in 
an individual patient, but across the population it appears that air trapping of 0-50% is 
associated with very minimal, if any, bronchiectasis, whereas patients with over 50% air 
trapping show almost all have evidence of bronchiectasis, in some cases just as high as that 
seen in CF. 
 
 
 
5.1.4 Discussion of HRCT scores between groups 
In this cohort, there was no difference between lung function measures (LCI, FEV1 and FEF25-
75%) in CF and PCD patients; LCI was also similar for non-CF bronchiectasis, but spirometry 
was less severe. 
Despite this, there were several differences in the results of the HRCT scoring.  CF patients in 
general had worse disease, particularly in measures of proximal airway disease.  They had 
worse extent of bronchiectasis and wall thickening than either PCD or non-CF bronchiectasis, 
they had significantly higher results for severity of bronchiectasis than PCD patients, and 
significantly more large plugs than non-CF bronchiectasis.   
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For measures of distal lung disease, there was no difference in measures of small mucus 
plugs between the three groups, though non-CF bronchiectasis patients had less air trapping 
than the other two conditions, perhaps reflecting the milder changes often associated with 
this condition.   
Therefore these results further suggest a different relationship between proximal and distal 
lung disease in PCD compared with CF.  In these two cohorts with similar lung function (LCI, 
FEV1 and FEF25-75%) there is much more severe proximal disease in CF compared with PCD, 
with similar levels of distal disease, further supporting the hypothesis that there is a 
different relationship between proximal and distal disease in these two conditions. 
When a compound score of distal and proximal changes is included, this difference is even 
more apparent.  CF and non-CF bronchiectasis show similar, linear relationships (though 
there is more mild disease in non-CF bronchiectasis), but PCD shows a clearly non-linear 
relationship.  It appears that there is relatively low proximal airway disease until distal 
airway reaches a certain threshold, and then both rise dramatically.  This phenomenon 
would explain the patients who show a preserved FEV1 but poor LCI; it would not, however, 
explain the patients with a preserved LCI in the presence of a poor FEV1 (though the sudden 
sharp increase in proximal disease without so sharp an increase in distal disease may explain 
varying FEV1 results in patients with a given LCI).   Ultimately, it is not possible to resolve this 
with current data. 
Non-CF bronchiectasis patients in general had less pathology visible on HRCT than the other 
groups, and they also had less abnormal FEV1, Scond* and Curv than PCD and CF.  Despite this, 
their LCI results are similar to the other disease groups and they do clearly show (in some 
cases quite severe) pathology on certain CT measures, particularly (and predictably) 
bronchiectasis.  It can be concluded from this that in general they do have more mild disease 
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than the CF and PCD patients, which may have an impact on their suitability as a control 
group.  
A strength of this section is the relative similarity of the groups.  PCD and CF patients were 
matched as far as possible for age, infection with P. aeruginosa and gender, and have 
matching numbers in each group.  Non-CF bronchiectasis recruitment was opportunistic and 
only when HRCT scans were clinically indicated, so this is a weakness, but overall number, 
age, and LCI results are similar, though there are significantly more males, none are 
chronically infected with P. aeruginosa, and they have better spirometry.   
A drawback of this scoring system is that it is not commonly used compared with, for 
example, the Brody scores (Brody et al., 2006; Brody et al., 2004).  It has been published 
(Horsley et al., 2013), and perhaps provides more information than some more established 
measures (particularly the two different scores for extent or severity of bronchiectasis, as 
other systems allow only one overall score to describe, for instance, mild widespread 
bronchiectasis and very severe but highly localised bronchiectasis).  However, the 
introduction of any novel methodology may preclude comparisons with existing literature 
and this is an acknowledged weakness. 
The other chief weakness of this methodology, when compared to more established scores 
such as the Brody score, is a lack of overall HRCT score. 
Qualitative scoring of any feature, even by an experienced radiologist, is not exact, a further 
weakness.  However, when robust protocols are followed a good agreement between 
observers can be achieved, as seen by the Kappa scores, and such HRCT scores are 
commonly used in obstructive lung disease literature and well validated. 
Also, patients in all three groups were affected differently by collapse and consolidation.  
Though a collapsed or wholly consolidated lobe cannot almost by definition be scored for 
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other HRCT pathology, there is no method of knowing what the pathology was in that lobe 
prior to the collapse or consolidation. Furthermore, a normal lobe that has collapsed 
transiently because of a mucus plug, and which has the potential to re-inflate completely, is 
scored the same as a chronically destroyed, fibrotic lobe with no potential for re-expansion 
A totally collapsed or consolidated area should not affect LCI; only ventilated areas can 
contribute to VI as measured by LCI and other similar methods.  However, if the area is even 
partially communicating with the wider airway tree, even only sporadically, it may affect the 
measured VI (unless the time constant is such that it cannot contribute during the length of 
the washout), and so these units not being reflected in the HRCT scores when they may 
account for variance in the LCI, which represents an acknowledged weakness.  Removing the 
small number of patients with lobar collapse does not affect the conclusions (data not 
shown). 
 
The compound scores for proximal and distal disease have been calculated without an 
established basis from the literature, as the relationship between the two is of very specific 
interest in this thesis where as it would not have been a focus in similar studies, and is 
therefore an untested methodology.  There is in particular a compromise in the handling of 
air trapping scores.  Normally given as a percentage, it has here been divide by twenty to 
give a 1-5 score in common with the other features, but this is arbitrary.  This is presented as 
an acknowledged compromise.  
One measure of proximal lung disease, large mucus plugs, was similar in PCD and CF, despite 
a broader pattern of worse proximal disease in CF and fairly similar distal disease compared 
with PCD.   Though the median is higher in CF, the difference fails to reach statistical 
significance.  This could be the result of large mucus plugs being one of the few proximal 
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pathologies that PCD patients exhibit as severely as CF, however it is possible that these 
large plugs are worse in CF patients, but the study is underpowered.  It is possible that a 
larger or more severely unwell cohort would resolve this, and this is a topic for future work.  
The results reported above further suggest a difference in proximal and distal lung disease in 
PCD compared with CF, supporting the original hypothesis.  The hypothesis would then 
predict that the relationships between structural and functional parameters will also be 
different in PCD and CF.  If this is the case, then it can be speculated that the nature of the 
distal (or possibly even proximal) disease may be difference in PCD when compared to CF. 
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5.2 HRCT comparisons with physiology 
5.2.1 Introduction and hypothesis 
So far, the HRCT scores show PCD and CF patients both have extensive changes in many 
individual scores but, compared with CF, PCD patients have lesser proximal changes in the 
presence of similar distal airway changes.  Measures of bronchiectasis in particular are 
considerably worse in the CF cohort than in the PCD group.  Despite these differences, these 
groups show similar results for LCI and FEV1 and FEF25-75%. Non-CF bronchiectasis patients 
had milder disease on HRCT.   
The next step is to explore the relationships between these physiological (MBW and 
spirometry) and structural markers (HRCT), to further clarify the disconnect between distal 
and proximal airway disease in PCD (as compared to CF) and also what relationship (if any) is 
found between proximal and distal indicators in these patients. 
The hypothesis for this work is that will be a different relationship seen in structural and 
functional markers here, due to the differences in distal airways disease shown in PCD so far. 
5.2.2 Subjects and Methods 
All CF, PCD and non-CF bronchiectasis patients described previously (see Table 5-1 for 
subject details) with HRCT data had LCI derived from MBW, and FEV1 and FEF25-75% derived 
from spirometry, as described in Chapter 4.   These physiological markers were compared to 
the scores for individual CT features (Table 5-2).  Phase III analysis from the previous chapter 
was not included in detail in this analysis as it seems likely that their estimated airway 
generation reflected is so far below the resolution of HRCT one would not expect such 
comparisons to be meaningful, other than them both acting as a general marker of airways 
disease.    The exception to this is air trapping, which may reflect more distal pathology, and 
so these comparisons have been included. 
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One non-CF bronchiectasis patient was excluded from the FEF25-75% analysis, as her mid-
expiratory flow results were not repeatable using standard ATS/ERS criteria. 
5.2.3 Results of HRCT comparisons with physiology 
Table 5-3 shows how these three physiological measures compared with the 6 HRCT 
parameters described above (extent of bronchiectasis, severity of bronchiectasis, wall 
thickness, large mucus plugs, small mucus plugs and air trapping).  It would be expected that 
FEV1, as a measure of proximal lung disease, will correlate better with proximal structural 
disease measures, and LCI and FEF25-75% will compare with better with distal HRCT scores, as 
they better represent small airways disease (though LCI may contain some proximal 
component as well, FEV1 does not represent small airway disease).  All correlations have 
been calculated however, as previous studies in CF have shown LCI to be a better indicator 
of all HRCT scores and indeed global HRCT scores, than FEV1 so the relationships may not be 
that clear cut. 
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Table 5-3 The correlations between HRCT scores and lung function measures across the three 
disease groups. Correlations with LCI are shown in red, FEF25-75% in green and with FEV1 in 
blue.   CF patients show a statistically significant correlation between LCI and all HRCT 
    
Extent of 
bronchiectasis 
(median) 
Severity of 
bronchiectasis 
(median) 
Wall 
thickness 
(median) 
Small 
mucus 
plugs 
(median) 
Large 
mucus 
plugs 
(median) 
Air 
trapping 
(median) 
PCD              
 FEV1 p=0.9, r=-0.01 
p=0.9, r=-
0.002 
p=0.5, r=-
0.1 
p=0.9, r=-
0.02 
p=0.3, 
r=-0.3 
p=0.5, r=-
0.1 
 FEF25-75% p=0.4, r=-0.2 p=0.3, r=-0.2 
p=0.8, r=-
0.04 
p=0.8, r=-
0.3 
p=0.9, 
r=-0.02 
p=0.4, r=-
0.15 
 LCI p=0.1, r=0.3 p=0.2, r=0.3 
p=0.2, 
r=0.3 
p=0.07, 
r=0.3 
p=0.045, 
r=0.4 
p=0.009, 
r=0.5 
CF              
 FEV1 
p=0.01,            
r=-0.5 
p=0.01,               
r=-0.4 
p=0.06, 
r=-0.4 
p=0.25, 
r=-0.2 
p=0.02,                          
r=-0.4 
p=0.002,                
r=-0.6 
 FEF25-75% 
p=0.005,  
r=-0.5 
p=0.05,  
r=-0.4 
p=0.09, 
r=-0.3 
p=0.9, 
r=-0.003 
p=0.1,  
r=-0.3 
p=0.001,  
r=-0.6 
 LCI 
p=0.0001,  
r=0.7 
p=0.006,  
r=0.6 
p=0.04, 
r=0.4 
p=0.03, 
r=0.4 
p=0.03, 
r=0.4 
p<0.0001, 
r=0.7 
Bronchiectasis        
 FEV1 
p=0.006, r=-
0.6 p=0.02, r=-0.5 
p=0.02, 
r=-0.5 
p=0.09, 
r=-0.4 
p=0.2, 
r=-0.3 
p=0.003, 
r=-0.6 
 FEF25-75% p=0.09, r=-0.4 p=0.4, r=-0.2 
p=0.4, r=-
0.2 
p=0.2, r=-
0.3 
p=0.4, 
r=-0.2 
p=0.8, r=-
0.06 
 LCI 
p<0.0001, 
r=0.8 p=0.005, r=0.6 
p=0.0009, 
r=0.6 
p=0.0004, 
r=0.7 
p=0.08, 
r=0.4 
p<0.0001, 
r=0.7 
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parameters, FEF25-75%  correlates with two HRCT parameters (extent of bronchiectasis and air 
trapping), and  FEV1 correlates with four (extent and severity of bronchiectasis, large mucus 
plugs and air trapping).  In patients with non-CF bronchiectasis, HRCT correlates with LCI in 
everything but large mucus plugs, nothing for FEF25-75% , and for FEV1, everything but large 
and small mucus plugs.  In contrast, PCD only shows correlations for LCI with large plugs and 
air trapping. 
 
In CF and non-CF bronchiectasis, there were significant correlations between LCI and all six 
HRCT parameters.  These were particularly strong (r=0.7 and r=0.8) with the extent of 
bronchiectasis and with air trapping.   
FEV1 also showed good correlations with HRCT scores in CF and non-CF bronchiectasis, with 
4/6 HRCT parameters in each correlating with FEV1 score.  This included a mix of proximal 
and distal changes.  In general the r values were lower than for comparisons with LCI (r is 
between 0.4-0.6) suggesting FEV1 is not so closely related to these changes as LCI in these 
patients.   
FEF25-75% is a poor predictor of HRCT abnormalities in these groups however.  The only 
correlation was with extent of bronchiectasis and air trapping in CF patients. 
It is clear that the relationships between HRCT markers of proximal and distal airway disease 
and physiological markers of proximal and distal airway disease in PCD are very different 
from the results seen in the other two groups.  The only two correlations seen are LCI (none 
at all are seen with either spirometry parameter) with one measure of proximal disease 
(large plugs, with a poor r value of 0.4) and one distal (air trapping, r=0.5). The statistically 
significant correlations are plotted in Figures 5-3 and 5-4 below to illustrate these points 
graphically.
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Figure 5-3 Correlations between LCI and HRCT features.  All features are shown in black are significantly correlated (sequence A, CF, extent of bronchiectasis 
(p=0.0001, r=0.7) severity of bronchiectasis ( p=0.006, r=0.6),  wall thickness ( p=0.04, r=0.4), small mucus plugs( p=0.03, r=0.4), large mucus plugs( p=0.03, 
r=0.4), air trapping( p>0.0001, r=0.7); sequence B, PCD, large mucus plugs( p=0.045, r=0.4), and air trapping (p=0.009, r=0.5); sequence C, non-CF 
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bronchiectasis, extent of bronchiectasis ( p<0.0001, r=0.8), severity of bronchiectasis( p=0.005, r=0.6), wall thickness( p=0.0009, r=0.6), small mucus plugs 
(p=0.0004, r=0.7), air trapping( p>0.0001, r=0.7.).  Non significant values are given in Table 5.3, above. 
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Figure 5-4 Correlations between FEV1 and HRCT features.   All features shown in black are significant correlations between FEV1 and HRCT (Sequence A, CF, 
extent of bronchiectasis ( p=0.01, r=-0.5), severity of bronchiectasis( p=0.01, r=-0.4), large mucus plugs ( p=0.02, r=0.-4), air trapping( p=0.002, r=-0.6); 
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sequence B, PCD, no significance; sequence C, non-CF bronchiectasis, extent of bronchiectasis( p=0.006, r=-0.6), severity of bronchiectasis( p=0.02, r=-0.5), 
wall thickness( p=0.02, r=-0.5), air trapping( p=0.003, r=-0.6). Non significant values are given in Table 5.3, above. 
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Comparisons of phase III parameters from the previous chapter, Scond, Scond*, Sacin and Sacin* 
with air trapping, the only HRCT pathology likely to represent very distal airway disease were 
performed. 
Figure 5.5 below shows Scond and Scond* compared with air trapping, and Figure 5.6 shows Sacin 
and Sacin* 
 
 
 
Figure 5-5 - Air trapping and Scond and Scond*.  There is no significant relationship between Scond 
and air trapping in CF (A, p=0.7, r=0.08), PCD (B, p=0.3, r=0.2) or non-CF bronchiectasis (C, 
p=0.1, r=0.4).  There is a relationship between Scond* and air trapping in CF (D, p=0.004, r=0.6) 
but not PCD (E, p=0.5, r=-0.1) or non-CF bronchiectasis (F, p=0.3, r=0.3). 
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Figure 5-6 Air trapping and Sacin and Sacin*.  There is a significant relationship between Sacin 
and CF (A, p=0.01, r=0.5) and non-CF bronchiectasis (C, p=0.002, r=0.8) but not PCD (B, p=0.2, 
r=0.3).  There is also a significant relationship between Sacin* and air trapping in CF (D, 
p=0.004, r=0.6), PCD (E, p=0.03, r=0.5) and non-CF bronchiectasis (F, p=0.0006, r=0.7)
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5.2.4 Discussion of HRCT and physiology comparisons 
As hypothesised, the relationships observed between distal and proximal physiological and 
structural markers of lung disease were different in PCD when compared with those seen in 
CF and non-CF bronchiectasis, with PCD showing almost none of the significant correlations 
seen in the other two groups.   
The relationship between LCI and HRCT parameters in CF is well established in the literature, 
with LCI known to be sensitive to HRCT changes, in particular bronchiectasis, in this group 
(Owens et al., 2011; Ellemunter et al., 2010; Gustafsson et al., 2008) and the results  
reported here support these previous findings, a useful positive control.  LCI is significantly 
correlated with all HRCT parameters, being particular sensitive to extent of bronchiectasis 
and air trapping.    
Correlation between LCI and air trapping, and LCI and extent of bronchiectasis were 
particularly strong.   Air trapping reflects areas of pathology too small to be directly 
visualised on HRCT. It is unsurprising LCI is highly influenced by these widespread changes, 
as one would expect this from the nature of VI.   
When phase III parameters are considered, it seems that the modified phase III analysis of 
Scond* and Sacin* is an improvement on Scond and Sacin, as was seen in the previous chapter, with 
more significant correlations with air trapping (the only HRCT parameter likely to reflect very 
distal disease) when these are used.  Sacin* is significantly correlated with air trapping in all 
three groups, suggesting this measure reflects diffusion-convection front disease of a similar 
nature in all three groups.  However, Scond* was only significantly correlated with air trapping 
in CF.  Values of Scond* are very low in PCD and non-CF despite (particularly in PCD) quite high 
values of air trapping in some individuals, which may account for this and further suggests 
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that differences in Scond* are potentially important in this condition, as discussed in the 
previous chapter. 
FEV1 is also correlated with several HRCT parameters in CF, this is unsurprising as weaker 
associations have previously been reported (Owens et al., 2011; Gustafsson et al., 2008).  
There is a trend towards correlation with proximal HRCT pathology rather than distal, with 
extent and severity of bronchiectasis and large mucus plugs correlating in this group, though 
this is not wholly consistent as wall thickness, a marker of proximal airway disease does not 
correlate and air trapping, thought of as a distal airway disease marker, does correlate.  Also, 
large airway plugs were better correlated with FEV1 than LCI but bronchiectasis was a more 
significant correlation with LCI.   
There could be several reasons for this.  Firstly, wall thickness on HRCT is assessed on 
comparatively proximal airways, as these are visible on HRCT, but it probably is present in 
the small airways, where indeed it may contribute to air trapping.  If it occurs in the distal 
airways to a similar extent as in the proximal, where it will just not be visible, that may 
explain the better correlation with LCI.  Likewise, bronchiectasis as visible on HRCT is 
relatively proximal but the airways below this level may also be to be dilated and damaged, 
which is reflected in an increased LCI.  As to the lack of sensitivity of FEV1 to these proximal 
pathologies, it could also be that bronchiectasis and wall thickness do not necessarily greatly 
reduce the diameter and therefore resistance of affected airways, and so little or no effect 
on FEV1 would be seen.  FEV1 is also known to be insensitive to mild lung disease, so it might 
be only in the more severe patients these relationships are observable.   
Overall, the results in CF are very similar to that found by other authors previously, a useful 
positive control and confirming that LCI is a better predictor of HRCT abnormalities than 
spirometry. 
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Non-CF bronchiectasis patients have very similar results to CF, which again supports the 
hypothesis that it is primary versus secondary ciliary dyskinesia that causes the core 
observation of this thesis, not the difference of CFTR versus non-CFTR disease.  There are 
fewer significant correlations found between physiology and structural disease markers, 
particularly in mucus plugging which was not often seen.  Overall, considering this group 
generally show more mild changes on HRCT the correlations are extremely similar to CF. 
In general, for CF and non-CF bronchiectasis LCI is a good marker of structural lung disease, 
particularly distal pathology where that can be assessed.  FEV1 however is a poorer marker 
of structural lung disease in these patients. 
Other studies (Owens et al., 2011; Gustafsson et al., 2008) have included comparisons of LCI 
and FEV1 sensitivity and specificity for detecting abnormal or normal HRCT results in CF.  
Unfortunately, this cannot be replicated in this group no patient had a normal HRCT.   
The chief finding of relevance to the hypothesis of this chapter is that in PCD, there is clearly 
a very different relationship between LCI, spirometry and structural disease as seen on HRCT 
than is seen in CF or non-CF bronchiectasis.  Almost no correlations were found, with only 
two reaching statistical significance (between LCI and air trapping and large mucus plugs), 
and these were only weakly significant and have r values of less than 0.5.  Air trapping is a 
marker of distal airway disease and large mucus plugs a marker of proximal disease, so these 
two weak correlations do not give a consistent picture of large or small airway damage. 
Spirometry did not correlate with structure.   
It is unclear why FEF25-75% produced very poor results in this area of the study, when previous 
literature has shown this to be a useful parameter to include in this type of analysis.  
Previous studies have shown it to be a better predictor of HRCT changes than FEV1, but this 
is clearly not the case in the present cohort.  FEF25-75% does show significant correlations with 
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air trapping and extent of bronchiectasis, the two HRCT parameters that gave the strongest 
correlations with LCI, which suggests it relates to small airway disease, but the lack of further 
correlations is unexpected.  Only one of the studies in the literature gives raw data for FEF25-
75%  ((Owens et al., 2011) and from that, the current patients seem to represent a cohort 
with much more abnormal spirometry and much worse impairment of FEF25-75%.  One 
explanation may be that in these more abnormal patients with advanced lung disease the 
relationship is more complex, and only one remaining distal airway HRCT parameter, air 
trapping, has any association at all.  FEF25-75% is known to be a good marker of early lung 
disease, it may be that it is a poor marker of more advanced disease.  This could be tested 
with recruitment of a greater number of more mild patients, though it may be harder to 
obtain ethical approval to carry out HRCT scans on mild CF patients with little evidence of 
lung disease for purely research purposes.  It is also possible that there is greater variability 
in this measure, particularly in more severe patients, as has been suggested in work on 
spirometry in CF previously (Chavasse et al., 2003; Phillips et al., 1998; Cooper et al., 1990). 
The main weakness is that no patient had a normal HRCT.  This prevents sensitivity and 
specificity analysis, and also means that conclusions cannot be generalised to more mild 
patients.  Unfortunately, as scans could only be performed when clinically indicated for 
patients under 12, and the majority of those over 12 recruited purely for research were 
adults, this has biased the cohort towards adults, and children in whom there is clinical 
concern as to the extent of their lung disease, unintentionally creating a bias towards more 
unwell patients.  
Another weakness is that the scoring system used here (as stated above) is not the most 
commonly used one in the literature, although it was selected by the Radiologists for use in 
the Gene Therapy study, and hence also used here. It was thought important not to 
‘cherrypick’ from multiple scoring systems to select the one that gave the ‘best’ results. 
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Though it provides very useful data, it has yet to be used or verified in as many wide patients 
groups as the scoring systems of Brody et al, which are the most established in this field.   
Appendix Four shows a brief comparison with the Brody scoring system undertaken with a 
small group of our patients, which shows no substantial differences in conclusions when 
using the more established system. 
A strength of this chapter is that, despite using a smaller cohort for HRCT scan than could be 
analysed for the physiology markers in earlier chapters, the groups remained well matched 
and comparable, particularly CF and PCD.  Due to the numbers of patients available to 
recruit from the Royal Brompton Hospital, I was able to keep intervals between the HRCT 
scan and physiological measurements to a minimum.  Many opportunistic cohorts in which 
HRCT scans are only done when clinically indicated can sometimes have long delays between 
investigations, whereas all these patients were scanned and tested within one month of 
each other, and the majority had both tests on the same day, which was only possible with 
large cohorts to select from, despite these being rare diseases.   
The PCD HRCT data in this chapter raises an interesting management point separate to the 
main hypothesis of this thesis.  In PCD patients (with less morbidity and mortality from lung 
disease than CF patients) spirometry is often the only investigation carried out routinely, and 
the results here suggest it bears absolutely no relationship to structural disease on HRCT and 
using spirometry as a marker to track disease progression in these patients may be highly 
insensitive; clinical studies are needed to determine the utility (if any) of other markers.  
Overall, this chapter shows very different relationships between structural lung disease (as 
shown on HRCT) and physiology disease markers (LCI, FEV1 and FEF25-75%) in PCD, when 
compared to the established relationship in CF.  Non-CF bronchiectasis gives very similar 
results to CF, again suggesting these differences result from primary as opposed to 
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secondary ciliary dyskinesia as opposed to the effect of CFTR disease.  The lack of correlation 
between large and small airway disease pathology in PCD is again in evidence in this section, 
further reinforcing that a disparity between the two in PCD is the cause of these unusual 
relationship which led to the work of this thesis. These findings have important clinical 
implications, which will be discussed in the final chapter; in summary, monitoring strategies 
which may be perfectly satisfactory for CF and non–CF bronchiectasis may be wholly 
unsatisfactory in the PCD clinic.  
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Chapter Six – Distal and proximal airway Inflammation in PCD 
and CF 
 
Airway inflammation is part of most obstructive lung diseases.  Inflammation plays an 
important part in the vicious cycle of bronchiectasis (as in 1.2.3.), where a constant cycling of 
infection, inflammation and tissue damage result in the development of bronchiectasis.   
In CF evidence of airway inflammation is found on samples directly taken from the airways 
(such as BAL) and from systemic markers of inflammation in blood (Hilliard et al., 2007).  
Airway inflammation increases during acute pulmonary exacerbations.   It is not clear 
whether the CF airway is intrinsically pro-inflammatory, or mounts an exaggerated 
inflammatory response to infection. 
There is less evidence on the role of inflammation in PCD.  Patients with PCD also experience 
airway inflammation (Zihlif et al., 2006), upper and lower respiratory tract infections, and 
may also develop bronchiectasis (Bush & Hogg, 2012), in which inflammation will play a role, 
but it is generally less well studied and less well understood. 
The work of this thesis sprung from observations about the different relationships in LCI and 
FEV1 in PCD as compared to CF.  The hypothesis studied in this chapter is that this different 
relationship may arise from differences in either the nature or the distribution (or both) of 
airway inflammation in the two conditions. 
Exhaled nitric oxide (FeNO) is used in the first section of this chapter, followed by 
biochemical assays for inflammation in the second part.   
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Though non-CF bronchiectasis patients have proved a useful control in previous chapters, in 
this chapter there are unfortunately less results for this group.  Though FeNO measurements 
were attempted and are included they are generally not of good quality (shown and 
discussed below), and there was no ethical approval for blood, breath, urine or sputum 
sampling. 
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6.1 Exhaled nitric oxide (FeNO) 
6.1.1 Introduction  
Nitric oxide (NO) functions as a mediator and “messenger molecule” of airway inflammation, 
affecting vasodilation and bronchodilation amongst other functions.  It is produced by nitric 
oxide synthase (NOS), which occurs in three main forms nNOS (neuronal NOS, found in 
nerve tissue), eNOS (endothelial NOS) and iNOS (inducible NOS).  Both eNOS and iNOS can 
be found in the lung, stimulating NO production in presence of inflammation.  It can be 
measured in exhaled air. 
NO is produced by airway epithelium and is upregulated in response to inflammation.  A 
subset of patients performed fractional exhaled nitric oxide measurements (FeNO), a 
technique most used in asthma.  NO has been shown to correlate with disease severity and 
response to treatment in asthma (Barnes et al., 2010).  In CF, NO production is impaired 
(Barnes et al., 2010; Keen et al., 2010).  NO is also low in PCD, and low nasal NO is 
considered a valuable screening test for the condition (Bush et al., 2007).  In the presence of 
eosinophilic airway inflammation, an elevated NO will be detectable in the exhaled breath of 
patients. However, it is not particularly elevated by neutrophilic inflammation. 
The most commonly used measure, FeNO50, requires patients to exhale at a steady rate of 
50ml/s.  It is possible for FeNO to be partitioned into production from the acinar region or 
the larger airways (Paraskakis et al., 2006; Tsoukias et al., 2001).  This method separates the 
alveolar concentration (CALV) from the bronchial flux (JNO) by measuring FeNO at different 
flow rates.  Full details of the calculation are included below; in brief JNO is calculated for 
each expiratory flow (Ve) as JNO = FeNO x Ve; JNO is then plotted against Ve, and the slope of 
this line is CALV and the intercept JNO.  
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In general, FeNO50 alone is very unlikely to give good data on airway inflammation in PCD 
and CF.  As primarily neutrophilic conditions there are known problems with these 
measurements in these patient groups ((Walker et al., 2012),(Michl et al., 2013)), and it 
would be expected to be very low despite the likely presence of airway inflammation.  
However, by calculating JNO and CALV, it may be possible to gain some information about 
distal airway inflammation specifically, an otherwise extremely complex parameter to 
measure, and so despite these limitations these measures were attempted here. 
 
6.1.2 Subjects and methods 
FeNO at variable flow rates was measured in a subset of CF, PCD and non-CF bronchiectasis 
patients in the same visit as an MBW test, spirometry, and height and weight were 
measured.   
20 CF patients, 15 PCD patients and 5 non-CF bronchiectasis patients were recruited, of 
whom 18, 10 and 4 respectively had usable data for at least a 50ml/s flow rate.   
Demographics for those patients that obtained usable data are shown in Table 6-1. 
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 Subjects  
Age (mean, 
range) 
Gender 
(males, %) 
LCI 
(median, 
range, 
95%cl) 
FEV1 z 
score(median
, range, 
95%cl) 
FEF25-75% z 
score 
(median, 
range, 95%cl) 
CF 18 12.63 
(8.4-16.7) 
11 (61%) 8.45 (5.67 
– 12.45), 
(6.6-9.06) 
-1.87                    
(0.34- -3.33), 
(-3.25--1.22) 
-1.98 (0.16- -
4.13)(-3.74--
1.07) 
PCD 10 14.03 
(12.7-15.7) 
2 (20%) 7.91 (6.21 
– 13.79) 
-1.45                      
(-0.65 - -4.21) 
-1.57 (0.05- -
4.88) 
Non-CF 
bronchiectasis 
4 11.68  
(6.2-14.4) 
2 (50%) 7.09 (6.4-
10.85) 
-2.135 (0.1- -
2.42) 
-1.78 (0.08- -
2.75) 
 
Table 6-1 Demographics for those patients with successful FeNO measure.  2 CF patients, 5 
PCD patients and 1 non-CF bronchiectasis patient were recruited but were unable to 
complete even the initial FeNO50 measurement and so are not included here.  95% confidence 
limits of the median have only been given for CF as the sample size for the other two groups 
is too small) 
 
FeNO in patients was measured using a Niox Flex (Aerocrine AB, Sweden) machine, a 
chemiluminescence analyser capable of detecting nitric oxide (NO) at  1ppb (part per billion).   
Data was gathered in accordance with current guidelines (Dweik et al., 2011), but  briefly, 
the child inhales air that has been scrubbed of ambient NO, and then performs a single 
breath exhalation at a set rate, usually 50ml/s, over 10 seconds (Barnes et al., 2010).  Minor 
variation of flow over the course of the breath is tolerated as the machine is equipped with a 
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flow control system capable of restricting flow to 50ml/s if it is slightly faster, by means of a 
software operated electronic valve which prevents flow rising above a certain value. 
In addition to the standard 50ml/s method, by obtaining measurements at other flow rates, 
two further parameters can be calculated, the bronchial flux NO (JNO) and the alveolar 
concentration of NO (CALV).  These were calculated according to the method used by 
Paraskakis et al (Paraskakis et al., 2006), originally developed by Tsoukias and colleagues 
(Tsoukias & George, 1998).  A full protocol is included in Appendix three but in brief, patients 
exhale steadily into the Niox analyser at each of the selected flow rates (for this study 
100ml/s, 200ml/s and 260ml/s were used, in addition to the standard measurement at 
50ml/s), whilst following an incentive graphic on the analyser software that indicates when 
flow rates are in the correct range, and when the subject needs to adjust their expiratory 
flow rate.  The software then calculates ppb of NO for each flow rate, and from this the plots 
required to calculate CALV and JNO were calculated in Microsoft Excel (Microsoft, USA). Where 
results at different flows were found to be linear, JNO and CALV were calculated.  In brief, total 
production of nitric oxide in exhaled gas (ENO) is calculated by the FeNO at that given flow 
rate, multiplied by the rate.  Flow and ENO are then plotted against one another, and the 
slope of this regression line gives CALV, and the intercept JNO. 
If, when plotted, the flows are not linear then these parameters cannot be calculated.  In the 
original study (Tsoukias et al., 2001), 70% of children attempting the test produced usable 
data, with 15% not able to perform the test at multiple flow, and 15% able to perform the 
test but the data subsequently did not fit the linear model. 
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Figure 6-1 Linear and non-linear results in calculation of CALV and JNO.  Panel A shows a non-
linear result, panel B a linear one. 
6.1.3 FeNO results 
FeNO50 was first studied as an independent marker of inflammation 
CF patients had significantly higher FeNO50 than the other two groups (Figure 6-2), p= 0.017, 
although most patients had results in the published normal range (Barnes et al., 2010).  
There was no significant difference between PCD and non-CF bronchiectasis. 
In CF, only 6 of 18 patients had abnormal FeNO50 (in contrast to 12/18 having abnormal LCI, 
and 10/18 having abnormal FEV1, and 12/18 having abnormal FEF25-75%). Mean FeNO50 for 
these patients was well within the normal range at 15.7, with values ranging from 1.7-36.2 
(Figure 6-2).  There was no correlation between FeNO50 and LCI, FEV1 or FEF25-75%. 
In PCD, all patients had very low FeNO50 measurements with no values abnormal values.  Of 
this subset, 8/10 patients had abnormal LCI, and 6/10 had abnormal FEV1 and FEF25-75%.  The 
mean was 5.0 with a range of 2.6 to 10.15 (Figure 6-2).  There was no correlation with LCI, 
FEV1 or FEF25-75%  
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In the very small non-CF bronchiectasis group, all patients had normal values (mean 8.3, 
range from 3.5 to 13.3, Figure 6-2) and no correlations were attempted as numbers were 
too small. 
 
Figure 6-2 FeNO50 across the disease groups.  The dotted line shows the upper limit of normal 
at 20ppb.  Only 6 CF patients, and no PCD or non-CF bronchiectasis patients showed 
abnormal results.  The mean for all three groups was below the ULN (20ppb).  CF is 
significantly higher than the other two groups (p=0.017).  The CF patients shown in red were 
atopic. 
When data for variable flow is considered, 14/18 CF patients were able to produce data for 
multiple flow rates, but only 7 produced a linear result.  In PCD, 4/10 patients produced 
multiple flow data, of which 3 were linear.   2 non-CF bronchiectasis patients produced 
multiple flow data, but neither were linear.  JNO and CALV were calculated for the CF and PCD 
patients who had linear results.  Results are shown below for the two groups, but the sample 
size is too small for statistical testing. 
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Figure 6-3 JNO and CALV between CF and PCD.  The small number of tests in which these values 
could be assessed prevents any statistical analysis, but there is a possible trend towards 
higher values in the CF patients. 
The sample size is too small for comparisons between LCI and CALV (as small airway 
measures) and FEV1 and JNO (as larger airway messages) to have been attempted. 
 
6.1.4 Discussion of exhaled nitric oxide results 
Overall, the results for FeNO are not particularly informative, partly due to the low success 
rate of obtaining linear, variable flow FeNO results with which to calculate CALV and JNO, and 
partially as, when compared to very abnormal LCI and spirometry results for these patients, 
FeNO is largely normal or extremely low, suggesting they have little utility for measuring 
inflammation in this group of patients. 
Low nitric oxide is known to be a feature of PCD (Walker et al., 2012), and nasal nitric oxide 
levels are used as a screening test in this condition, so an overall lower FeNO50 is not 
surprising.  Reports on nitric oxide in CF are conflicting but generally are reported to be low 
or normal despite the pronounced inflammation (Michl et al., 2013).  Previous work on 
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variable flow nitric oxide in PCD(Paraskakis, Zihlif & Bush, 2007) found normal CALV despite 
low FeNO and JNO, but not enough results were obtained here to confirm this. Some authors 
have hypothesised that this results from NO being prevented from diffusing into breath by 
the thick, abnormal CF mucus (Grasemann et al., 1998), or else that NO is denitrified by 
anaerobic bacteria within the CF lung (Balfour-Lynn, Laverty & Dinwiddie, 1996); others that 
NO in genuinely lower in this group, either by reduction of NO synthase (Meng et al., 1998) 
or a lack of the NO substrate L-arginine (Grasemann et al., 2005) .  However, JNO and CALV 
analysis on these patients has been successful previously by other authors (Suri, Paraskakis 
& Bush, 2007) and lower absolute values would not necessarily have prevented correlations 
with physiology being found. However the results have been unable to confirm or refute the 
hypothesis of this chapter. 
Atopy here appeared to have little or no effect on the FeNO results, which is unexpected.  
The only documented measure of atopy available in these patients was a raised IgE, found in 
the routine monitoring blood tests of the CF patients.  This is not an ideal definition (skin 
prick testing results, for instance, would have been a far more desirable measure but are 
rarely, if at all, carried out in these patients groups), and so this could be why no signal is 
seen.  Also, the sample size is very small, which could also have affected these results. 
The problems obtaining good quality JNO and CALV data were particularly disappointing.  This 
occurred mainly due to difficulties with the technique.  For almost all patients this was the 
first time they attempted a continuous stable flow breathing technique.  Asthmatic patients, 
who this data is frequently obtained from, often perform this measure many times for 
routine FeNO50 measurement, and so measurement at higher flow rates may be easier for 
them.  In general, the CF patients performed the test better than the other groups, and this 
is perhaps as they are more familiar with controlled breathing techniques from frequent 
lung function testing and physiotherapy.  The non-CF bronchiectasis patients, who have the 
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least physiology and physiotherapy input generally as they are the fitter patients, performed 
least well suggesting experience of breath control manoeuvres may help. 
Even where data was obtained the linear model frequently did not fit.  In asthmatic patients, 
it has been shown that those with less good lung function have a tendency to less linear 
results (Paraskakis et al., 2006) so it may be that in these CF and PCD patients, who suffer 
quite severe obstructive lung disease compared with most asthmatics, this effect is also 
seen. 
There is also a known failure rate with this test (Paraskakis et al., 2006) even in patients that 
do perform these tests well and regularly.   
Most of the data obtained was completely normal.  As the physiology results were generally 
abnormal, it was always unlikely that there would be strong correlation between the two.  
The normal FeNO data was simply not able reflect airway inflammation in CF or PCD. 
The next section explores markers of inflammation in sputum, blood and breath.   
 
 
261 
 
6.2 Biochemistry results 
6.2.1 Introduction  
For this thesis, biochemical data from blood and sputum samples for 22 PCD and CF patients 
has been made available by Principal Biochemist Dr Jackie Donovan, who performed these 
tests as part of her PhD thesis.  Dr Donovan was working as part of the UK CF gene therapy 
consortium during her work, and the biochemical markers used were set by the demands of 
that study, and I was not able to influence them for the work of this thesis.  This patient 
group also appears in her PhD thesis and more detail on the methods used can be found 
there (Donovan, 2013). 
These measurements include: 
1) Sputum cell counts – total cells, viable cells, absolute and percentage neutrophils. 
2) Sputum pro-inflammatory cytokines interleukins IL 6, IL8, IL1b, tumour necrosis facotr-
alpha (TNFα) 
3) Additional sputum measures: calprotectin, neutrophil elastase and myeloperoxidase. 
4) Exhaled breath condensate: pH, ammonium and nitrite. 
5) Serum analysis (routine blood tests); full blood count, renal and liver function tests and C-
reactive protein, immunoglobulins IgG, IgA, IgM, IgE, allergen specific IgE and IgG to 
aspergillus fumigatus. 
6) Serum cytokine analysis: IL-1β, IL-6, IL-10, IL-12(p70) and TNFα. 
IL-10 is an anti-inflammatory cytokine; all others studied are pro-inflammatory. 
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An additional hypothesis for this section of the chapter is that proximal markers of airway 
inflammation should correlate with FEV1.  Systemic inflammation as reflected by blood 
samples will better correlate with distal disease as reflected by LCI.  
6.2.2 Subjects and methods 
Inflammatory markers in blood, exhaled breath and sputum were analysed on a subgroup of 
PCD and CF patients.  These PCD patients were recruited as a sub-study of the CF gene 
therapy run-in study, and were then matched for gender, age and infection with 
Pseudomonas aeruginosa with CF patients from the main study.  These analyses were not 
performed by the author, but by the biochemists working for the UK CF Gene Therapy 
Consortium, except where the test was a routine clinical test, where it was done by the main 
Royal Brompton clinical laboratories.  The Principal Biochemist overseeing this was Dr 
Donovan. 
Blood samples were collected by research nurses, clinicians or hospital phlebotomists and 
were sent for routine tests including full blood count, renal and liver function tests, C-
reactive protein (CRP), IgG, IgA, IgM, IgE, and allergen specific IgE and IgG to aspergillus 
fumigatus.  A 3ml sample was reserved in an anti-coagulant free tube for processing in the 
research laboratories for cytokines and calprotectin. 
 The serum cytokines IL-1β, IL-6, IL-10, IL-12(p70) and TNFα were measured using  Bio-plex 
cytokine assay reagents (Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire UK) and 
analysed on a Luminex 100 analyser (Luminex Corporation, Oosterhout, The Netherlands) 
following manufacturers’ instructions, in the London research laboratories.  In addition, 
serum IL-8 assays were performed in Edinburgh, using a commercially available kit 
(KHC0083, Biosource, Invitrogen, CA, USA), also following manufacturers’ instructions. 
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Serum calprotectin was also measured in Edinburgh using an in-house enzyme-linked 
immunosorbent assay (ELISA) analysis.  Antibodies and protein standards for this assay were 
the kind gift of Erling Sundrehagen, Oslo, Norway. 
Sputum was collected into polypropylene tubes and placed on ice immediately.  The sputum 
plugs are manually separated from the saliva using forceps and the sample then separated 
into two parts.  The first was sent to the clinical microbiology laboratory for quantitative 
culture, and the second was processed in the research laboratory for cell counts, cytokines, 
calprotectin and proteases. 
For the cell counts, the sputum was processed by standard methods (Pavord et al., 1997) 
stained with  May Grunwald-Giesma (MGG) and cell counts performed from 300 cells under 
a light microscope. 
In the research laboratory in London, the Biosource ELISA for TNFα and the R&D Systems 
ELISAs for IL-1β and IL-6 were used, and in Edinburgh the IL-8 assays were performed using a 
commercial kit (KAC1301, Biosource, Invitrogen, CA, USA). 
Sputum calprotectin was performed using the same assays as for serum calprotectin. 
Sputum neutrophil elastase (NE) was analysed on an automated analyser (COBAS-MIRA, 
Roche, Lewes East Sussex, UK) in London, and myeloperoxidase (MPO) was analysed in 
Edinburgh using a commercial kit (Assay Designs, Michigan, USA). 
pH of EBC was measured using a handheld pH meter (pHBoy, Camlab, Cambridge, UK).  
Nitrite was measured using the Griess reaction using the method described by Cunningham 
et al(Cunningham et al., 2000).  Ammonium was measured using a solid state ion selective 
electrode and ion meter (Jenway, Dunmow, UK) as described by MacGregor et al(MacGregor 
et al., 2005). 
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Demographics for these patients are shown in Table 5-1 in Chapter 5. 
6.2.3 Results 
Though some significant results were observed, when a Bonferroni correction for multiple 
comparisons is made, none remains significant at the required level (p<0.0001). 
The only correlation even approaching significance is between LCI and CRP, a marker of 
systemic inflammation, in CF. 
 
 
Figure 6-4 CRP and LCI in CF (A) and PCD (B), the relationship is approaching significance in 
CF (p=0.008, r=0.5, which is non-significance in this instance after Bonferroni correction) but 
not at all significant in PCD. 
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When results are compared between the groups, systemic markers of inflammation were higher in 
CF, with blood neutrophils (p=0.007) and IgG (p=0.009), serum IL8 (p=0.001) and serum calprotectin 
(p=0.034) all higher in the CF group (Figure 6-5).  Serum IL6 was also significantly higher in CF, with 
all PCD patients having results either undetectable or at the lower limit of detection for this test. 
 
 
Figure 6-5 Systemic markers of inflammation, these 4 are all significantly higher in CF than PCD.  
(Serum IL6 is also higher but not shown as all PCD results and all except 6 CF results are at lower limit 
of detection for this assay). 
 
 
 
266 
 
In the sputum and EBC markers on inflammation sputum IL6 (p<0.0001) and sputum IL8 (p<0.0001) 
CF patients in general had lower levels than PCD.  CF patients however had higher levels of sputum 
IL1b (p=0.013) (Figure 6-6). 
 
 
Figure 6-6 Sputum and EBC airway markers of inflammation.  Levels are higher in PCD for sputum IL6 
and IL8, and in CF for sputum IL1b. 
 
6.2.4 Discussion of Biochemical markers of inflammation 
There were no correlations seen between l biochemical markers of airway inflammation and distal 
and proximal physiology tests.  Thus the hypothesis that the different physiological relationships 
between LCI and FEV1 in CF and PCD was due to differences in inflammation could not be confirmed 
by these methods. There are several reasons for this lack of correlations, almost all of which are 
methodological. 
Despite CF normally being considered the more severe disease, in the sputum markers of 
inflammation sputum IL6 and IL8 CF patients in general had lower levels than PCD, which has been 
shown previously (Bush et al., 2006; Zihlif et al., 2006).  Dr Donovan, in her PhD thesis, explores this 
surprising finding in more detail (Donovan, 2013).  In brief, there is a general lack of correlation 
between sputum inflammatory markers in CF (whereas broad correlations are found in PCD), and 
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this may point to degradation of the sputum markers in CF due to an exaggerated proteolytic 
environment.  It cannot be ruled out that an altered immune response is present in CF compared 
with PCD however. It is also possible that the differences between these diseases relates to active 
resolution of inflammation, but this is speculative and beyond the scope of this thesis. 
A large number of comparisons were made, and so the burden of statistical significance is 
considerably higher than it would be in a more focussed study; in other words, power is an issue.  A 
large number of assays were performed because there was no focussed hypothesis in the 
Consortium, and as any could have yielded positive results all were performed in a ‘fishing 
expedition’ looking for biomarkers in a large study, but it meant any form of correlation was unlikely.  
A number of the assays were at or below the lower limit of detection for many results, particularly in 
PCD, and so little useful data could be gained from them.  Many of these techniques, particularly 
EBC, are still quite novel and so the most appropriate panel of tests are still being decided and 
others may be more appropriate (Patel et al., 2013).  There may be problems with biomarkers being 
broken down in the thick and viscous sputum by neutrophil elastase and other proteolytic enzymes 
in PCD and CF (Donovan, 2013).  Overall, there are differences in inflammation between CF and PCD, 
(proximal inflammation for instance appears more marked in PCD) and it is possible that these may 
contribute to the different LCI and FEV1 relationships in the two diseases, but as these results are 
based on small numbers drawing any firm conclusions from this data is not possible. 
 
268 
 
Chapter Seven – Conclusions and further work 
 
7.1 Aims and hypotheses 
Aims 
1) To confirm the original observation of a different relationship between LCI and spirometry 
between PCD and CF in a larger cohort of patients. 
This aim was accomplished by increasing the PCD and CF cohorts considerably, to 125 CF patients 
and 38 PCD patients.  PCD recruitment remained opportunistic however, due to the rare nature of 
this disease 
2) To explore the relationship between LCI and spirometry in a control group with non-CF, non-
PCD bronchiectasis as a further model of secondary ciliary dyskinesia 
Despite also being a rare, a small cohort of children and adults with non-CF (non-PCD) bronchiectasis 
was recruited to act as a control group.  Despite having a varied aetiology, these patients form an 
additional model of secondary dyskinesia without known significant CFTR dysfunction, so make a 
good control group to test if the discrepancies between results in PCD and CF were a result of 
secondary versus primary ciliary dyskinesia or a result of CFTR mediated disease versus non CFTR 
disease. 
Though this cohort in general had more mild disease than CF or PCD, most of their physiological and 
imaging results have been similar to those seen in CF (See Table 7-1).  LCI and FEV1 results are 
correlated, and their LCI was abnormal in more patients than was FEV1, suggesting that in this group 
(as in CF) LCI may be a more sensitive indicator of lung disease than FEV1.  Throughout the 
comparisons, the PCD are different from CF and non-CF bronchiectasis, in which two groups the 
results were similar, suggesting the observed differences result from the effects of primary versus 
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secondary ciliary dyskinesia.  A primary MCC defect at birth should result in more uniform changes, 
whereas a secondary defect may result in patchier disease, leading to different patterns of disease 
process. 
3) To use sophisticated phase 3 and other MBW analyses further to explore the physiological 
similarities and differences in the airway disease of CF, PCD, and non-CF bronchiectasis. 
Scond and Sacin, Scond * and Sacin*, and curvilinearity were calculated for a subset of healthy controls, 
PCD, CF and non-CF bronchiectasis subjects. 
The newer indices of Scond and Sacin provided superior information in our patient group.  Scond * was 
very low in PCD.  The novel parameter Curv, that assess VI without deadspace effects (unlike LCI 
which includes them) was the same in PCD and CF.  The only parameter that could affect Scond* but 
not LCI or Curv is flow asynchrony.  Though these analysis methods are very novel and not well 
characterised as yet, it suggests there is a lack of flow asynchrony in PCD lung disease when 
compared with CF. 
4) To determine similarities and differences in structural lung disease in PCD and CF, and a non-CF 
bronchiectasis control group, with specific attention to the relationships between proximal and 
distal disease. 
HRCT scans were scored for patients in all three disease groups.  As limited ethical approval was 
available for children and adults over 12 years of age, the bulk of these scans are in that age range, 
although some younger children who had clinically-indicated scans in the same time period have 
also been included. 
There are several studies on CF HRCT results and LCI in the literature, and the present results were 
very similar to these, with LCI shown to be the best predictor of abnormality on HRCT, particularly 
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bronchiectasis, though FEV1 also correlated with these HRCT scores including bronchiectasis, albeit 
more weakly than LCI.   
The results in non-CF bronchiectasis were very similar to CF, with particularly LCI showing a high 
degree of sensitivity to HRCT changes, although in general this group showed more mild changes 
than PCD and CF. 
As with the comparisons of LCI and FEV1, PCD showed very different results to the other two groups, 
with almost no correlations between HRCT scores and LCI or FEV1. 
5) To explore differences in airway inflammation between these groups and relate these to 
structure and function. 
This was attempted with measures of FeNO and biochemical analysis on sputum, blood and exhaled 
breath condensate.  Unfortunately, these experiments were frequently unsuccessful and largely 
negative.  It is not possible to say certainly that inflammation does not play a role in these 
differences as so many assays were unsuccessful, but there was no evidence for this in this data. 
Hypotheses: 
Hypothesis One – “the different relationship found in a pilot study between LCI and spirometry 
seen in PCD compared with CF is related to differences in the fundamental pathophysiology of the 
two diseases, rather than to the milder clinical course of PCD as against CF”. 
This hypothesis has been proven.  The results in Chapter Three have clearly shown that the 
relationship is fundamentally different in PCD to that in CF, not simply a weaker version of the same 
relationship, and the introduction of a non-CF bronchiectasis cohort has shown this difference to be 
due to a the effects primary rather than secondary ciliary dyskinesia. 
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Hypothesis Two – “the different relationship between LCI and spirometry seen in PCD compared 
with CF is related to differences in distal airway structure and inflammation between the two 
diseases”. 
This hypothesis has been partially proven.  It appears from the HRCT and phase III and curvilinearity 
analysis that distal disease in PCD is different to that seen in CF, with possibly lower flow asynchrony 
and potentially more diffuse disease on HRCT.  However, the inflammation results were entirely 
negative from the methodologies attempted here and so no evidence of a difference in 
inflammation could be found. 
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7.2 Summary of results 
The table below contains a summary of comparisons made in the Results chapters.  Work from 
Chapter 6, the largely negative inflammation work, has been excluded as it will not be discussed 
further. 
 CF Non-CF bronchiectasis PCD 
Chapter 3 LCI and FEV1 abnormal LCI and FEV1 abnormal LCI and FEV1 abnormal 
 LCI and FEV1 correlated LCI and FEV1 correlated LCI and FEV1 not 
correlated 
Chapter 4 FEF25-75% abnormal FEF25-75% abnormal FEF25-75% abnormal 
 FEF25-75% and LCI 
correlated 
FEF25-75%and LCI 
correlated 
FEF25-75% and LCI 
correlated 
 Sacin* abnormal Sacin* abnormal Sacin* abnormal 
 Scond* abnormal Scond* approaching 
normal 
Scond* approaching 
normal 
 Curv abnormal Curv just abnormal Curv abnormal 
Chapter 5 Abnormal HRCT findings Abnormal HRCT findings, 
although milder 
Abnormal HRCT findings 
 LCI correlated with all 
HRCT features, 
particularly 
bronchiectasis 
LCI correlated with all 
HRCT features, though 
this group generally do 
not show mucus 
plugging. 
LCI only correlated with 
two HRCT features, large 
plugs and  air trapping 
 FEV1 correlated with 
most HRCT features, 
though less strongly 
than LCI, as shown by 
other authors previously 
FEV1 correlated with 
most HRCT features, 
though less strongly than 
LCI 
FEV1 correlated with NO 
HRCT features 
 Proximal and distal 
HRCT features show 
linear, correlated 
relationship 
Proximal and distal HRCT 
features show linear, 
correlated relationship 
Proximal and distal HRCT 
features show threshold 
relationship 
 
Table 7-1 Summary of results.  Key differences are shown in red. 
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7.3 Key findings 
In this thesis, I have shown that the relationship between distal airway disease and proximal 
airway disease in PCD is different to that seen in conditions characterised by secondary ciliary 
dyskinesia, specifically CF and non-CF bronchiectasis. This would account for the initial observations 
upon which the work of this thesis was based, and were confirmed in Chapter 3. 
“In CF, there is an established relationship between LCI and FEV1, whereby one broadly predicts the 
other (though distal airways disease as reflected by LCI occurs first) and non-CF bronchiectasis 
appears similar, but in PCD this appears not to be the case, with sometimes very abnormal LCI 
results with a relatively normal FEV1, and also the other way round.  However, this was primarily 
tested by correlation, which is a limitation, and would be stronger if confirmed in another larger 
sample group, although it was confirmed in the findings of another group previously (Green et al., 
2012).”This is not a result of the lack of distal airway disease in PCD patients.  Their LCI and mid 
expiratory flow spirometry results are as abnormal as an equivalent CF cohort matched for age, 
gender, and infection with P. aeruginosa.  
However, the nature of this distal disease is physiologically different, with detailed phase III 
analysis suggesting a lack of flow asynchrony in PCD unlike the findings in CF patients.  There are also 
differences in HRCT results, again a lack of relationship is seen in PCD as HRCT scores, LCI and FEV1 
hardly correlate, unlike the relationships seen in CF.  This may relate to primary ciliary dyskinesia 
resulting in more uniform changes where secondary MCC failure results in more patchy disease. 
It is possible that different patterns of  inflammation proximally and distally may play a role in this 
process, but the techniques used here of measuring airway inflammation at any level were 
inconclusive and so my results can neither confirm nor exclude inflammation  from the list of 
possible causes of this discrepancy. 
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Ultimately, there are few further physiological tests available with which to pursue the underlying 
cause any further.  Phase III is an extremely sophisticated analysis technique but at the current time 
it cannot provide any further resolution on the site or nature of the differences in distal airway 
disease in PCD when compared with CF.  The ideal to take this further would be pathological 
examination of lung tissue. This is unlikely as there is a low mortality from lung disease in PCD 
patients and so post mortem specimens are rarely available, and would in any event likely only 
represent the very end stage disease. As morbidity from lung disease is also low, invasive procedures 
such as transbronchial biopsy with the attendant risk cannot be justifiably performed purely for 
research purposes. The only likely source of tissue would be from CF or PCD patients who died from 
an unrelated cause, such as trauma, while still having mild airway disease. 
However, advanced imaging techniques such as MRI may in the future provide valuable information, 
as their superior resolution compared with HRCT may be able visualise very small differences 
between features such as ventilation distribution.  This is covered in more detail in Further Work, 
below. 
 
275 
 
7.4 Weaknesses of the study 
A key weakness of this study is that it is cross sectional in nature.  Large, longitudinal datasets of 
MBW may allow long term trends, such as whether proximal or distal airways disease occurs first, 
and possible correlations with other biomarkers, to become more apparent.  This will be facilitated 
by newer MBW equipment, and this is also covered in Further Work, below.  In PCD, there are only a 
few good longitudinal lung function datasets in general, as well as in MBW specifically, and so any 
further and more detailed analysis in this PCD group may allow us to determine which, if any, of the 
wide variety of measures available is most useful in predicting outcomes, improvement, and other 
clinically-relevant parameters in these patients. 
Figure 7-1 below is modified from that in 3.2.3; it shows that in PCD, there are similar numbers of 
patients with poor LCI and preserved FEV1, poor FEV1 and preserved LCI, and preserved LCI and FEV1.  
This is different to the established pattern in CF. 
 
Figure 7-1 Differences in the relationship between FEV1 and LCI in PCD and CF, adapted from Chapter 
3.  These distributions are statistically different, and PCD in particular has a large number of patients 
with a preserved LCI but poor FEV1 results. 
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PCD patients with preserved FEV1 in spite of poor LCI results could have mild, early changes that LCI 
is more sensitive to (as in CF), and the threshold effect shown in Chapter 5 between structural 
proximal and distal disease could easily account for this group, with distal disease increasing until a 
certain point, at which proximal changes begin. 
The large number of patients (compared with the CF group) with preserved LCI in the presence of 
poor FEV1 results is more of a challenge to explain however.  The most likely explanation in this case 
seems to be that the distal airways in these patients are virtually occluded and so have too long a 
time constant to contribute to an LCI, but show as a loss of volume contributing to a lower FEV1.  
Theoretically, it is possible that some large airway obstruction could be reducing volume but not 
affecting VI at all, but there is no evidence of this on HRCT and so this seems highly unlikely.   
I have not reported it in the results as the groups are too small for statistical analysis, but there 
appears to be a trend towards these patients being younger than the other groups, but no other 
distinguishing feature is obvious.  If longitudinal data can be obtained, it may be possible to track if 
the relationships between the two can change over a patients’ lifespan. 
No attempt was made to measure mucus rheology differences between the groups.  It is known the 
underlying defect in CF causes abnormal mucus however, and throughout the thesis their results 
were broadly similar to non-CF bronchiectasis so it seems unlikely this would account for the 
differences seen here. 
Similarly cough strength was not measured between the three groups, which is an additional 
weakness, but it seems unlikely there would be any reason for cough to be impaired in the groups 
used here.  
CF is currently primarily diagnosed on newborn screening in the UK, and as such CF patients have 
involvement from health professionals from the first few weeks of life.  There is no such program for 
PCD, and so diagnosis is very rarely made in the newborn period (in all probability only those 
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extremely symptomatic or with a family history of the condition will be diagnosed that early).  This is 
a problem as it means the first few months and years of a patient’s life will likely be quite different, 
CF patients will have physiotherapy from birth, nutritional support, frequent physician review and 
aggressive treatment of infections whereas PCD patients will likely not.  Therefore even quite young 
patients with either condition may already have quite different patterns of lung damage, simply due 
to later diagnosis.  As best practice PCD diagnosis is still evolving, with genetic analysis still ongoing, 
newer methods of electron microscopy being trialled, and the possibility of immunofluorescence 
becoming a clinically available methodology, it is likely to be some time until PCD can be screened 
for reliably on a large scale, assuming it is felt to be cost-effective for such a rare disease .  This 
makes it an impossible weakness to overcome at the present time, as matching PCD and CF for age 
at diagnosis is not possible. It also means that getting PCD patients with very early stage disease is 
also very difficult. 
Another weakness of this study is opportunist sample size for the rarer diseases (PCD and non-CF 
bronchiectasis), which this has recently been discussed (Rowan et al., 2014; Irving et al., 2013).  The 
core work of this thesis, on the different relationship between LCI and FEV1 in PCD when compared 
with CF, and the findings from HRCT, was published in 2013 (Irving et al., 2013).  Following this, 
another article covered a similar area, looking at adults with mixed aetiology non-CF bronchiectasis 
(Rowan et al., 2014).  They observed similar results to those presented in this thesis, that non-CF 
bronchiectasis were similar to CF.  They concluded that our paper was underpowered to show this 
relationship (despite it being present in much smaller and matched CF cohorts) and gave a stated 
figure of 54 (with no statistical justification) for the minimum sample size to detect the relationship 
between LCI and FEV1.  They also stated (incorrectly) that we had hypothesised a lack of relationship 
and thus proved our own negative hypothesis with an inadequate sample size, when in fact the 
original hypothesis for much of our early work in this area, and that paper, was that PCD would show 
similar results to CF. 
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The sample size of 54 represents a challenge in terms of recruitment of PCD patients.  PCD is a rare 
condition, so finding patients to recruit that are frequently visiting a tertiary respiratory clinic is 
difficult.  However, if the true minimum sample is 54 then this would have to be achieved to publish 
any work in this area, and so I investigated the sample size calculation. 
Full details are not given in their paper, but the figure of 54 seems to result from the rarely used z-
transformation of Pearson’s r (Altman, 1991).  When n=54 is used as a sample size and the 
calculation is back-engineered, it is given as the minimum sample needed to find a relationship of 
r=0.815 with a lower confidence limit of r=0.7. 
It is unclear from their paper what data these figures are based on.  It is stated to be a prospective 
rather than post hoc calculation but is highly specific for those exact figures.  This transformation is 
very sensitive to very small changes - for instance, if r was set at 0.800 rather than 0.815 the sample 
required would be n=74.  Even changes in the lower confidence limit can produce large effects - if 
the lower limit is 0.65, it would be around n=26, but if the lower limit was 0.74 it would be n=270.  In 
CF, the group most widely studied in this area, the r for the relationship between LCI and FEV1 is 
generally between 0.6 and 0.8, but there is certainly no consensus that would allow such specific 
figures to be taken from the literature. 
For this reason I do not believe this suggested minimum sample size affects work of this thesis, as I 
have not able to verify that this calculation is correct or applicable in these circumstances.  Sample 
size in rare conditions remains opportunistic due to the challenges recruiting these patients, and is 
an acknowledged weakness of this thesis.  
Another weakness seen throughout the thesis is that the PCD cohort appears, on the basis of 
spirometry at least, to be sicker than either of the other two cohorts.  However, the poor correlation 
of spirometry with structure and other physiological measurements mean caution in interpretation 
is mandate.  However, there may be several possible reasons for this. PCD patients have less 
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morbidity than CF patients, and are therefore often not in as frequent contact with a tertiary centre 
as their CF counterparts.  Those who are more unwell, however, have more contact, and therefore 
there are more opportunities to recruit them, they are likely to have better relationships with clinical 
teams, and anecdotally they seemed to be more interested in research than those whose burden of 
disease is lower.  Other reasons are a lack of any screening for PCD, and since symptoms may 
overlap with common childhood ailments (rhinitis, glue ear, cough) and it is a relatively rare disease, 
the lack of profile among primary care medical staff may often lead to patients not receiving a 
tertiary care referral until late on, and in fact the mean age of diagnosis in PCD is 4.4 years (Coren et 
al., 2002), despite the presence of neonatal respiratory symptoms in most patients.  None of these 
problems are easily resolved, and the present results should not be uncritically extrapolated to fitter, 
or at least younger, PCD patients. 
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7.5 Further work 
Following the work of this thesis, there are several avenues of research that need to be pursued.  
The first is a relatively straightforward small study which should be completed within the next 12 
months (7.5.1 below), the remainder (7.5.2) are more ambitious plans that would nevertheless 
provide more definitive answers to some of the questions raised here. 
7.5.1 PCD – a five year follow up. 
A weakness of this thesis is the lack of longitudinal LCI data in PCD, unlike in CF.   Longitudinal data 
would delineate whether LCI has any role in monitoring disease progression in PCD.  In CF it is known 
that LCI is more sensitive than FEV1 to early stage disease, but in PCD it is possible there is no 
relationship.  It is also possible there is some level of PCD disease severity at which the two will start 
to correlate but that is currently unknown.   
Mechanistically, seeing if LCI worsens over time or remains stable may allow inferences about what 
pathology is contributing to abnormal LCI.  If it is stable over time, that points to the primary MCC 
defect causing increased VI, whereas if LCI worsens over time it may be that increasing lung disease  
from the vicious cycle of infection, inflammation and bronchiectasis is the main contributor.  In CF, 
pathology on HRCT such as bronchiectasis is very strongly correlated with LCI, and both LCI and HRCT 
improve with treatment of infection (Horsley et al., 2013), but in PCD this is not known to be the 
case. 
To address this lack of longitudinal data, the 21 PCD patients that formed the initial observations of 
this work, and were used for the main paper published so far from the work of this thesis (Irving et 
al., 2013) were primarily recruited in the autumn/winter of 2009/2010.  They will be approached 
again this year, and attempts made to recruit them for a repeat of the spirometry and MBW tests, 
but not HRCT as it is unlikely ethical approval could be obtained for this. From this work, it should be 
possible to gain some idea of whether either MBW or spirometry (or both) have worsened over five 
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years, or whether they appear to be stable.  If they have worsened, risk factors for that worsening 
(for instance, infection with P.Aeruginosa) will be identified, as far as is possible in a small cohort.  
Exacerbations of respiratory disease requiring admission to hospital for intravenous antibiotics will 
be recorded and used as the gold standard assessment for their current clinical state.  
It would be clinically useful if it can be determined if LCI or FEV1 better predicted subsequent 
morbidity and mortality from lung disease. 
Comparisons with patient reported outcomes would be useful; and a PCD-specific QOL 
questionnaire is currently undergoing validation and could be used in future studies as a surrogate 
mortality/morbidity measure in this relatively well cohort. 
 
7.5.2 – Longer term goals for further work 
Chapter 4 of this thesis presents some detailed analysis of the MBW to try to distinguish different 
causes of VI.  Ultimately, however sophisticated the analysis, measurements at the mouth will 
always have limitations, particularly when attempting to obtain information on the very distal 
airways, within the acinar, diffusion-dependent zone, not least of which is that the large airways and 
conducting airway region that is between the two may obscure the signal.  The lack of elevation in 
Scond in PCD, despite high LCI, Sacin and Curv, suggests that some of the altered physiological 
relationships described in the work of this thesis may result from a lack of flow asynchrony between 
units.  But at this point, on current methods, the ability of MBW to assign a location to VI appears to 
be reaching its limit and other, more direct, measures of assessing ventilation will be needed. 
It has previously been reported that hyperpolarised helium MRI results may correlate well with LCI, 
and also give a visual picture, in real time, of ventilation.  Though work currently published (Horn et 
al., 2014) is confined to CF and healthy controls, the results look extremely promising.  It may be that 
use of this novel methodology may answer this question of the location and nature of VI in the PCD 
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lung and how it differs from that seen in CF.  Work completed in asthma showed more focal areas 
and in general a patchier ventilation defects rather than the previously thought likely diffuse 
changes in this condition, and so this technique may be the ideal method of answering the question 
of whether there patchy, focal disease is seen in PCD or CF (Svenningsen et al., 2014; Tgavalekos et 
al., 2007; de Lange et al., 2006).  Patchiness has already been established in pulmonary 
exacerbations of CF lung disease by positron emission tomography (PET) (Klein et al., 2009) scanning 
and so determining if it occurs in PCD should be relatively straightforward using this technique, 
albeit the radiation burden is not trivial.   The main problem with MRI, is that the machinery, 
expertise and the hyperpolarised helium itself make this an expensive test (at time of writing around 
£1000 per patient as a minimum), and it is likely even if it did prove useful that cost alone would 
keep it out of routine clinical practice.   
Some very recent work suggests that a full hyperpolarised helium study may not be necessary for 
MRI to possibly give greater information, particularly about ventilation and perfusion.  Conventional 
scanning may also be able to detect early disease changes in CF, and therefore might have a 
potential to shed further light on any difference in PCD (Wielputz et al., 2014). 
In addition to further imaging work, it is clear that there is a definite weakness in the measurements 
of inflammation attempted for this thesis, and so more sophisticated measurements may in future 
provide better non-invasive biomarkers for distal airway inflammation.  The “e-nose” or electronic 
nose, is a sensor able to detect volatile organic compounds (VOCs) in exhaled breath.  Work to date 
suggests these are strongly correlated to inflammation, and different compounds may provide a 
“breathprint” that is specific for different respiratory conditions (Montuschi et al., 2013).  It is 
possible this technology may identify differences in inflammation between PCD and CF, and 
potentially even tie this to physiology results from MBW and spirometry.  The main potential 
drawback with this technique is that it is unclear at this stage whether it will be able to distinguish 
between compounds given off in the larger airways and those originating from more distally. 
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BAL may allow the assessment of inflammation at different levels of the airway.  When BAL is 
performed, the first aliquot of fluid is considered to be primarily bronchial in origin, and the later 
ones primarily alveolar (Ratjen et al., 2000).  By this method, inflammatory markers found in these 
two regions can be separately assessed.  This method has been used successfully in CF (Ratjen et al., 
2000) and therefore should be suitable for PCD patients also, and may allow any differences in distal 
and proximal inflammatory profiles to be detected. 
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7.6 MBW and LCI – future concerns 
When planning further work, it should be acknowledged there has been a change in how MBW tests 
are carried our during the work of this thesis, with both equipment, tracer gas and protocols being 
adapted to allow the test to be more widely and easily performed in the future, for both clinical and 
research work. 
7.6.1 Reference equations 
Several papers have acknowledged there is variation in LCI with age.  Though this seems primarily 
confined to preschool children and older adults, and attempts have been made to generate 
reference equations to provide age-, and possibly gender-, appropriate normal ranges.  This is 
considered to have the potential to improve sensitivity of these measures, as at present upper limits 
of normal are mostly extrapolated from mixed age range groups, whereas for young adults (who 
tend to show the lowest predicted LCIs) the true upper limit may be lower than that normally 
quoted and so it is possible early disease changes may be missed in this group.  There are currently 
two main papers, one (Verbanck et al., 2012) exploring the changes due to aging in older adults, and 
another dealing primarily with the under 6s (Lum et al., 2012), though these have yet to be 
combined into a verifiable set of equations covering all of life. 
Although the basis for wanting these equations is right, in practice their implementation may be 
difficult.  It is to be expected that they will vary with methodology, equipment, and washout gas 
used, so any equations produced using, for example, SF6 on the AMIS 2000, will not necessarily apply 
to a nitrogen washout on an Exhalyzer D.  It may be that a more practical solution is to ensure that 
age matched controls are recruited and tested with the same methodology. 
7.6.2 Nitrogen washout 
Though originally conceived as a nitrogen washout using pure oxygen, MBW in recent years has 
tended to be using an inert tracer gas, either SF6 or helium.  However, this is changing again.  SF6 is 
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harmless to human health but is an environmental pollutant, specifically a “greenhouse gas”.  
Though the quantities used in MBW are very low, the supply is increasingly restricted, particularly in 
the USA and France, and it is likely to become the case within the rest of the European Union in the 
near future, and so it is being phased out. 
Helium, although not a pollutant, is becoming increasingly expensive as the industries that produced 
it as a by-product have declined.  It is still available, but simply not economically viable for repeated 
tests in most clinical or research budgets. 
Nitrogen analysers, by contrast, have become smaller, cheaper and more portable in the 60 years 
since the MBW was first conceived, and nitrogen washouts are now a viable alternative to SF6 and 
helium. 
There are some differences between nitrogen washouts and inert tracer gas washouts, some of 
which are desirable and some less so.  Nitrogen MBWs require less time on the mouthpiece/mask 
than an inert gas washout, as the wash-in phase can be conducted simply by breathing normally in 
room air.  This is clearly desirable for patients as it is less uncomfortable, and it will likely improve 
patient compliance.  Also, the machines can be made more portable as oxygen and room air are 
normally much more easily available in a hospital environment than specialist inert gas mixtures, 
and even raise the possibility of LCI measurement in outreach centres or even primary care. 
However, the choice of inert gas does make some important differences to the MBW.  Gas 
movement by convection should be the same for all options, but this is not the case at the lung 
periphery where diffusion begins to predominate; the diffusion-convection front is more proximal 
for lighter gases, which in this case gives helium the most proximal, SF6 the least, and nitrogen 
between the two.  This effect will lead to differences in results between different gases, particularly 
in the measurement of phase III, and results should not be extrapolated between gases. 
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Furthermore, nitrogen is not in the strictest sense metabolically inert; it diffuses in very small 
quantities from lung tissue down a concentration gradient, particularly if it large, such as after 
alveolar wash out with pure oxygen.  The current guidelines do not recommend attempting to 
correct for this phenomena however, due to lack of data with which to inform a correction, though 
this may change should more data become available (Robinson et al., 2013).   
It is known in patients with obstructive lung disease that a heavily diseased and completely non-
ventilating lung unit cannot take part in an LCI, and that lung units with very long time constants may 
not register in the wash in or washout phase.  These units often manifest as a larger-than-usual 
discrepancy between the FRC as measured by MBW, and FRC as measured by body 
plethysmography; however, it should be noted that FRC measured by plethysmography is 
overestimated in the presence of airflow obstruction <REFS>, so air trapping may be over-estimated.   
If resident nitrogen is used as a test gas, however, it is likely these very poorly ventilating units will 
contain nitrogen at the start of the washout.  So, during the washout phase these poorly ventilated 
units, particular at the very end of the washout when very low concentrations are found throughout 
the better ventilating parts  of the lung, may start to contribute their contained nitrogen to the point 
it is actually visible on the test, thus increasing the test time and the eventual LCI. 
Though technically this is actually an improvement on inert gas washout, as this is a more accurate 
representation of lung health in these patients, it will nevertheless change the LCI result, another 
reason why nitrogen washout results cannot be extrapolated to other methods. 
 
7.6.3 Automated analysis 
Though the principles of LCI analysis are not particularly complex, the use of systems never designed 
for their measurement (such as the AMIS2000 mass spectrometer or the Innocor) made calculation a 
slow process, normally conducted offline in research derived software after the test was completed.  
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Newer systems are being produced with the calculation included in the online analysis and largely 
automated, giving a “real time” result and therefore potentially increasing usefulness in clinical 
practice. 
Though many observers are, quite rightly, sceptical of these newer automations, they are essentially 
faster versions of the already existing software, and the operator still has the ability to review the 
test fully, and to select or exclude breaths according to a protocol and their judgement.  This is 
essential to maintain quality control of the tests, and any switch to “black box” environments where 
such a thing is impossible is not desirable. 
 
7.6.4 New MBW machines 
Several other MBW methods became available after this thesis was started, outlined below.  The 
main driver for these new techniques is to make the measurement quicker and more accessible in 
the clinical setting.  Most newer methodologies therefore use nitrogen washout. 
The ndd EasyOne Lab Pro measures nitrogen washout using an ultrasonic flowmeter.  As mentioned 
previously (2.1.2), these systems use parallel ultrasonic beams passing from a transmitter to a 
receiver across the flow chamber.  Airflow through the chamber deflects these beams, and the 
deflection corresponds to the flow, which is calculated and displayed as such by the software.    By 
an additional application of this technology (molar mass detection) that focuses on the density of 
gases, gas concentrations can be worked out. 
Unfortunately, the system’s large deadspace (38ml) makes it unsuitable for use in babies and young 
children but it shows considerable promise in other age groups.   
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The machine is also much more portable, although not a handheld device (Figure 7-2). 
 
 
 
Figure 7-2 The EasyOne Pro Lab during a MBW.  This device uses ultrasound for both flow detection 
and gas concentration reading, and its relatively small size, use of atmospheric nitrogen as a tracer 
gas, and automatic calculation make it suitable for clinical use. 
The interface for performing an LCI is automated and very user friendly, with software algorithms 
determining if tidal breathing has been achieved, when the washout gas should be connected, when 
the test end point has been reached, and when to terminate the test.  The LCI calculation is also 
automatically performed by this software.  A separate software environment called WBreath runs in 
the background to the user interface and contains more detail of the washout and allows more 
complex analysis of the flow curves.  Despite this, more complex parameters such as phase III slopes 
cannot be calculated. 
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There are published data showing that the analyser generated similar results to mass 
spectrometry(Fuchs et al., 2008; Fuchs et al., 2006), that the prototype setup showed results within 
previous ranges (Fuchs et al., 2009), and that the commercial version may be suitable for use in 
multicentre trials (Fuchs et al., 2011).  
One more minor but relevant drawback is the hardware used to supply oxygen makes a loud clicking 
and hissing noise with each inhalation and exhalation, which is distracting and intimidating for young 
or nervous patients.   
The Ecomedics Exhalyzer D is the second automated commercial LCI analysis machine, also using N2 
washout, with very different strengths and weaknesses from the ndd machine. 
 
Figure 7-3 The Ecomedics Exhalyzer D machine, showing the flow meter and sample line, the nitrogen 
analyser and its’ control PC, and the wall outlets for oxygen and medical air. 
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The Exhalyzer D uses an ultrasonic pneumotach for flow detection using the same technology as the 
EasyOne Pro Lab.   A sidestream flow sampler attached to the mouthpiece samples 200ml/min of gas 
for testing in the Exhalyzer D unit.  The analyser and pneumotach are both connected to a control 
PC, which in modern units is incorporated into the screen and keyboard to reduce the amount of 
equipment (though on some older units an entirely separate PC is still used).  The signal outputs of 
flow and concentration are aligned by the software after the delay has been automatically 
calculated.  The software then allows the user to track breathing and nitrogen concentration in real 
time until both are stable and then the machine indicates that the test is ready to be started.  This is 
manually triggered (though an automated protocol is available), and the patient begins to breathe 
100% oxygen supplied via the Exhalyzer D unit.  End tidal gas concentrations are automatically 
calculated and shown throughout the test, and the test is manually terminated by the user (although 
again an automated protocol can be used). At this point, LCI is automatically calculated by the 
software and displayed on screen, along with FRC, and other more complex parameters such as 
phase III are available. 
The method still has some drawbacks.  The system itself is not very portable, because although the 
nitrogen analyser unit can be moved, it takes some time fully to stabilise when reconnected.  The 
setup and calibration of the system is complex and technical so requires a specialised physiologist. 
The deadspace however is extremely small so it can be used down to infancy and perhaps even 
premature babies (with an appropriate mask).  The software used is extremely sophisticated and 
very robust, calculating phase III parameters Scond and Sacin as well as LCI (though it does not currently 
include curvilinearity analysis (Singer et al., 2012).  
This machine has been recommended by the European Cystic Fibrosis Clinical Trials Network as their 
equipment of choice for the MBW test. 
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The remaining piece of equipment is the “automated analysis” Innocor module.  This uses SF6 on a 
closed circuit system with a CO2 scrubber, produced very poor results when tested, is not currently 
available and so will not be considered further. 
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Analyser AMIS2000 
 
Innocor (modified) 
 
EasyOneProLab 
 
Exhalyzer D 
 
Software DOS based Windows XP 
embedded 
Windows XP 
embedded 
Custom – will run in 
Windows XP or later 
Servicing Annual, specialist Annual, unspecialised Annual, remote Annual, specialist 
Gas used SF6 washout SF6 washout Nitrogen washout Nitrogen washout 
Washout type Open circuit Open circuit Open circuit Open circuit 
Portability Very low (immobile 
equipment, control PC 
and two cylinders) 
Medium (mobile 
equipment, immobile 
cylinder) 
High (mobile 
equipment, oxygen 
supply only) 
Medium (mobile 
equipment, takes time 
to stabilise on moving, 
oxygen and medical 
air supply) 
Analysis type Manual analysis Manual analysis Automated analysis Automated analysis 
Flow type Separate flow 
measurement 
Integrated flow 
measurement 
Integrated flow 
measurement 
Integrated Flow 
measurement  
Consumables 
type 
Reprocessible 
consumables 
Reprocessible 
consumables 
Single use 
consumables 
Reprocessible 
consumables 
MBW 
Parameters 
LCI, phase III LCI, phase III LCI only (at present) LCI, phase III 
Age range Suitable from birth Suitable from early 
childhood (slow rise 
time prevents use in 
infants) 
Suitable from early 
childhood (large dead 
space prevents use in 
infants) 
Suitable from birth 
References (Gustafsson et al., 
2008; Gustafsson, 
2007; Gustafsson, 
2005; Gustafsson, 
Aurora & Lindblad, 
2003) 
(Macleod K et al., 
2010; Horsley et al., 
2008a) 
(Fuchs & Gappa, 2011; 
Fuchs et al., 2009; 
Fuchs et al., 2008) 
(Singer et al., 2012) 
Table 7-2 Comparison of equipment for LCI.  Information is taken from manufacturers’ own 
specifications where possible. 
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In summary, there are advantages and drawbacks to all methodologies.  The ideal equipment would 
run modern software, have easily maintained hardware, use nitrogen washout (increasingly 
portability and decreasing expense and environmental concerns), automated and unbiased (whilst 
still being accurate and verified) analysis of multiple parameters, integrated flow measurement, 
single use consumables, and be usable across all age ranges.  As the above table shows, no 
equipment completely fills these requirements 
Equipment should be consistent within a study, and results must not be uncritically extrapolated to 
those obtained with different equipment. Also, in the enthusiasm for online analysis, care must be 
taken that systems are not becoming “black boxes”.  Tidal breathing, particularly in children, can be 
very variable, and some MBW parameters (particularly phase III analysis) can be very sensitive to 
even one poorly performed breath in a washout.  The ability to monitor breathing pattern and the 
corresponding exhaled gas signal, ideally in real time, is vital, even if LCI is calculated automatically, 
and the desire for streamlined software and intuitive protocols should never compromise this key 
feature. 
It seems likely the newer machines will help drive MBW in general (and LCI in particular as a 
sensitive, straightforward and easily obtained parameter) forward into increasing clinical use; 
showing that this is useful in a routine clinical setting will also be essential. 
7.6.5 Shortened washouts 
Particularly in paediatric practice, there is current interest in reducing the duration of an MBW in 
order to make the test more tolerable for young children.  Though MBW is non-effort dependent 
and requires only passive cooperation, the fact is that if all cooperation is withdrawn the 
measurement cannot be made, and this problem is particularly acute in pre-school children.  MBW is 
potentially a very good tool for detecting early lung changes in sedated pre-schoolers, but sedation 
is not practical on a regular clinical test. 
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Attempts have been made to shorten the washout duration.  The easiest would be to perform 
duplicate not triplicate measurements; a successful MBW run requires two washouts with 
comparable FRCs (within 10%, see 2.4 for full details) to be achieved, and so (with offline analysis 
that prevents the user from checking the results instantly) three washouts are normally performed 
in order to increase the chances of two being comparable.  If just two are taken without checking for 
comparison, this does reduce the time by a third but unfortunately increases the number of patients 
in whom two comparable washouts are not recorded, thus lowering the test success rate. 
Instead, focus has been on altering the end point of the LCI from 1/40th of the tracer gas 
concentration to a larger fraction.  1/40th is purely historical rather than physiological, and was based 
on the resolution of the early nitrogen analysers not on any ventilatory mechanics.   
Two studies (Yammine et al., 2012) and (Hannon et al., 2014), found that shortened measurements 
correlated well with standard LCI in healthy controls and CF patients.  Both papers concluded that 
particularly LCI0.5 or LCI1/20 (an LCI where the inert tracer gas is measured at 1/20
th of the tracer gas 
starting concentration as opposed to 1/40th in a standard LCI) provided a good balance between 
time saved and sensitivity to disease changes. 
Though in older, compliant subjects who will perform the full test there is no real reason to apply the 
shortened measure unless they have really severe airflow obstruction, in younger patients who 
cannot be tested reliably and repeatedly whilst awake even a relatively small increase in the end 
concentration may give data where none would have otherwise been available. 
Also, although phase III analysis is focussed on the first three turnovers of a washout and should still 
be possible on truncated washouts, Curv analysis would not be possible on these data. 
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7.7 Final conclusions 
The original observation on which the work of this thesis was based was that there was a different 
relationship between FEV1 and LCI in PCD from the established one in CF. I have confirmed this inso 
far as was possible in a larger cohort in this thesis, and demonstrated physiological differences in 
distal airway disease, particularly with regard the relationship with more proximal disease, in PCD 
compared to CF patients. My original hypothesis is thus proven. 
Though the exact nature of this difference, particularly the pathological basis, cannot be fully 
explored with current methodology and there are distinct limitations with the approaches taken 
here, it likely relates to primary ciliary dysfunction, as opposed to the secondary dyskinesia caused 
by lung disease in CF and non-CF bronchiectasis; it is not related to CFTR dysfunction. 
Whether these differences result from differences in inflammation, my second hypothesis, could not 
be proven due to the largely negative results in a panel of markers, and especially the difficulty of 
partitioning proximal and distal inflammation. 
These differences, particularly between CF and PCD, are important for three main reasons.  Firstly, 
the care and monitoring of PCD patients is frequently extrapolated from that of CF, but if there are 
underlying differences between these two apparently similar obstructive diseases this may not be a 
good strategy.  Specifically, the work of this thesis casts doubt on whether either FEV1 or LCI are 
sensitive to structural airway changes in PCD, and underscores the need for a critical re-evaluation of 
how to monitor this disease clinically, or in randomised controlled trials. Secondly, PCD patients have 
significantly lower mortality and morbidity from lung disease than CF, and any differences 
discovered in the disease processes could be useful in determining what confers this milder course 
in PCD, and perhaps even ultimately provide future targets for therapy in CF lung disease. Finally, the 
work of this thesis underscores the dangers of uncritically extrapolating from one airway disease to 
another.
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509-514. 
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Appendix One- Innocor SOPs 
 
Contained in this Appendix are the SOPs used in data capture, analysis and handling on the Innocor 
device used during the work of this thesis. 
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Multiple breath washout test using modified Innocor device 
 
Risk assessment 
The main risks involved in this protocol are: 
1. Explosion caused by build-up of pressure in gas cylinders with insufficient 
release valve mechanisms (or if cylinders are heated up by fire). 
2. Inadequate infection control between patients. This risk is minimised by 
adherence to a strict infection control policy (see below) 
3. PTFE tape or any grease/oil -based substances being used on regulators or 
any gas couplings – due to risk of ignition when using flammable gases.  
4. Ensure hands clean, dry and free of creams/oils when changing regulators. 
5. Keep cylinders chained to wall or lab bench to prevent falls of heavy cylinders 
onto personnel. 
 
 
Standard operating procedure for multiple breath washout using modified 
Innocor 
 
Equipment required 
 Innocor device, modified and set up as described in previous sections. 
 Supply of 0.2% SF6 in air 
 Sterile filter 
 Clean mouthpiece and noseclips 
 Calibration syringe 
 Fan 
 
Before starting 
 Switch machine on. Ignore onscreen instructions about Innocor gas cylinder, 
press OK to continue. 
 Go to Setup, Calibration, Adjust flowmeter.   
 Press Calibrate and follow on screen instructions to fill and empty the 
calibration syringe – you should include the filter between the syringe and 
PNT when doing this.  The gain must be between 0.9 and 1.1 or the flow 
meter may require linearization (see separate SOP)   
 Make a note of the gain on the log sheet. 
 Make note of the humidity, the atmospheric pressure and the temperature.  
Also check the gas pressure at the cylinder. 
 Under Measurement, select the patient given as “fgd”.  There is not need to 
change the patient information, this is simply to record the Flow Gas Delay.   
 Select Test and then Washout, and perform 10 breathing manoueveres of a 
slow exhale and sharp inhale.   
 Stop and exit the test when finished, this will be analysed later. 
 
Entering patient data & patient codes 
 From the Measurement screen select New Patient. 
 Use the keyboard to enter the relevant data and then select OK. 
 Enter the Hospital Number with NO PUNCTUATION as the I.D. 
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 Confirm the height and weight – these may need changing if using the 
patient‟s record from a previous visit. 
 Select Test and the program called WASHOUT 
 Connect the patient to the breathing circuit as shown below. 
 OK the load of 0 watts and start the test. 
 
 
 
 
Instructions to Patient 
 Ensure patient is comfortably seated and suitably distracted. 
 Attach noseclip and ensure that a good mouthpiece seal can be achieved 
comfortably. 
 Instruct patient to breathe normally. 
 It is important that a good seal around the mouthpiece is maintained at all 
times. 
 
Carrying out the MBW 
 SF6 levels as well as flow can be monitored on the Show Graphs, Show 
Online Data option. 
 When the patients SF6 concentration has plateaued at about 0.2% 
(fluctuations in the region of 0.197 and 0.201% are acceptable) disconnect the 
t-piece from the patient and allow them to breath room air to begin the 
Washout phase.   
 The disconnection should be done on expiration, and you should check to 
ensure the SF6 concentration goes straight down to zero – if it doesn‟t 
reconnect the patient and “re-washin” them as the analysis requires their first 
inspiration of the Washout to have NO SF6.  Warn the patient prior to 
disconnection so the breathing pattern remains normal. 
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 The gas is considered washed out when the concentration in the lungs is 2% 
the original level –0.004% or under.   
 Try to have a least 4 breaths less than this before the end of the test to 
ensure they are properly washed out. 
 At the end of the test close the online data window and stop the test by 
pressing Stop protocol from the right hand menu.  
 
 
Infection control policy 
 
 
Multiple Breath Washout 
Equipment 
 
 
Innocor 
 
Not in contact with patient. Can be wiped with hard 
surface wipes (not touchscreen). 
Flow-meter  
 
Protected from patient by bacterial/viral filter. Requires 
periodical cleaning by dismantling and disinfection –           
every 10-15 patients. 
Pressure lines Protected from patient by in-line filter. Should be wiped 
thoroughly after each patient (hard surface wipes). 
Flow-meter stand (if 
applicable)  
Should be wiped (hard surface wipes) after each patient 
Bias flow elephant tubing 
and T-piece   
 
 
 
Protected from patient contamination by filter but 
attention should be made to any evidence of 
condensation inside tubing. Given that patient‟s breath 
is exhaled through exhaust end, tubing should be 
changed periodically – every 10-15 patients.  
T-piece should be disinfected 
Gas tank and flow tap 
 
Not in contact with patient. 
Mouthpiece  Disinfected after every patient. Strict separation of clean 
and used. 
Noseclip  Single use. Disposed of after testing. New noseclip for 
each patient and visit 
In-line filter  
 
Single use. Disposed of after testing. New filter for each 
patient and visit 
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Summary of recommendations 
 Use a new disposable filter and noseclip for each patient. 
 Wash hands between patients. Either use gloves to handle filters, 
mouthpieces and noseclips or wash hands after doing so. 
 After each patient use, wipe the machine, swing arm and seat with detergent 
wipes. 
 Mouthpieces should be sterilised. 
 Flowmeter should be thoroughly cleaned once per week, flowmeter 
linearization must be repeated after cleaning. 
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Setting up the Innocor for LCI measurement 
 
. 
 
Washout Program 
 
On occasion, particularly if the Innocor‟s windows-based system has crashed, it may 
“lose” the Washout program and this will have to be added again.  To do this:- 
 Select Measurement, then Test. 
 Leave the following window blank and press OK. 
 Select New. 
 Enter “Washout” as the protocol name, then press the RB/NIBP button until 
the symbols disappear from the left hand column. 
 Set load to 0 watts and the time to 60 minutes. 
 Select OK. 
 Select BB graphs setup.  This is not too important as we mostly pay attention 
to the Online Monitoring graph with this test, but ideal options are Graph 1 
Time vs Vt, Graph 2 Time vs VCO2 and VO2, and leave Graph 3 blank. 
 Select OK, then press the arrow symbol until the Exercise Device says 
Manual Control, or the Innocor will keep looking for an exercise bike or 
similar. 
 
Flowmeter Linearisation 
 
After washing or changing the pneumotac, or when the gain on the flowmeter 
calibration becomes unacceptable, the flowmeter should be linearised.  To do this:- 
 
 Exit to windows. 
 Go to C:/Innocor/Programme and select Flowmetercalibration.exe. 
 Select Calibrate, and then Prepare Syringe Size to make sure the correct 
volume (normally 3 litres) is selected. 
 Select Add Stroke.  Follow the onscreen instructions for filling and emptying 
the syringe using a variety of flow rates. 
 You can use the Use/Skip button to deselect and run you know was done 
incorrectly at the end so it will not be included in the calculation. 
 Press Accept when finished. 
 Repeat the process until the percentage error shows as less than 3%.  This 
will normally take several attempts. 
 When happy with the error percentage, select Accept then Cancel and you 
will be given the option to save the data.   
 Use the file name bbblin1.cal, then select Yes to overwrite the previous file. 
 Exit back to windows. 
 
 
Innocor delay calculation 
In our Innocor, the oxygen analyser has been bypassed to give a better gas delay 
time which is more suitable for paediatric patients.  Therefore there is no oxygen 
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analysis going on whatsoever – any oxygen trace will show a zero signal or a flat 
line, and any parameter the machine could normally calculate using this figure (e.g. 
VO2) will either not be calculated or give a nonsense answer.  Also, the automatic 
delay calculation on the Innocor will not function.  The ten breaths recorded by the 
operator before the test however, can be analysed and delay calculated from this. 
 
 Retrieve the “fgd” file created on the day of test. 
 Convert using “innofileconverter” to show “Flow” and “CO2” (not this is 
different from the normal procedure, where “Flow” and “SF6” should be 
selected. 
 Load text file produced in Testpoint software.  Crop to show ten breaths 
produced. 
 On first slider bar, find point flow changes.  Reduce inspired volume by 15 mls 
to account for dead space. 
 Note 4 digit number eg 1234 
 Using last bar, find maximum CO2 concentration, and note down.  Then find 
minimum concentration and subtract this. 
 Find half way point of CO2 concentration. 
 Note 4 digit number e.g. 5678 
 Subtract first four digit number from second (e.g. 5678-1234), this gives the 
delay in number of samples. 
 Multiply this by ten to give delay in milliseconds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
314 
 
 
 
 
Innocor data analysis 
 
To prepare .inno files 
 Open Innofileconverter. 
 Click „Load File‟. 
 Pick .inno file you wish to analyse. 
 Go in to Rawdata. 
 Make sure SF6 and Flow boxes are checked but no others. 
 Click „Convert to Text File‟. 
 Exit when finished. 
 The program will save a text file with the same name as the original .inno file 
in the same location. 
 The file can be opened directly using the „Open in Excel‟ option. 
  
 
Analysing the data in the Washout SF6 Program 
 Open Washout SF6.  Make sure the delay is entered correctly and the “Re-
insp” box is crossed. 
 Click „File‟, and select and open the required text file. 
 Set the „Crop start‟ and „Crop end‟ bars to the beginning and end of the 
washout, including a few breaths of the washin. 
 Click „Crop‟ to get the image below.  This should be screen captured so the 
graph can be used in the final report. 
 When ready, click „Next‟ and the software will identify the first breath. 
 Click „Next‟ until the first breath of the washout phase has been correctly 
identified.  Mark this as „Init Value‟.  Give the test a Filename and check the 
Test # is correct. 
 Click „Save‟ to identify the next breath, and continue doing this until the 
concentration of SF6, shown as the Cet% in the bottom right corner is 1/40th 
the starting amount.  When the (Cet%) is equal to or lower than this target 
(End%) it will display a red “stop” circle.   
 Save this breath, and then check the next is also below this. 
 You can then view the data by clicking „Results‟.  This brings up the Results 
screen, where the data can be saved. (Figure One below shows these steps)
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Figure 1 – Steps of analysis in sequence (refer to bullet points above) 
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Moving the data into a spreadsheet 
 In C:\WASHOUT, find the excel file created by the analysis program that ends 
in _mo and open it. 
 Select and copy all 3 lines of data. 
 Open the template file INNOCOR CLINICAL. 
 Paste the data into the first 3 lines of the Raw data input worksheet. 
 Select the Data Selection worhsheet, input the correct environmental data and 
select and copy the data in cells A1:H3. 
 In the Results worksheet and select the area B3:I5, go into Edit, Paste Special 
and select the „Values‟ option. 
 With the data correctly copied the spreadsheet will calculate the parameters 
and means for you.  Enter the patient information beneath this. 
 In the Report worksheet there is a summary of the data.  You can add the 
graph screen captured earlier.  
 This page can now be printed for the notes and a copy saved to the T drive. 
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Phase III slope Analysis on Innocor 
 
 
Data Analysis 
 
During an MBW (Multi-breath washout) analysis using Innocor data, the Phase III 
slope is identified and saved at the same time as recording each breath for LCI (lung 
clearance index) calculation. 
 
 
 
 The slope can be seen here (red portion). 
 It can be adjusted using these sliders. 
 After adjustment you can either save the new limits you have chosen or return 
them to the default using these buttons here.   
 Remember if you have adjusted the limits manually you must select one of 
these two options for the normal “Results” button to reappear! 
 
Convention states that the phase III (alveolar slope) should be measured from 65-
95% of the end tidal concentration. The default should only be temporarily altered to 
account for “problem breaths” – e.g. cardiac oscillations or breath pauses. 
Once the washout has been analysed, the Phase III slope data is saved in the excel 
file named as “filename_mb” in the Washout folder, along with the “filename_mo” file 
that is normally used for obtaining the LCI data. 
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Obtaining the Results 
 
In the “filename_mb” file you will find each breath of each washout listed with various 
parameters calculated.  Select the entirety of the first washout (not including the 
header row, or any additional columns on the left hand side) and Copy it. 
 
Remember that any half analysed attempts or discarded washouts will also be saved 
in this file, so make sure you select one full and complete washout.  Checking 
column “C” and making sure the sequence of breath numbers is correct can help 
with this. 
 
 
 
This block of data now needs to be copied into the SnIII analysis spreadsheet. 
 
Open the “Input(1)” tab and Paste the washout in, and then on the next tab “SnIII 
actual (1)” put the patients‟ weight in kg in the pink box in cell “P4”.  In Column “H”, 
much of the data will replaced with the word “ignore”.  This is the spreadsheet 
automatically selecting only those values that occur between 1.5 and 6 turnovers, 
which are the data required for Phase III analysis.    
 
In Column “J”  (with a pink header) the initial Phase III data is displayed.  At this 
point, any odd outliers can be removed from the data by deleting them.  The graphs 
further down the page can be useful in spotting these outlaying values. Outliers are 
not simply values that do not conform to the expected trend, but rather SnIII values 
that are physiologically impossible (very high or very negative). In CF patients these 
tend to be rare, but in healthy controls there are often negative values as the overall 
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trend in SnIII is flat over the washout. It is not scientifically justifiable to remove all 
negative values. 
 
 
The next washout goes in “Input(2)”, again enter the weight in “SnIII actual (2)”, and 
so on. The spreadsheet assumes there are 3 washouts for each patient, so when 
entering only two for an individual remember that you must leave a blank set of tabs 
before putting the next patient in, otherwise the results will become muddled when 
they are exported. 
 
The results for each washout can be viewed in the “SnIII x VT” tabs (those is “SnIII 
actual” have not yet been adjusted for breath size) and also in the Export tab at the 
beginning of the file, which also shows mean values for each set of washouts. Both 
“actual” and tidal volume (Vt) adjusted results are shown in the export tab. Most 
studies in children now quote Vt adjusted results as described by Aurora at al (resp. 
phys. & neurobiol. 2005). 
 
The export tab can be copied in to “sheet 1” using “paste special” and selecting 
“values”. This results in a sheet of numerical values with no linked cells, appropriate 
for statistical analysis. Also, the original data are preserved. 
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Appendix Two- AMIS2000 SOPs 
 
Contained in this Appendix are the SOPs used in the MBW data capture, analysis 
and handling on the AMIS2000 mass spectrometer device in use in our laboratory. 
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Components: 
 Mass Spec – Amis 2000 
 Gas sample capillary and sample tubing 
 Gas supply and regulator 
 Calibration gas and regulator 
 Fleisch pneumotach flow meters (PNT)  
 Pneumotach pressure transducer 
 Flow gas delay switch 
 White analogue-digital board box 
 Laptop and installed testpoint software items 
  
Mass Spectrometer 
The Mass Spectrometer should be left on throughout the week to avoid a long warm-
up period each day. Full calibration is required at the start of each day, with 2-point 
calibration required before each subject. 
 
Full Calibration: 
1. Emission on for at least 1 hour before study (optimal) 
2. Use capillary number 2  
3. Go to “gas setup” 
4. Check Teflon capillary not blocked, and is flush with end of capillary tip 
5. Feed sampling line with a low flow of calibration gas (barely felt with lips). 
6. F4 – optimise, check readings. Signal in volts should be as high as 
possible to reduce signal noise (8-9V is good). 
7. If readings too high (saturated) for a particular gas, alter range “E – # “ 
using F1/2 to toggle 
8. SEM alters all readings to optimise voltages 
9. F6 auto-optimise 
10. F9 to move forward 1 screen and check helium values  
11. “Peaking” can be viewed to check the peaks are measured at the right 
mass. Not essential. 
12. F7 calibration, F7 auto calibration. No quick calibration.  
13. Check results that signal noise ratio is ~200. 
14. Save results, select file and overwrite. 
15. Look at online signals, F7 to check signals. 
16. Y-axis scale is set to 0-5 to give good visual of SF6. Other gases can be 
viewed by altering scale if required. 
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Calibration of other components 
 
The flow-gas delay and pneumotach pressure transducer must be calibrated daily to 
ensure values are appropriate and can be incorporated during analysis. This also 
ensures the equipment is working properly. 
 
Flow-gas delay 
Flow-gas delay is documented as the time taken for the gas concentration to rise 
50% of the full value after a sudden change in concentration. This time is made up 
from the time taken for the sample to travel down the sample capillary to the 
analyser and the response time of the analyser. The flow gas delay is used to align 
the gas signal with the flow signal at the time of analysis. Even a slightly inaccurate 
flow gas delay value may cause error in gas volume estimation. 
The measurement is made using the black box, which contains a gas inlet and a 
small valve. The valve is opened at the same time the clock starts, and the time for 
the gas to rise is recorded. Multiple repeats are done to obtain an average value. 
 
Flow-gas delay calibration: 
1. Check connections 
2. Make sure box has power supply 
3. Connect gas supply line 
4. Take calibration gas supply (open main valve, then regulator) 
5. Make sure secondary gauge is 5PSI to prevent it rising above this 
6. Turn on gas with low flow 
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7. Select “delay” on computer desktop 
8. Insert sample capillary into small hole on the front of the box. The capillary 
should be inserted 9mm (full length) and pulled back one, to ensure the 
needle does not interfere with the valve opening. 
9. Select “delay test” once or twice to check signal rises visually 
10. Baseline and plateau positions may need to be changed if delay v. long or 
v. short 
11. Select “reset” then “start” 
 
 
 
 
12. View results as produced, check reproducibility 
13. Wait until 20 loops produced (may be reset to 10) 
14. Check results are similar to previous days 
15. Click “save delay”, then “save to log” 
16. All results should be written and stored in logbook file on desktop shortcut. 
Write down subject details in next tab in same file. 
 
Pneumotach  
The pneumotach (PNT) works on the principle that as air is passed through a partial 
obstruction, the difference in pressure on either side of this partial obstruction is 
linear the airflow. The Fleisch pneumotachs are robust, accurate devices with 
minimal deadspace; ideal for measurements in small children. 
Small leaks or defects in the device may affect the linearity of the pressure changes 
with flow. Leaks will cause a drift in pressure leading to inaccuracies. 
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The pressure changes are measured using the pressure transducer, which 
generates a linear voltage response to changes in pressure. The magnitude of this 
voltage response must be quantified in terms of flow. 
The calibration process makes sure this voltage response is accurate by delivering a 
known volume over a measured time to calculated flow rate. 
Pneumotach calibration: 
1. Take appropriately sized pneumotach, check for defects 
2. Connect pressure lines (observe colours). Red near to x (patient side), 
blue in the other port. 
3. Attach pneumotach to arm 
4. Remember to calibrate the pneumotach cold 
5. Connect 1L syringe to positive side of pneumotach. Have sample capillary 
in place during calibration. 
6. Select “PntCal” on desktop 
 
 
 
 
7. Check correct volume syringe is selected 
8. Check that baseline flow (voltage) is zero (may need to adjust trim using 
long small screwdriver) 
9. Check “auto” and then click “start” 
10. Pump syringe at rate the patient will be breathing. Repeat a number of 
times (~20). 
11. If constant difference between inspiration and expiration then switch PNT 
round and redo breaths 
12. If difference persists check all connections and equipment for reason 
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13. At the end press “save”. Not necessary to press update unless “auto” box 
not checked. 
14. Write numbers into logbook file.  
15. Save and close logbook and exit calibration program. 
16. Now switch on pneumotach heater and connect PNT cable to heater box 
(takes 5-10mins to heat up) 
 
 
Setting up for a test 
 
1. Collect mouthpiece and plastic adaptor (hole at 10 O‟clock) and put onto 
PNT 
2. Mouthpiece should be fixed with tape to ensure it won‟t come off during 
the test. 
3. Assemble elephant tubing (4 section lengths either side) with t-piece and 
plastic adaptor.  
4. Apply silicon grease to plastic adaptor to make detachment easy 
5. Put gas cylinder connection to other end of elephant tubing 
6. Do “quick cal” of Mass Spec.  
 
 
Performing a Multiple Breath Washout test. 
Once the calibration is done, the patient needs to be present for the next steps (or at 
least the patient details). The patient numbers are generated sequentially so that 
each visit is recorded as the next highest number over the calendar year. 
  
1. Open “collect data” program 
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2. Enter patient data and 6-digit file number (<year><4-digit number>) e.g. 
080001.  
3. Save and exit 
 
 
4. Select “2-point calibration” – this measures zero sf6 gas and cylinder 
calibration gas as a final step before testing. 
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5. Open valve by switching “delay box” to “on”. 
6. Press zero gas, wait for values 
7. Press test gas, wait for values 
8. Save and exit 
9. Select “perform test”  
10. Do a dummy test 
11. Select “next” 
12. Show volume feedback bar to patient (click volume button and drag to 
subject viewing screen). 
13. Start patient washing in. Encourage slow relaxed breaths while watching 
the inspiratory volume display. The target volume can be decided 
beforehand (~12-14ml/kg), but can be adjusted if the patient finds it too 
limiting. 
14. Once patient washed in, press “log to file” 
15. Let patient do 3 tidal breaths 
16. Detach flow-past circuit at middle of expiration. The detachment should be 
clean and swift to avoid upsetting the tidal breathing or inspiration of large 
volume of gas at the first washout breath. 
17. Continue washout, scale of display can be changed as concentration falls 
18. Once end-tidal SF6 is visibly lower than 0.1% for 3-4 consecutive breaths, 
get subject to inspire to vital capacity, then expire to residual volume. 
19. Once tidal volume restored, test can be stopped. 
20. Press stop. 
21. Repeat procedure to make 3 washouts, then make dummy file 
 
Performing a Single Breath Washout test 
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1. SBW tests are performed on the same washout screen but SBW is 
selected instead. Alter scale of volume graph to allow larger breath (+/- 
4000ml) 
2. Change patient feedback screen to show flow and stick tape on the screen 
at -4 and +4 to show limits of flow during test 
3. Click start and log to file 
4. The patient begins with tidal breathing with no gas supply 
5. The patient is asked to take a slightly larger breath in, then to breath right 
out to residual volume 
6. During this breath out, the gas supply is attached 
7. The patient is asked to breathe in to full vital capacity, limiting flow to 
4l/min 
8. At full vital capacity the patient begins immediately to breathe out slowly, 
limiting to -4 l/min, right out to residual volume.  
9. During this breath the gas supply is detached 
10. Once expired fully, the patient completes a normal tidal breath.  
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Data Analysis 
 
Data analysis is done offline, once the patient has completed the tests and left. A 
quick analysis may be done in-between washouts to ensure consistent FRC 
measurements (press FRC button on data analysis screen) 
The important elements of data analysis are: 
 Making sure the patient data matches the patient who completed the test.  
 Visualising the washout to look at evenness and evidence of gas trapping at 
final vital capacity breath of MBW. 
 Ensuring each breath is captured accurately 
 Ensuring the measurements are reproducible throughout washouts and 
determining reasons for lack of reproducibility (e.g. breathing pattern, leak, 
error in analysis) 
 Aligning the phase III slope regression lines for SF6 and He. 
 
 
MBW data analysis 
 
1. Open Patient data folder 
2. Make patient folder (<ptnmbr>, <pt name>, <DOBintials>, tested <date>) 
3. Copy all recordings and calibration files to this folder. Keep originals in folder 
“prov”. 
4. Make a new PowerPoint file with a series of blank sheets for storing screen 
captures 
5. Open “washout” program, selecting the 08**** file corresponding to the patient 
number. 
6. Select first washout number (after dummy test) 
7. View washout, save screen capture in PowerPoint file. (Final vital capacity 
breath can show qualitative evidence of gas trapping) 
8. Advance to the first breath of the washout 
9. Select “init value”, then “calculate” 
10. On the SF6 and He screen, check limits of phase III slope measurement 
(usually 65% to 95% of final concentration) 
11. Important information is the slope values (absolute - S and concentration 
normalised – Sn) and airway deadspace values. Slopes may need to be 
adjusted using the slider (check “manual slope” box) to make sure slope line 
is accurate and represents the true slope (accommodating cardiac oscillations 
or coughs etc.) 
12. Capture screen 
13. Click capnogram, look at airway deadspace values. 
14. Click save 
15. Back to washout screen 
16. Press “calculate” to go to next slope screen, adjust as appropriate, then 
“capnogram” screen. 
17. This process needs to be repeated for the whole washout until 1 breath where 
the end-tidal SF6 is below 0.1% (1/40th of start) has been saved. 
18. At this point the washout is complete 
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19. Some patients with more inhomogeneity have fluctuating end-tidal SF6 values 
(Cet) making it difficult to decide on the end of the washout. One breath may 
have a Cet <0.1% but the next one may be above. The convention is to stop 
the analysis when two breaths below 0.1% have been saved. 
20. Click results. View and capture to PowerPoint file. 
21. Look at LCI, Moment ratios and slope analysis values 
22. Save values, and close results screen. 
23. Select the next washout and follow the same process to analyse. Remember 
to make screen captures and save values before closing or exiting. 
 
 
SBW data analysis 
 
1. While in the data analysis program, remove check from “multiple/single” box 
open the SBW washout number 
2. View tracing  
3. Advance along by pressing next repeatedly. 
4. Make sure the last line corresponds with the end of the breath 
5. Advance the “start inspiration” line to the level maximum SF6 point to make 
sure the max level is known 
6. Capture screen to PowerPoint 
 
 
 
7. select “init value” 
8. press “calculate” 
9. Remember that the slope is normalised to make it look like a nitrogen 
washout test. 
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10. Capture screen into PowerPoint 
 
       
 
11. Press “save SBW”, then close 
12. Move to next SBW and do the same for all 
 
Storing of Results 
 
1. Copy the results template and rename with patient data (<Nr <pt number>, 
<dobinitials> results <date>), e.g. Nr 080001, 310378km results 040408 
2. Multiple tabs have space for all information 
3. Input patient information 
4. Copy MBW, SBW and capnography data from “results” file. 
5. This will give mean values etc. There are further tabs that allow viewing and 
storing in either vertical or horizontal format. These can be copied into other 
spreadsheets or databases for further analysis. 
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Analysis of Phase III data 
Phase III slope analysis is done on an excel worksheet (see templates). The raw 
slope and normalised slope values are already saved from the washout analysis but 
need to be processed in order to calculate ventilation heterogeneity indices (e.g. 
Scond and Sacin) 
 
1. Copy the SnIII template (SF6 or He) and rename with the patient data as 
above (e.g. Nr 080001, 310378km, SF6 SnIII 040408) 
2. There are 3 “input” tabs which must be populated from the raw data. These 
data are located in the MB file 
3. Open MB file and sort by gas, descending 
4. Copy the section of data for each SF6 and He washout into the relevant tabs 
on the worksheets. 
5. The first tab, “input – He/SF6” contains the average values from the 3 
washouts for each breath. 
6. This averaged data is then automatically fed into the “SnIII – actual” and “SnIII 
x VT” (tidal volume corrected) tabs to generate the results 
7. The pink boxes at the top right require manual entry of FRC, equipment dead 
space and patient weight values. Also, the slope (x-multiplication value) and 
R2 of the SnIII values needs to be manually entered from the graph on the 
lower left of the screen. 
8. Scond can be calculated first. By convention it is the best line drawn through 
all the normalised slope values of the mid-portion of the washout (lung 
turnover – TO – 1.5-6). The slope of this line is the Scond.  
9. To calculate this line, delete all the slope values before TO 1.5 and after TO 6. 
Keep the first breath SnIII dcdi value (highlighted in red) to calculate the 
Sacin. 
10. Sacin is the contribution of the convective-diffusive front to the total 
normalised phase III slope of the first breath. This is calculated from the total 
SnIII of the first breath, minus the Scond contribution of that breath. This is 
done in cell I2. 
11. Scond and Sacin are calculated twice. Once as measured, and once 
corrected for tidal volume (to allow comparison with other studies using 1L 
breath washout techniques). Tidal volume correction involves multiplying each 
SnIII by the respective tidal volume and then calculating Scond and Sacin in 
the same way as before. 
12. You should notice that in patients with more advanced disease the Scond and 
Sacin values tend to be higher. Often, in those with normal lungs, there is 
more scatter of values. There should be a good visible trend in those with 
abnormal values. Outlier breaths may be removed with good reason (may 
required going back to the washout analysis to look at the breath). 
13. The results of this analysis are stored in the last tab “Exportfil”. They can be 
copied and pasted elsewhere if required. 
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Appendix Three – Multiple flow FeNO SOP 
 
The following protocol is used for both research and clinical multiple flow measurements in 
the paediatric department at the Royal Brompton Hospital. 
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Niox variable flow FeNO measurements 
 
 
 
Infection Control 
NIOX uses single use patient filters, this must be discarded at the end of each 
test. 
Mouthpiece is post-filter but will be held by patient and so should be cleaned 
with soap-based cleansing wipes between patients (e.g. Clinell wipes) 
 
Calibration 
NIOX is calibrated at regular intervals rather than on daily basis (arranged 
though SD) –check date of calibration and due date of next calibration before 
each test.  
 
Carrying out the test 
 Replace filter before use.  Between tests a dummy filter (marked with 
stickers) is placed on mouthpiece to prevent excessive contamination 
with dust.  Remove this and fit a clean filter before each patient. 
 Select Mode, Research Mode 
 Select Flexflow Mode.  This will give you access to multiple flow rates. 
 Enter Patient, New Patient to add name, date of birth and hospital 
number of patient 
 Load test profile – Difficult Asthma (DA).  This is the standard multiple 
flow rate protocol in use at RBH and gives 3 additional flow rates to the 
standard 50ml/s. 
 Select Incentives (balloon for younger children, gauge for older 
children) and follow on screen instructions to begin test. 
 Instruct patient to take a large breath in, and then exhale slowly at the 
rate indicated by the incentive screen. 
 Repeat the test until a minimum of two acceptable measurements have 
been obtained on the flow rate, then attempt the next flow rate up. 
 Repeat until full set of measurements is obtained. 
 Discard filter used by patient, replace dummy filter and clean 
mouthpiece. 
 Remember to screen capture or otherwise record data as the machine 
does not store readings. 
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Appendix Four - Comparisons with the Brody score. 
 
The Brody score is an established (Brody et al., 2006; Brody et al., 2004) HRCT score used in 
many studies of obstructive lung diseases.  The individual features scoring system used in 
this thesis is not well established, and so a comparison of results obtained from both 
systems has been performed to determine if any information is lost or missed by the choice 
of scoring system.   
The 21 PCD and matched CF patients recruited originally as an addition to the Gene Therapy 
run-in study had their HRCT scans also Brody scored by a radiologist (Dr Nair)(Brody et al., 
2006).  He was blinded to the diagnosis, the earlier score, and he did not conduct the 
original features scoring on these patients.   
The Brody method gives a global score, and also individual elements (bronchiectasis, mucus 
plugs, peribronchial thickening, parenchymal abnormality and air trapping (defined 
differently to the criteria used in the individual score)) 
The Brody score was then compared with the individual features score system, used in this 
thesis. 
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Figure 1 - The global Brody score compared with individual features or the scoring system 
used in the bulk of this thesis. All individual features scored correlate with the Brody global 
score except for air trapping, as defined by this protocol.  Results shown include both disease 
groups. 
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Table 1 – Correlations between the elements of Brody scores and their corresponding feature 
on the  individual score system.  As would be expected, correlations between relative 
measures of bronchiectasis, wall thickening, and mucus plugs are strong. Air trapping is 
defined differently under the two systems.  There is no direct comparator for parenchymal 
abnormality, but this showed some weak correlation with most features studied. This was 
conducted to show that no information is lost by using the less common score of the 
individual elements. 
 
There is no global score in the individual elements system used in the first part of this 
chapter, which could represent a possible loss of information and thus some correlations 
could be missed.  However, this global compares extremely well with the scores of the 
individual elements (Figure 1) so it seems unlikely information is being lost this way. 
Most elements of the Brody score correspond with counterparts in the individual features 
system as one would expect – bronchiectasis with bronchiectasis and so forth.  Parenchymal 
  Bronchiectasis Mucus plugs 
Peribronchial 
thickening 
Parenchymal 
abnormality Air trapping 
Extent of 
bronchiectasis  p<0.001, r=0.6 - - p=0.04, r=0.3 - 
Severity of 
bronchiectasis  p<0.001, r=0.8 - - p=0.01, r=0.4 - 
Small Plugs  - 
p=0.002, 
r=0.5 - p=0.03, r=0.4 - 
Large Plugs  - 
p=0.01, 
r=0.4 - p=0.03, r=0.4 - 
Wall thickness  - - 
p<0.0001, 
r=0.7 p=0.03, r=0.3 - 
Air trapping  - - - p=ns p=ns 
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abnormality has no direct comparator and instead correlates with most features other than 
air trapping, and so it seems again unlikely information is lost by this test not forming part of 
the individual features scored originally.  
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